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Abstract 
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Doctor of Philosophy 
 
Rapid and definitive identification of pharmaceutical drug 
metabolites using mass spectrometry 
 
by Stephen William Holman 
 
Low-energy collision-induced dissociation-tandem mass spectrometry (CID-
MS/MS) is a well-established approach for identifying pharmaceutical drug 
metabolites.  The technique fulfils many necessary requirements for this task, 
such as a low limit of detection, simple interfacing to chromatographic 
techniques, capability of fast analyses and automation, and high sensitivity, 
selectivity and accuracy.  However, one of the main limitations of low-energy 
CID-MS/MS is that unambiguous assignment of the site of metabolism is often 
not possible, particularly for oxidised metabolites.  Further, data interpretation 
can be time-consuming, thus producing a bottleneck to high-throughput 
analyses.  The aim of the presented study was to identify structurally dependent 
dissociation pathways using low-energy CID-MS/MS that could facilitate rapid 
and definitive assignment of the sites of metabolism of new chemical entities. 
 Chapter 4 details a specific loss of 50 m/z units in a model S-oxide that 
arises due to an ortho-effect.  This loss could be used to definitively assign the 
site of oxidation and discriminate between multiple sulfur atoms in a parent 
compound.  The 50 m/z unit loss was also shown to be a two-step process 
involving sequential radical losses; a rare observation for even-electron 
precursor ions under low-energy CID conditions.  Chapter 5 discusses the 
experimental investigation of two unexpected rearrangements during the 
dissociation of a model S-oxide that could prevent correct assignment of the site 
of metabolism.  Chapter 6 presents a rapid and definitive approach to the 
characterisation of dialkyl tertiary amine-N-oxides.  The work also elucidated 
generic dissociation behaviour under low-energy CID conditions.  Finally, 
chapter 7 considers an observation of site-specific intra-ionic 
hydrogen/deuterium exchange in the gas phase.  Seven sets of compounds 
were analysed to investigate the substructures that facilitate the exchange.  The 
work demonstrates a method by which a deuterium label can be inserted into 
the carbon skeleton of a small molecule without having to synthetically produce 
the compound, which could be useful in performing timely and cost-effective 
structural elucidation studies.  In summary, the presented study provides two 
potentially useful approaches for the rapid and definitive identification of 
oxidised metabolites, as well as increasing the body of knowledge relating to 
ion-chemistry under low-energy CID conditions. 
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Chapter 1 
 
Introduction to mass spectrometry 
 
1.1 Synopsis 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-
charge (m/z) ratio of gas-phase ions.  It is capable of providing qualitative and 
quantitative information with high sensitivity, selectivity, speed, accuracy and 
precision, and at low limits of detection.1  In this study, structural elucidation of 
pharmaceutically relevant compounds, including model oxidised drug 
metabolites, was performed using MS.  The aim was to identify structurally 
dependent dissociation pathways that were indicative of sites of oxidation of 
pharmaceutical compounds, thus facilitating rapid and definitive 
characterisation.  Additionally, an increased understanding of ion-chemistry 
under low-energy collision-induced dissociation (CID) conditions was sought. 
 
1.2 Construction of a mass spectrometer 
A mass spectrometer is made up of six key components; an inlet, an ion source, 
a mass analyser, a detector, a data analysis system and a vacuum system.  These 
components are shown schematically in Figure 1.1.  Various technologies are 
available for each of these components.  Those that vary most, and also have 
the greatest impact on the analysis of compounds by MS, are the ion source and 
the mass analyser.  This is because the selections of these components are 
dictated by the chemistry of the analyte(s) of interest and the information that 
is required.  Detailed discussions of the ionisation technique and the mass 
analysers utilised in this study are given below. 
 
 
 
 
 
Chapter 1 
2 
 
Figure 1.1 Schematic of the key components of a mass spectrometer 
 
1.3 Ionisation techniques 
A fundamental requirement for an atom or compound to be analysed by MS is 
that it must exist as a gas-phase ion.  Many techniques have been developed to 
ionise analytes from the solid, liquid and gas phases.  These techniques can be 
broadly separated into two categories, the second of which being subdivided 
into a further two groupings; those performed under vacuum and those 
undertaken at atmospheric pressure with samples either in the solution or solid 
phases.  Table 1.1 gives commercially available examples from each of these 
categories.  The ionisation technique used throughout this study was 
electrospray ionisation (ESI). 
 
Table 1.1 Commercially available ionisation techniques defined by the 
conditions under which ionisation takes place 
 
In vacuo ionisation 
techniques 
Atmospheric pressure ionisation (API) 
techniques 
 
Solution phase Solid phase 
Electron ionisation (EI)2  Electrospray ionisation 
(ESI)3  
Desorption 
electrospray 
ionisation (DESI)4  
Chemical ionisation (CI)5  Atmospheric pressure 
chemical ionisation 
(APCI)6  
Direct analysis in real 
time (DART)7  
Matrix-assisted laser 
desorption/ionisation 
(MALDI)8  
Atmospheric pressure 
photoionisation (APPI)9  
Atmospheric pressure 
solids analysis probe 
(ASAP)10  
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1.3.1 Electrospray ionisation (ESI) 
Electrospray was first demonstrated as a method for generating gas-phase ions 
by Malcolm Dole and co-workers.11  This work provided the inspiration for the 
group of John Fenn to use MS as a method for detecting both positive and 
negative ions generated by electrospray, leading to the development of what is 
referred to today as ESI-MS.3, 12  The pioneering work performed by Fenn led to 
him sharing the Nobel Prize in Chemistry in 2002.13  
 
A number of reviews focussing on the principles,14 fundamentals,15 and 
applications16 of ESI have appeared in the literature.  ESI was selected for this 
study because it is the established ionisation technique in the pharmaceutical 
industry,  being utilised in both discovery and development for the 
identification, characterisation and quantification of new chemical entities 
(NCEs),17 metabolites,18 degradants19 and impurities.20  The wide application 
stems from the many strengths of the technique.  Firstly, compounds can be 
analysed directly from solution at atmospheric pressure.  This is advantageous 
in a pharmaceutical setting because the analytes of interest are frequently 
within the liquid phase e.g. a plasma or urine matrix or stored dissolved in 
dimethylsulfoxide.14, 21  A further benefit of directly sampling from solution is 
that non-volatile and/or thermally unstable species are amenable to analysis by 
MS.  This property broadened the range of compounds that could be easily 
analysed by MS to include biological macromolecules, such as peptides,22 
nucleotides,23 saccharides24 and protein complexes.25  These types of compound 
were difficult or impossible to ionise by techniques such as EI and CI because 
they would thermally degrade before volatilising due to their high boiling 
points.  A number of ionisation techniques, including fast atom bombardment 
(FAB),26 field desorption (FD),27 field ionisation (FI)28 and thermospray (TSP),29 
did allow the ionisation of thermally unstable compounds of low volatility.  
However, either limitations in the analytical performance or the requirement 
for highly skilled analysts to conduct the experiments meant that routine 
application was difficult to realise.  ESI alleviates the need to transfer analytes 
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to the gas phase prior to ionisation, thus allowing compounds not amenable to 
ionisation by EI and CI to be studied by MS.  Further, the ease of use meant that 
ESI became the preferred ionisation technique amongst the biological 
community.  Although ESI has been extensively applied to the analysis of 
biological macromolecules, it is equally suited to ionising small polar 
compounds.  It is frequently used in areas of science where small molecules are 
of primary interest,  including environmental science,30 forensic science,31 
metabolomics32 and toxicology,33 as well as pharmaceutical science.21  
 
Another useful property of ESI is that the ionisation event imparts very little 
energy to the analyte, leading to it being referred to as a “soft” ionisation 
technique.34  The result of this phenomenon is that predominately molecular 
species are observed in an ESI mass spectrum with rarely any evidence of 
fragmentation, unless induced via in-source CID.  Depending upon the 
experimental conditions used, either positive or negative ions are produced by 
the ion source.  Molecules with basic or acidic sites can be analysed by virtue of 
protonation or deprotonation respectively (Equations 1.1 and 1.2, where M = 
molecule).  Adduct ions can also be formed, especially for those compounds not 
possessing strongly basic or acidic sites.  Examples of adducts observed using 
positive ion ESI are cationised molecules, particularly with alkali metals such as 
sodium ions (Equation 1.3).  Adducts with deprotonated acid molecules, for 
example formate anions (Equation 1.4) and halide anions are common in 
negative ion ESI.35  The soft nature of the ionisation event, and the consequent 
lack of dissociation, means that molecular mass information, and additionally 
elemental formulae when high-resolution mass spectrometers are employed, is 
easily obtainable using ESI-MS.36, 37  
 
Equation 1.1  M + H+ → [M + H]+ 
Equation 1.2  M → [M – H]- + H+ 
Equation 1.3  M + Na+ → [M + Na]+ 
Equation 1.4  M + HCO2
- → [M + HCO2]
- 
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An analytically useful characteristic of ESI is that multiple-charging is observed 
for macromolecules i.e. [M + nC]n+, where C represents a charged species such 
as a proton or an ammonium ion.  This was first demonstrated by Wong and co-
workers, who showed data for oligomers of poly(ethylene)glycol bearing up to 
twenty-three sodium cations.38  Multiple-charging thus leads to a range of 
species of a given analyte existing in solution, differentiated only by the number 
of positive or negative charges on the ion for positive and negative ion ESI 
respectively.  When the solution is electrosprayed into the mass spectrometer, 
these species will be recorded at different m/z values due to the relationship 
shown in Equation 1.5; 
 
Equation 1.5  
z
n nC]  [M
 
 
where: M = Molecule 
C = Charged species 
 n = Number of charged species 
 z = Number of charges on ion 
 
The resultant distribution of peaks is referred to as the “charge envelope”.  An 
example is shown in Figure 1.2 for the proteins cytochrome C and myoglobin.39  
The reduction of the m/z value of a macromolecule through multiple-charging 
means that it can be analysed on mass spectrometers that have a low value 
upper mass range limit e.g. quadrupole mass spectrometers.40  This increases 
the scope of biological MS by allowing a greater number of researchers to 
perform analyses in this area.14  Another advantage of multiple-charging is that 
the molecular mass determination can be averaged over all of the observed 
charged states, leading to mass accuracies with errors of ± 0.01% i.e. 1 Dalton 
(Da) error at 10,000 Da molecular weight.41 
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Figure 1.2 ESI mass spectra of A) cytochrome C and B) myoglobin.  The 
annotations show the number of protons associated with each 
peak.  Deconvolution of the spectrum allows the determination 
of the molecular weight of the protein analysed 
 Reproduced from reference 39 with kind permission from the 
American Association for the Advancement of Science 
 
Multiple-charging is generally restricted to analytes in excess of approximately 
1000 Da.  Below this value, most molecules are sufficiently small that coulombic 
repulsion prevents the addition or removal of a second charge.  Thus, small 
molecules are typically observed as singly charged ions, although Kaufmann and 
co-workers reported doubly charged ions in the ESI mass spectrum of 
difloxacin.42  All of the compounds investigated in this study were analysed as 
singly protonated molecules i.e. [M + H]+. 
 
Finally, ESI also enables the simple coupling of separation science techniques, 
such high performance liquid chromatography (HPLC)43 and capillary 
electrophoresis,44 to MS.  A number of interfaces were evaluated for the 
coupling of the two techniques,45 such as TSP and continuous-flow (CF)-FAB,46 
with varying degrees of success.  However, ESI provided one of the most robust 
and user-friendly approaches, and thus has become widely applied.47  The ease 
of coupling, along with the high sensitivity of ESI,48 has led to LC-ESI-MS 
becoming the staple technology for the analysis of pharmaceutical 
metabolites.49 These analytes are typically at low levels in complex matrices, 
thus necessitating the strengths of LC-ESI-MS for their successful analysis. 
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Figure 1.3 shows a schematic of the production of ions at the tip of the capillary 
in an ESI ion source, which is operated at atmospheric pressure.  To ionise a 
sample, it is first dissolved in a polar solvent; typically acetonitrile, methanol or 
water, or combinations thereof.50  In the design shown, the resultant solution is 
passed through a metal capillary to which a high voltage of several kilovolts (kV) 
is applied.  If positive ion ESI is being performed, this voltage is of positive 
polarity.  The polarity is reversed for negative ion ESI.  A counter electrode is 
held at 0 volts (V), causing a strong electric field to be created.  A different 
approach to creating the strong electric field is to hold the capillary at 0 V, 
typically using a glass capillary, whilst applying a high voltage to the counter 
electrode; a negative voltage is used for positive ion ESI, whilst a positive 
voltage is applied when performing negative ion ESI.  Upon reaching the end of 
the capillary, the electric field causes the positive ions to be attracted towards 
the counter electrode, leading to charge separation at the surface of the 
solution.  The result is that the liquid forms a “Taylor cone”, which protrudes 
from the end of the capillary with charge of the same polarity localised on the 
surface (Figure 1.3).15  Subsequent evaporation of solvent causes the charge 
density on the surface of the Taylor cone to increase until the “Rayleigh limit” is 
reached i.e. when the forces of coulombic repulsion between the like charges 
and surface tension of the solution are equal.40  At this point, fission occurs, 
thus producing smaller droplets that carry the same amount of charge.51 
 
 
Figure 1.3 Schematic of a Taylor cone and subsequent droplet fission in an 
ESI ion source operated with a positive polarity 
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Repeated evaporation and fission eventually leads to the production of 
desolvated ions.52  The ions present in solution are thus transferred to the gas 
phase.  However, gas-phase reactions can cause the ions to be qualitatively 
different to those present in the solution phase.53, 54 
 
More efficient ion production, and the capability to accept faster HPLC flow 
rates, is achieved by using pneumatically-assisted ESI (Figure 1.4).  In this 
design, a counter-current drying gas is applied to the source; typically nitrogen.  
Collisions between ion-solvent complexes and the drying gas destroys the non-
covalent interactions and releases desolvated ions.55  Most ESI ion sources 
nowadays also use a sheath gas, which helps nebulise the solution, aids 
desolvation and collimates the spray;  a modification originally proposed by 
Bruins and co-workers.56  Application of heat can also assist desolvation, and 
prevent resolvation, of the ions.57-59  
 
Figure 1.4 Schematic of a pneumatically-assisted ESI ion source 
 
Two desolvation mechanisms have been proposed for the formation of isolated 
gas-phase ions produced by ESI.  Dole and co-workers suggested the charged 
residue model (CRM) (Figure 1.5), whereby the repeated solvent evaporation 
and droplet fission eventually leads to a complex of an analyte with a few 
molecules of solvent.11, 60  Evaporation of these solvent molecules, with 
concurrent retention of the droplet’s charge by the analyte, forms an isolated 
gas-phase ion that can be sampled into the mass spectrometer.61  Iribarne and 
Thomson proposed an alternative mechanism; the ion evaporation model (IEM) 
(Figure 1.5).62, 63  This model begins as being qualitatively the same as the CRM, 
with repeated solvent evaporation and droplet fission steps.  However, it differs 
when the droplets reach approximately 10 nm in radius.  The model proposes 
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that at this point, the electrostatic force on the surface of the charged droplet is 
sufficiently high to overcome the solvation forces.  As a result, direct field 
desorption of an analyte ion into the gas phase is able to take place.53  
 
There is much conjecture as to which model applies, with conflicting 
experimental evidence and opinion.61  However, a general consensus is that 
multiply-charged macromolecules are formed via the CRM,64 whilst small ions 
are proposed to form by either the IEM53, 65-67 or the CRM.68, 69  These 
generalisations are based on a number of rationalisations, including the fact 
that a high activation energy barrier would exist to the desorption of 
macromolecules directly from the charged droplet, thus precluding the IEM.70  
However, various authors acknowledge that there are assumptions in the 
proposals as to which model applies for different types of analyte.  There is an 
acceptance that a combination of the models could be involved at any one time 
in the formation of gas-phase ions.71 
 
 
Figure 1.5 Schematic of the desolvation of gas-phase ions as described by 
the charged residue model (CRM) and the ion evaporation 
model (IEM) 
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The mixture of ions and solvent molecules generated from the tip of the 
capillary supersonically expands as it passes through the ESI ion source.72  The 
desolvated ions, along with any surviving ion-solvent clusters, pass through the 
orifice in the counter electrode into the mass analyser because they experience 
limited diffusion over the distance traversed.  The lighter solvents molecules 
diffuse much faster from the centre of the spray and thus are less likely to be 
sampled into the mass analyser.  Various source configurations have been 
developed to maximise ion transmission whilst minimising sampling of solvent 
molecules, neutrals and salts.73  For example, Voyksner and Lee demonstrated 
an off-axis nebuliser, positioned 90-95o from the sampling orifice, which 
increased the signal for the protonated molecule of lincomycin by a factor of 
six.74  Upon passing through the orifice, the ions experience a pressure gradient 
as they travel to the mass analyser.  A gradient is required to gradually lower 
the pressure from atmospheric pressure at the source to the high vacuum 
required in the mass analyser, in order to make them compatible.  This gradient 
is created using a differentially pumped interface made up of a series of 
compartments separated by skimmers, which act as baffles, between the source 
and the mass analyser (Figure 1.3).75  Initially, rotary vane vacuum pumps are 
used to decrease the pressure to approximately 0.01 mbar.41  Once pressures of 
this order are reached, high vacuum pumps can be utilised.76  Typically, a 
turbomolecular vacuum pump is attached to the mass analyser to quickly attain 
the high vacuum at which it operates.41  The ion motion must be controlled 
during the passage along the pressure gradient to ensure high transmission 
efficiency.  This is achieved using ion optics.77  The use of radio frequency (RF)-
only multipoles,78 charged lenses76 and ion funnels79 collimates the beam of 
ions, thus allowing efficient transfer.  The exertion of electrostatic forces also 
accelerates the ions and prevents their removal by the vacuum pumps.  
Collisions caused by accelerating the ions desolvates any remaining ion-solvent 
complexes, with the solvent removed by the vacuum system.75 
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1.4 Mass analysers 
Once an isolated gas-phase ion has been formed, a mass analyser is used to 
determine its m/z value.  The three mass analysers used in this study were a 
quadrupole ion trap (QIT) mass spectrometer, a quadrupole time-of-flight 
(QqTOF) mass spectrometer and a Fourier transform-ion cyclotron resonance 
(FT-ICR) mass spectrometer.  All three instruments are capable of performing 
the tandem mass spectrometry (MS/MS) experiment. 
 
The use of soft ionisation techniques has had a significant positive impact on the 
field of MS.  However, the limitation of these ionisation techniques is that little 
or no dissociation occurs due to the low amounts of energy imparted to the 
molecule.  Thus, little or no structural information can be derived from a single 
stage of mass analysis.  This limitation is overcome through the use of the 
MS/MS experiment, which involves two stages of mass analysis.80  Bridging 
these two analytical scans is a period where an “ion activation” method is used 
to impart energy to the ions.81  This leads to their dissociation, thus allowing the 
elucidation of structural information. 
 
1.4.1 Tandem mass spectrometry (MS/MS) 
The MS/MS experiment can be performed either “in-time” or “in-space”.82  Of 
the mass spectrometers used in this study, the QIT and FT-ICR mass 
spectrometers are “in-time” MS/MS platforms, whilst the QqTOF mass 
spectrometer performs MS/MS “in-space”.  “In-time” MS/MS platforms perform 
the two stages of mass analysis and the ion activation in the same mass analyser 
but at different points in time.  “In-space” MS/MS instruments have two mass 
analysers separated by a collision cell where the ions are dissociated, all of 
which are arranged in series.83  The type of MS/MS platform i.e. the mass 
analyser(s) used and whether MS/MS is performed “in-time” or “in-space”, has 
a bearing on the MS/MS scans that can be performed.  Figure 1.6 shows the 
four MS/MS scan modes that can be conducted. 
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Figure 1.6 The MS/MS scan modes; a) product ion scan; b) precursor ion 
scan; c) constant neutral loss scan; d) selected reaction 
monitoring1 
 
The different scan types can enable different information to be obtained about 
an ion of interest.  All of the MS/MS experiments performed in this study were 
product ion scans.  This experiment involves selecting a specific m/z value, for 
example that related to the protonated molecule of an analyte of interest, 
which is then isolated.  The ions (precursor ions) then undergo activation, and 
all of the fragment ions (product ions) within a defined mass range are recorded 
by scanning the mass analyser during the second stage of mass analysis.  This 
allows the analyst to determine structural components of the precursor ion.  
The precursor ion scan involves detecting a specific product ion during the 
second stage of mass analysis whilst scanning over a mass range during the first 
stage.  This scan is useful for screening experiments where a group of 
compounds all dissociate to produce a common product ion.  A frequent 
application of this experiment is the detection of the product ion at m/z 85 
produced via the dissociation of butylester derivatives of acylcarnitines, which 
are biomarkers for inborn errors of fat metabolism.84, 85  The constant neutral 
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loss scan is also useful for screening for a specific class of compounds.  In this 
experiment, both mass analysers are scanned at the same rate during mass 
analysis.  However, the second mass analyser is scanned with an offset in m/z 
value equal to the mass of a diagnostic neutral loss from the precursor ion.  
Thus, a signal is only generated when the specific neutral loss takes place during 
ion activation, allowing the recording of the product ion during the second stage 
of mass analysis.  A recent application of this approach was reported by 
Bessette and co-workers, who used the constant neutral loss of 116 m/z units 
from protonated DNA adducts to identify different classes of carcinogens.86  
Finally, selected reaction monitoring experiments are used in quantitative MS to 
improve the limit of detection.  A precursor-product ion pair is detected by 
scanning only for the m/z value of the precursor ion during the first stage of 
mass analysis and only for the m/z value of the product ion during the second.  
As well as lowering the limit of detection, this MS/MS scan mode also improves 
the selectivity of the experiment.87  
 
1.4.2 Collision-induced dissociation (CID) 
The MS/MS experiment requires an ion activation technique to induce 
dissociation of the precursor ions, with a variety of approaches reported.81  The 
technique used throughout this study was CID (Figure 1.7).  In this process, the 
precursor ion is accelerated and collides with an inert gas of high ionisation 
potential; typically helium, nitrogen or argon.88  The collisions cause conversion 
of the translational energy of the precursor ions to internal energy.89  In low-
energy CID, such as that used in this study, the precursor ions undergo multiple 
collisions that gradually increase the internal energy.90  High-energy CID can also 
be performed, using sector and time-of-flight (TOF) mass spectrometers, which 
can produce qualitatively different mass spectra.91-93  The increased internal 
energy provides the activation energy for the dissociation reactions to occur.  
The stepwise heating due to multiple collisions produces a spread of energies in 
the precursor ions that tend towards a Boltzmann distribution.83  Thus, 
precursor ions with different internal energies are produced, allowing a range of
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dissociations to take place. 
 
 
Figure 1.7 Schematic of the collision-induced dissociation (CID) process 
where (A) a precursor ion (purple circle) is accelerated and (B) 
collides with a neutral gas (green circles) (C) leading to the 
formation of product ions (red circles) 
 
The centre-of-mass (Ecom) reference describes the inelastic ion-neutral collision 
and is used to represent the maximum amount of translational energy that can 
be converted into internal energy.81  Equation 1.6 shows that increasing the 
translational energy of the precursor ion and/or the mass of the inert gas will 
allow greater internal energies to be attained.41  Greater collision gas pressures, 
as well as increasing the cross-sectional area of the atom or molecule used, also 
increase the likelihood of a collision.76, 81  Given that multiple collisions take 
place under low-energy CID conditions, these approaches provide alternative 
methods of increasing the internal energies of the precursor ions.  
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where: Elab = translational energy of the precursor ion provided by the 
electric fields in the mass spectrometer 
 mi = mass of the precursor ion 
 mc = mass of the inert gas 
 
1.4.3 Quadrupole ion trap-mass spectrometry (QIT-MS) 
The low-energy CID-MS/MS platform upon which much of this study was 
conducted was the QIT mass spectrometer.  This instrument has a single mass 
analyser in which MS/MS is performed i.e. it is an “in-time” MS/MS platform.  
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The QIT mass spectrometer became commercially available as a result of the 
development of the mass-selective instability mode of operation.94  Until this 
point, the QIT had mainly garnered interest amongst the physics community as 
a method of trapping and studying ions, either via mass-selective detection or 
mass-selective storage.95  However, limited analytical performance in terms of 
mass range, mass resolution and sensitivity meant that its use as a mass 
spectrometer was not widespread until the work of Stafford and co-workers.96  
The QIT mass spectrometer used in this study was an LCQ Classic, which 
operated in the mass-selective instability mode.  The key features of this 
process on this particular instrument are described below. 
 
A schematic of the QIT is shown in Figure 1.8.  The mass analyser is constructed 
from three electrodes; a ring electrode and two end-cap electrodes.  An 
oscillating electric field is generated through the application of an RF voltage to 
the ring electrode, whilst the end-cap electrodes are held at ground potential.97  
The electric field that is created allows ions of a range of m/z values to be 
trapped.98 
 
 
Figure 1.8 Schematic of the two-dimensional cross section of a quadrupole 
ion trap (QIT) mass analyser 
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The ions with a stable trajectory undertake a motion that has been likened to a 
“figure-of-eight”.99  The stability of ion motion within the QIT can be 
determined from solutions of the Mathieu equation.  These solutions allow the 
construction of a stability diagram in az, qz space (Figure 1.9) where the 
following relationships apply (Equations 1.7 and 1.8);94  
 
Equation 1.7 
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where: U = Maximum direct current (DC) potential between end-cap and 
ring electrodes 
  V = Maximum RF potential between end-cap and ring electrodes 
  m = Mass of ion in Da 
  z = Number of charges on ion 
  ro = Internal radius of ring electrode 
  Ω = Angular frequency of RF potential 
 
 
 
Figure 1.9 Stability diagram in (az, qz) space for a QIT mass analyser 
Reproduced from reference 105 with kind permission from John 
Wiley & Sons Ltd. 
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Ions which map onto the stability diagram within the defined boundaries have 
stable orbits within the electric field, and thus the QIT.100  As no DC potential is 
applied using the mass-selective instability mode of operation, all of the ions 
have a value of zero for az, hence maximising the range of m/z values that can 
be trapped.95  Ions are thus positioned along the qz axis, with values inversely 
proportional to their m/z value.  Mass analysis is achieved by linearly increasing 
the amplitude of the RF voltage applied to the ring electrode whilst maintaining 
a fixed frequency.101  This increases the qz value associated with each m/z value.  
When a particular m/z value reaches the qz value at the boundary of the 
stability region, the orbits of those ions become unstable in the axial direction.96  
This leads to ejection of the ions, in order of increasing m/z value, through one 
of the end-cap electrodes where they impinge on an external detector.  The 
solutions of the Mathieu equation produce a boundary of the stability diagram 
at qz = 0.98 when az = 0.  However, this value is decreased to 0.83 in the LCQ 
Classic QIT mass spectrometer used in this study due to the application of a 
supplementary RF voltage to the end-cap electrodes during mass analysis.  This 
voltage is called the resonance ejection amplitude and is applied so that all ions 
of a given m/z value are ejected simultaneously.  This ensures correct m/z value 
assignment and improves the mass resolving power of the instrument.  When 
the ions begin to become unstable inside the QIT, their orbits increase in size 
and decrease in regularity.  At the point in time when qz = 0.98, some of the ions 
will be closer to the end-cap electrodes than others.  This leads to the 
population of ions of a given m/z value leaving the trap and impinging upon the 
detector at different points in time.  Whilst these ions are exiting the end-cap 
electrodes, the amplitude of the RF voltage on the ring electrode will have 
increased.  As the QIT is calibrated such that there is a linear relationship 
between m/z value and RF amplitude, the ions reaching the detector at a later 
point in time will be detected at a higher m/z value than their true value.  By 
applying the resonance ejection amplitude at the secular frequency of the m/z 
value of interest i.e. the characteristic frequencies with which ions oscillate 
within the QIT, which are dependent upon their qz values,
95 all ions of that m/z 
value are caused to oscillate as a group.  Thus, they are ejected from the trap 
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simultaneously when qz = 0.83 and before the amplitude of the RF voltage on 
the ring electrode has increased.  The resonance ejection amplitude is increased 
proportionally to the amplitude of the RF voltage on the ring electrode during 
mass analysis to ensure that ions of increasing m/z value are grouped. 
 
Electrostatic repulsion between like charges inside the QIT decreases the mass 
resolving power of the instrument.  The interferences between ions and the 
modifications of the electric fields inside the QIT caused by coulombic 
interactions are called space charge effects.102  One method of overcoming 
space charge effects is by limiting the population of ions within the QIT using 
automatic gain control (AGC).  AGC determines a maximum allowable ion 
abundance that can be tolerated inside the QIT before space charge effects 
occur.  When this ion abundance is reached, the AGC prevents further ions 
entering the trap to allow optimal performance to be maintained.  Another 
method of improving the performance of the QIT, discovered by Stafford and 
co-workers, is to introduce a buffer gas of helium at a pressure of approximately 
1 μbar.94  The buffer gas causes collisional cooling of the ions entering the trap.  
The removal of excess kinetic energy prevents collisions with the electrodes of 
the QIT, which would cause neutralisation and thus loss of the ions.103  The 
collisional cooling also causes the ions to collapse towards the centre of the QIT 
where the electric field is homogeneous.100  This enables a more uniform and 
efficient ejection process during mass analysis, which leads to an improvement 
in mass resolution, sensitivity and the limit of detection.94  
 
The QIT allows structural information about an analyte of interest to be 
obtained using the MS/MS and mass spectrometry to the nth degree (MSn) 
experiments.  MS/MS and MSn are performed in the QIT by isolating and 
dissociating a precursor ion of interest to yield product ions.  The ability of the 
QIT to perform MSn means that the genealogy of a precursor ion can be 
followed.90  This allows extensive structural information to be obtained, with 
MS12 having been demonstrated.104  MSn is achieved by performing multiple 
stages of dissociation i.e. repeated isolation and fragmentation steps.105  The 
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isolation of ions is often achieved in two stages.  Firstly, the qz value of the ion 
of interest is increased to 0.83.  Thus, all ions of lower m/z values will be ejected 
from the trap.  This process also increases the differences in the qz values 
between the remaining ions in the QIT to allow more efficient isolation during 
the second stage, which is termed resonance ejection.  This involves applying a 
range of RF frequencies to the end-cap electrodes in a similar manner to that 
used to eject the ions simultaneously during mass analysis.101  However, the 
frequencies are chosen to resonate with the secular frequencies of the ions that 
are not required.  A large voltage (approximately 100 V) is used to ensure that 
the ions obtain sufficient energy to cause them to undergo unstable orbits.  
Thus, they are ejected from the QIT.  No frequency that resonates with the 
secular frequency of the ion of interest is applied so that it remains in the QIT.  
Resonance ejection can also be utilised to eject all of the unwanted m/z values 
from the QIT without the prior increase of the qz value of the ion of interest to 
0.83.106 
 
Dissociation of the isolated ion of interest is achieved using low-energy CID, 
which is effected in the QIT by initially decreasing the amplitude of the RF 
voltage applied to the ring electrode.  This reduces the qz value of the isolated 
ions.  The product ions, which for singly charged precursor ions will be of a 
lower m/z value, would instantly become unstable and be ejected from the QIT 
as they are formed if the qz value of the precursor ion was not decreased from 
qz = 0.83.  A qz value of 0.25 has been found to lead to optimal dissociation of 
the precursor ion.  Application of an RF voltage to the end-cap electrodes of 
secular frequency of the ion of interest leads to dissociation.  The amplitude 
used is smaller than that used to effect resonance ejection.  The voltage causes 
the ions to become excited; hence the process is known as resonance 
excitation.  The excitation of the ions increases their kinetic energy to facilitate 
higher energy collisions with the helium buffer gas.101  The gradual increase in 
the internal energy inside the QIT is a “slow heating” process, taking place over 
time spans of the order of tens of milliseconds (ms).107  Once formed, the 
product ions do not fragment further.  This is because they are not in resonance 
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with the applied RF voltage as their qz values are greater than 0.25 due to them 
being lower in m/z value, assuming that the precursor ion is singly charged.  The 
amplitude of the RF potential applied to the ring electrode is then increased 
linearly to eject the product ions in order of increasing m/z value.  A limitation 
of performing MS/MS in the QIT is that some low m/z value product ions 
formed through dissociation of the precursor ion will have qz values greater 
than 0.83.  Thus, they instantly have unstable orbits, causing their ejection from 
the QIT and preventing them from being recorded during the mass analysis 
stage.  This is referred to as the low mass cut-off (LMCO) and results in product 
ions with m/z values of approximately one-third of the precursor ion not being 
observed in the product ion spectrum.108 
 
Two parameters allow improved acquisition of product ion spectra using the 
LCQ Classic QIT mass spectrometer.  These are WideBand activation and 
normalised collision energies.  WideBand activation allows dissociation of the 
product ion resulting from the non-specific water loss observed for many 
compounds in the QIT.  The transfer of energy to the precursor ion during low-
energy CID in the QIT is lower than in other mass spectrometers that perform 
low-energy CID, such as a triple quadrupole (QqQ) instrument with a collision 
cell.109  This frequently leads to the dominant, and often only, product ion being 
[M + H – H2O]
+, as observed in the low-energy CID product ion spectrum of 
methyl red acquired without WideBand activation (Figure 1.10a).  The non-
specificity of this dissociation provides little useful structural information about 
an analyte of interest.  MS3 can be employed to fragment the [M + H – H2O]
+ 
product ion.  However, this is non-ideal when using chromatography because 
the extra scan event leads to fewer scans across an eluted peak.  This leads to a 
decrease in accuracy in quantitative experiments.  Further, the extra scan event 
decreases the number of co-eluting compounds for which structural 
information can be obtained.  WideBand activation overcomes this problem by 
applying a range of excitation frequencies during low-energy CID such that 
product ions within a 20 m/z unit range below the precursor ion are 
dissociated.110  Thus, WideBand activation allows the dissociation of a 
Chapter 1 
21 
protonated molecule and the [M + H – H2O]
+ product ion in a single scan i.e. a 
pseudo-MS3 scan takes place (Figure 1.11).  This can lead to product ion spectra 
with greater structural information (Figure 1.10b).110  
 
 
Figure 1.10 First-generation low-energy CID product ion spectra of 
protonated methyl red (m/z 270) acquired using a LCQ Classic 
QIT mass spectrometer with a) WideBand activation off and b) 
WideBand activation on 
 
 
 
Figure 1.11 Schematic of the operation of WideBand activation 
Reproduced from reference 110 with kind permission from John 
Wiley & Sons Ltd. 
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Normalised collision energies allow optimum dissociation of analytes covering a 
wide mass range.  A high mass ion requires a greater RF voltage i.e. a greater 
collision energy, than a low mass ion for effective dissociation by low-energy 
CID to be  achieved.110  An approximately linear relationship exists between the 
m/z value of the precursor ion and the optimal collision energy (Figure 1.12).  
Collision energies could be applied as a percentage of the fixed maximum value 
of which the LCQ Classic QIT mass spectrometer is capable.  In this 
circumstance, approximately the same amount of energy would be applied for a 
given percentage regardless of the m/z value of interest.  Hence, the RF voltage 
used would only be optimal for a single m/z value.  This would result in the 
structural information for ions of other m/z values being less informative.  The 
normalised collision energy parameter scales the applied RF voltage by 
accounting for the linear relationship shown in Figure 1.12.  The scaling of the 
RF voltage creates equivalent dissociation, and hence potentially structural 
information, for any precursor ion independent of its m/z value (Figure 1.13) 
 
 
Figure 1.12 Graph of optimal collision energy against precursor ion m/z 
value 
Reproduced from reference 110 with kind permission from John 
Wiley & Sons Ltd. 
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Figure 1.13 Scaling of applied RF voltage with increasing m/z values for 
different values of normalised collision energy 
Reproduced from reference 110 with kind permission from John 
Wiley & Sons Ltd. 
 
1.4.4 Quadrupole time-of-flight-mass spectrometry (QqTOF-MS) 
The second low-energy CID-MS/MS platform used in this study was the QqTOF 
mass spectrometer.  This is a hybrid instrument made up of two different mass 
analysers; a quadrupole mass analyser and a TOF mass analyser, coupled via a 
collision cell where low-energy CID takes place.  The components are arranged 
in series.  Thus, the QqTOF mass spectrometer is an “in-space” MS/MS platform.  
The instrument benefits from the ability of the quadrupole to isolate precursor 
ions with unit mass resolution and the TOF’s low limit of detection and capacity 
to record mass spectra with high speed and mass resolution, thus making 
accurate mass measurements (AMMs) of complex mixtures possible.41, 111  
 
The first QqTOF mass spectrometer was reported by Glish and Goeringer.112  
This instrument was constructed such that the quadrupole and the TOF were 
aligned on the same axis.  This configuration was compatible with the ionisation 
technique selected; thermal ionisation following desorption from a probe.  The 
compatibility arises from the requirement of the acceleration plates of the TOF 
to be operated in a pulsing fashion, thus facilitating transfer of ions along the 
flight tube (Figure 1.14).1  Thus, TOFs can only accept packets of ions that are 
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created by pulsed ionisation techniques.  Therefore, the Glish and Goeringer 
designed instrument would not have been compatible with ionisation 
techniques that create ions continuously, such as ESI, because the TOF could 
not tolerate the ion beam. 
 
 
Figure 1.14 Schematic of a time-of-flight (TOF) mass analyser 
 
The interfacing of continuous ionisation techniques with TOFs was solved by 
Dawson and Guilhaus, who reported an orthogonal acceleration (oa)-TOF mass 
spectrometer.113  This configuration involves arranging the TOF perpendicular to 
the beam of ions produced by the ion source (Figure 1.15).  The ion beam is 
collimated by a charged lens and then directed into the orthogonal accelerator.  
A voltage of like potential to the ions of interest is applied to the orthogonal 
accelerator for short time periods, typically 10-100 nanoseconds (ns), to repel 
the ions and direct them into the flight tube.114  These short voltage pulses thus 
make the TOF compatible with the continuous ion source generating the ion 
beam.  The orthogonal accelerator also imparts a number of other 
advantages.115  The filling time of the orthogonal accelerator is approximately 
equal to the time taken for ions to travel along the drift tube and reach the 
detector.  This means that mass analysis can take place whilst the orthogonal 
accelerator is filling with the next packet of ions, thus leading to a high duty
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Figure 1.15 Schematic of an orthogonal acceleration-time-of-flight (oa-TOF) 
mass spectrometer 
Reproduced from reference 115 with kind permission from 
Elsevier Ltd. 
 
cycle.  Further, collimation of the ion beam and collisional cooling in the 
orthogonal accelerator leads to a population of ions that have very similar 
velocities in the axis of the TOF.76  This leads to the ions passing through the 
acceleration plates at the same time, which results in an enhancement in mass 
resolving power.  Additional increases in mass resolving power are derived from 
the ion beam being dispersed along the axis of the orthogonal accelerator, 
which means that the subset sampled into the TOF are spread sufficiently to 
obviate space charge effects.  Finally, any neutral species produced by the ion 
source will not be affected by the electric pulse generated by the orthogonal 
accelerator.  Hence, no neutrals will enter the TOF, which can lead to improved 
sensitivity and prevention of contamination of the mass analyser and detector. 
 
The ability of an orthogonal accelerator to interface continuous ionisation 
techniques, specifically ESI, with TOFs led to interest from the biological 
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community and paved the way for the development of the QqTOF mass 
spectrometer as a commercially available instrument.116  The oa-TOF was used 
as the basis for the design of the QqTOF mass spectrometer, which has an 
additional quadrupole mass analyser and a hexapole collision cell preceding the 
orthogonal accelerator (Figure 1.16).  The construction and operation of the 
two mass analysers in this hybrid instrument will be discussed below. 
 
 
Figure 1.16 Schematic of a quadrupole time-of-flight (QqTOF) mass 
spectrometer with an orthogonal accelerator116 
 
Quadrupoles are made up of four cylindrical metal rods arranged equidistant 
from one another.  Opposite pairs of rods are electrically connected as denoted 
by “A” and “B” in Figure 1.17. 
 
 
Figure 1.17 Schematic of a two-dimensional cross section of a quadrupole 
mass analyser 
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During the operation of a quadrupole, a positive potential with both a DC and 
an RF component is initially applied in the x direction i.e. to the “A” rods.  At the 
same time, an equal negative potential, also with DC and RF components, is 
applied in the y direction i.e. to the “B” rods.117  Throughout the operation of 
the quadrupole, the polarities of the two pairs of rods are alternated rapidly i.e. 
from their initial states, the “A” rods change to a negative polarity and the “B” 
rods to a positive polarity, and then back to their initial conditions.  The 
connection of the pairs of rods with opposite polarities creates an electric field 
in the x-y plane (Figure 1.17). Ions enter the quadrupole along the z-axis and 
begin to oscillate in the x-y plane.99  Assuming that the ions are positively 
charged and the polarities of the rods are in the initial state described above, 
the ions will be attracted towards the “B” rods.  However, the rapid switching of 
polarities means that the ions will then be repelled by the “B” rods and 
attracted towards the “A” rods, a situation that will again be reversed when the 
polarities are changed once more.  These cycles of attraction and repulsion lead 
to the ions undergoing a spiralling motion as they travel along the quadrupole.  
As for the QIT, the stability of the ions within the electric field is determined by 
whether their a and q values from the simplified Mathieu equation, as given by 
Equations 1.9 and 1.10, produce a coordinate in the stable region of the 
stability diagram.118  
 
Equation 1.9 
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where:  z = Number of charges on the ion 
  U = Amplitude of the applied DC voltage 
  V = Amplitude of the applied RF voltage 
  m = Mass of ion in Da 
  ω = Angular frequency of the applied RF voltage 
  ro = Distance from centre to an electrode 
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Because there is a DC component contributing to the a value, both components 
of the coordinate will have a positive value on the stability diagram (Figure 
1.18).  Ions with az, qz coordinates that map onto the stability diagram will have 
a stable trajectory through the quadrupole.  Those ions with az, qz coordinates 
outside of it will have unstable trajectories, thus leading to them striking the 
quadrupoles and becoming neutralised. 
 
 
Figure 1.18 Stability diagram in (a, q) space for a quadrupole mass analyser 
Reproduced from reference 117 with kind permission from John 
Wiley & Sons Ltd. 
 
The only variables in Equations 1.9 and 1.10 are the amplitudes of the DC and 
RF voltages.1  Thus, these values are varied during mass analysis and determine 
whether an ion of given m/z value has a stable trajectory or not.  The ratio of 
the amplitudes is fixed at a constant value, which defines the operating line 
(Figure 1.18).76  Judicious selection of the ratio will ensure that only ions that 
map onto the stability diagram at the apex are stable.  The stable region defines 
the mass resolving power of the instrument because it determines how many 
m/z values have stable trajectories through the quadrupole for a given DC:RF 
amplitude ratio.  Thus, fixing the ratio such that only a small range of m/z values 
have stable trajectories at any one time maximises the mass resolving power.118  
In the example shown in Figure 1.18, m2 has a stable trajectory at the specific 
DC and RF amplitudes selected, whilst m1 and m3 have unstable trajectories.  
Thus, only m2 would travel the length of the quadrupole and reach the next 
mass analyser or detector, depending upon the configuration of the specific 
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instrument.  To acquire a mass spectrum, the amplitudes of the DC and RF 
voltages are increased over a range whilst maintaining a fixed ratio.  This 
sequentially changes, in an increasing fashion, the m/z values that have az, qz 
coordinates at the apex of the stability diagram, and thus stable trajectories 
through the quadrupole.117  
 
The TOF mass spectrometer is structurally simple, consisting of a flight tube 
held in a vacuum, a set of acceleration plates to direct ions along the tube, and 
a detector (Figure 1.14).119  The depicted configuration is referred to as a 
“Wiley-McLaren” or linear TOF mass spectrometer.120  The flight tube is referred 
to as a field-free region because neither electric nor magnetic fields are used in 
the operation of a TOF mass spectrometer.  Mass analysis in a TOF mass 
spectrometer is performed by measuring the time that it takes for an ion to 
travel along the flight tube and strike the detector.  The variation in flight times 
for ions of different m/z value arises from the relationship between the 
potential energy of the ion when present in the electric field created by the 
acceleration plates, and its subsequent kinetic energy derived through 
conversion of its potential energy.  An ion in the electric field created by the 
acceleration plates will have a potential energy given by Equation 1.11.  When 
the ion is pushed along the flight tube by the voltage of the acceleration plates, 
it obtains a kinetic energy as described by Equation 1.12.  Assuming 
quantitative conversion of this energy, Equation 1.13 can be formed.1  
 
Equation 1.11  VEp z  where: Ep = Potential energy 
      z = Number of charges on ion 
      V = Accelerating voltage 
 
Equation 1.12  2k v
2
1
E m  where: Ek = Kinetic energy 
      m = Mass of ion in m/z units 
      v = Velocity 
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Equation 1.13  2v
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The velocity term can be expressed in terms of the time, t, required to travel the 
length of flight tube, d (Equation 1.14); 
 
Equation 1.14  
t
d
v   where: v = Velocity 
      d = Distance 
      t = Time 
 
Substitution of Equation 1.14 into Equation 1.13 produces Equation 1.15; 
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Rearrangement of Equation 1.15 to express t in terms of the other parameters 
shows that the time taken to travel the length of the flight tube is proportional 
to the square root of the m/z value of the ion (Derivation 1.1).121  This can be 
simplified to Equation 1.16 because V and d are constant and hence can be 
expressed as k.  Thus, ions with lower m/z values will have shorter flight times 
than those of greater m/z values. 
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Equation 1.16  
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Thus far, a linear TOF mass spectrometer has been discussed i.e. the ions travel 
in a straight line between the acceleration plates and the detector.  However, 
this arrangement leads to very poor mass resolution; approximately 300-500 full 
width at half maximum (FWHM).122  This is because ions of the same m/z value 
generated by the ion source have both a spatial distribution i.e. they do not 
occupy an infinitesimally small space, and an energy distribution.  The spatial 
distribution means that ions of a given m/z value will reach the acceleration 
plates at different times.  Therefore, once accelerated, they will also reach the 
detector at different times, leading to peak broadening.  The energy distribution 
causes ions of the same m/z value to have different kinetic energies.  Derivation 
1.1 shows that the flight time is inversely proportional to the square root of the 
accelerating voltage.  Therefore, if ions of the same m/z value have different 
amounts of kinetic energy, their flight times will be different and peak 
broadening will result.  Furthermore, there are variations in the effect that the 
electric field has on the ions, which results from their spatial distribution.  This 
leads to ions of the same m/z value receiving different amounts of energy when 
they are accelerated, thus leading to a spread of kinetic energies.  Again, this 
leads to broader peaks than would be obtained if all ions of the same m/z value 
had equal kinetic energies.  The combined effects of the spatial and energy 
distribution of the ions leads to a significant deterioration in the mass resolving 
power of the linear TOF mass spectrometer.123 
 
Two approaches are used to improve the mass resolving power of TOF mass 
spectrometers.  The first is the use of time-lag focussing (TLF),120 which is 
sometimes referred to as pulsed-ion extraction (PIE)124 or delayed extraction 
(DE).125  This feature decouples the extraction of ions from the ion source and 
their acceleration down the flight tube i.e. ions are not continuously accelerated 
as soon as they are formed by the ion source.123  By allowing a short period of 
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time (between hundreds of ns to several microseconds *μs+)1 to elapse before 
applying the acceleration voltage, the ions are allowed to cool in the ion source.  
This helps to minimise the distribution of kinetic energies of ions of the same 
m/z value such that the spread of their flight times is tighter once accelerated.50  
Further, the ions separate according to their kinetic energies during the period 
between their formation and their acceleration because no force is acting upon 
them.  This results in ions of the same m/z value with greater kinetic energies 
drifting towards the detector due to the enhanced effect of the potential 
gradient.  When they are extracted from the ion source and accelerated along 
the flight tube, the applied voltage has a greater effect on those ions that have 
spent longer in the source and are further from the detector i.e. those with 
lower kinetic energies.1  The net result of the ions receiving different amounts 
of kinetic energy from the application of the accelerating voltage is that the ions 
that initially possessed less kinetic energy catch up with those that were more 
energetic at the outset.  Thus, the kinetic energy and spatial distributions of the 
ions are reduced, resulting in improved mass resolving power.41 
  
The second approach to improve the mass resolving power of a TOF mass 
spectrometer is the addition of a reflectron to the instrument (Figure 1.16).  
This is a stack of ring electrodes that typically have equal differences in voltage 
between them, creating a linear electric field.41  The lowest voltage is applied to 
the electrode nearest the orthogonal accelerator and the detector, with the far 
most electrode having the highest voltage.  The applied voltage creates an 
electric field that acts in the direction opposite to that produced by the 
orthogonal accelerator.76  This has the effect of reversing the flight direction of 
the ions.  The purpose of the reflectron is to correct for the differing velocities 
of ions of the same m/z value, which results from them possessing different 
amounts of kinetic energy.  This is achieved by causing ions with greater 
amounts of kinetic energy to undergo longer flight paths than ions of slower 
velocities.41  The ion beam penetrates into the reflectron after its passage from 
the orthogonal accelerator, whereby the ions are eventually repelled back 
towards the detector.  However, the distance of penetration by a given ion is 
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dependent upon its kinetic energy.  Increasing kinetic energies allow increased 
penetration, and thus longer residence times in the reflectron, before the ion’s 
direction is reversed.126  Therefore, for ions of the same m/z value but different 
kinetic energies, the faster travelling ions will traverse the flight tube quicker 
and enter the reflectron before the slower ones arrive.  However, the ions with 
greater kinetic energies will spend longer in the reflectron than the ions with 
less kinetic energy.  Hence, the difference in residence time, and thus flight path 
length, means that the ions of the same m/z value but different kinetic energies 
strike the detector at the same time, thus improving mass resolving power.127  
The use of a reflectron further increases the mass resolving power of a TOF 
mass spectrometer because the flight length is increased without having to 
make the instrument bigger, which would necessitate greater vacuum pumping 
capacity.121  Mass resolving power is increased because flight times scales 
linearly with the distance to be travelled (Derivation 1.1).  Thus, two ions of 
different m/z values with a constant difference in velocity will become 
increasingly separated in arrival time at the detector as the flight length 
increases.  This leads to a lower chance of overlap between peaks of different 
m/z values, thus improving the mass resolving power. 
 
Low-energy CID is performed on a QqTOF mass spectrometer using a collision 
cell, which is positioned between the two mass analysers.  This is an RF-only 
quadrupole, hexapole or octopole that contains the gas with which the ions of 
interest collide, leading to an increase in their internal energy.76  The pressure 
inside the cell is typically maintained at approximately 10 μbar, although this 
can be varied to affect the number of collisions that the ions undergo and thus 
the extent to which their internal energy is raised (Equation 1.6).128  The 
collision energies can be tuned through varying the accelerating voltages 
applied to the poles of the cell.  Only RF voltages are used so that all of the 
precursor and product ions have stable trajectories inside the collision cell.  This 
is because the absence of a DC component means that all of the ions will be 
positioned on the q-axis of the stability diagram (Figure 1.18).  This region is 
within the boundaries that define whether an ion has a stable trajectory or not 
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as it passes through the poles.  Hence, as all of the ions have stable trajectories, 
no mass filtering will take place.  Thus, all of the ions will traverse the collision 
cell and enter the orthogonal accelerator, and subsequently the TOF mass 
analyser.  Unlike the QIT, dissociation of product ions can take place inside a 
collision cell.  This is because the acceleration of ions of as they pass through 
the collision cell does not discriminate between precursor and product ions c.f. 
QIT where resonance excitation only causes the precursor ion to undergo high-
energy collisions with the buffer gas.  Thus, the formed product ions can 
undergo energetic collisions with the gas atoms or molecules before exiting the 
cell, which causes an increase in their internal energies.  This can facilitate 
further fragmentation, which is referred to as second-generation dissociation. 
 
1.4.5 Fourier transform-ion cyclotron resonance-mass 
spectrometry (FT-ICR-MS) 
The final low-energy CID-MS/MS platform used in this study was the FT-ICR 
mass spectrometer.  This instrument was used to acquire AMMs.  The ultra-high 
mass resolving power of this instrument makes AMMs possible, with accuracies 
of sub-parts-per-million (ppm) having been reported by McKenna and co-
workers in the identification of vanadyl porphorins.129  
 
FT-ICR-MS instruments have a trap mass analyser, which uses a combination of 
electric and magnetic fields to trap the ions c.f. a QIT which uses only electric 
fields.130  The magnetic field is typically generated using a superconducting 
magnet rather than a permanent magnet or an electromagnet.  This is because 
the latter two varieties are only capable of producing weak magnetic fields, and 
as will be seen below, advantages are gained from using increasingly strong 
magnets.131, 132  
 
Figure 1.19 shows a schematic of an FT-ICR-MS cell.  The cell is made up of 
three pairs of electrically connected plates; trapping plates, excitation plates 
and detection plates.  Ions enter the cell along the axis of the magnetic field but 
initially feel no force from it in this direction. 
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Figure 1.19 Schematic of a cubic FT-ICR-MS cell detailing the electrical 
connection of the pairs of plates and the direction of the 
magnetic field, B 
Reproduced from reference 134 with kind permission from John 
Wiley & Sons Ltd. 
 
To retain the ions in the cell, an electric current is applied to the trapping plates 
to create a potential well.133  The plates are positioned perpendicular to the 
magnetic field and a low potential of approximately 1 V is used to trap the 
ions.130  The magnetic field does impart a force on the ions in the plane 
perpendicular to their motion as they enter the cell.  The force, known as the 
Lorentz force, is given by Equation 1.17. 
 
Equation 1.17  FL = zVB where: z = Number of charges on ion 
      V = Velocity of ion 
      B = Magnetic field strength 
 
The Lorentz force causes the ions to be bent into a circular motion that is 
perpendicular to the plane of the magnetic field (Figure 1.20).  This is referred 
to as the cyclotron motion.134  
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Figure 1.20 The cyclotron motion of ions in a uniform magnetic field.  The 
magnetic field is in the direction of the plane of the paper.  
Positive and negative ions orbit in opposite directions 
 
The ions also describe two other motions inside the cell.  The ions undergo 
simple harmonic oscillation in the direction of the electric field created by the 
trapping plates; the so-called trapping motion.  Finally, the combination of the 
electric and magnetic fields induces a third motion called the magnetron 
motion.  This causes the ions to move in larger circular orbits in terms of radius 
than those described by the cyclotron motion, as shown in Figure 1.21.133  
 
 
Figure 1.21 Three fundamental motions described by ions trapped in an FT-
ICR-MS cell 
Reproduced from reference 131 with kind permission from John 
Wiley & Sons Ltd. 
 
Only the cyclotron motion is analytically useful.  From the frequency of these 
orbits, the m/z value of an ion can be determined.  The equation for cyclotron 
frequency (Equation 1.18) shows that the only variable is the m/z value of the 
ion. 
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Equation 1.18  
m2π
B
fc
z
 where: z = Number of charges on ion 
      B = Magnetic field strength 
      m = Mass of ion in Da 
 
The high mass resolving power of FT-ICR-MS stems from the fact that the m/z 
value of the ions is the sole variable that dictates the cyclotron frequency.  Thus, 
the cyclotron frequency is independent of an ion’s velocity, which correlates 
with its kinetic energy, and its location in the cell.  Hence, no energy or spatial 
focussing is required to allow accurate m/z values to be determined, which 
results in the ability to acquire high-resolution mass spectra c.f. TOF mass 
analysers whereby an increased spatial and energy distribution of the ions leads 
to a deterioration in the mass resolving power.135 
 
To measure the cyclotron frequency of an ion, it is first excited to increase the 
radius of the cyclotron motion.  The initial radius is much smaller than the 
dimensions of the cell and is insufficient to generate a recordable signal in the 
detection plates.133  The radius of the orbits of ions of a given m/z value is 
increased by applying an RF voltage to the excitation plates with a frequency 
that is in resonance with the m/z value’s characteristic cyclotron frequency.136  
This causes the ions to experience an outward force, which increases their 
kinetic energies and results in them moving coherently to an orbit of larger 
radius in a spiralling motion (Figure 1.22).133  A number of m/z values can be 
excited to larger radii cyclotron orbits by applying a range of frequencies.  This is 
achieved by performing a fast frequency sweep, referred to as an RF chirp.133 
 
Detection of ions is achieved by measuring the alternating current induced in 
the detection plates by the orbiting packet of ions, referred to as the image 
current.137  As the ions move past each detection plate, they attract electrons 
through the external circuit towards the plate (Figure 1.22).  The movement of 
electrons from one plate to the other as the ions orbit creates the alternating 
current, the frequency of which is equal to the reduced cyclotron frequency i.e.
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Figure 1.22 Excitation of ions to a larger radius cyclotron motion by the 
application of a resonant frequency RF voltage to the excitation 
plates and detection of ions using the image current generated 
in an external circuit 
Reproduced from reference 134 with kind permission from John 
Wiley & Sons Ltd. 
 
the difference between the cyclotron frequency and the magnetron frequency.  
The magnetron frequency is proportional to the trapping voltage used 
(Equation 1.19).133  Therefore, the cyclotron frequency of a given m/z value will 
be reduced by increasing amounts with increasing trapping voltage.  This 
prevents the frequency of the image current being used to determine the m/z 
value of the ion creating it from Equation 1.18.  However, this does not prevent 
AMMs being acquired using FT-ICR-MS, because calibration of the instrument 
can account for the reduction in the cyclotron frequency that results from the 
applied electric field used to trap the ions.133  The use of standard compounds 
of known elemental composition allows reduced cyclotron frequencies to be 
assigned to particular m/z values.  This allows for the production of a calibration 
line, applicable at the specific trapping voltage, from which the m/z value of an 
unknown can be interpolated from its recorded reduced cyclotron frequency.133  
 
Equation 1.19  
Bπa
αV
f
2m
    
 
where: α = Geometry factor dependent upon the shape of the cell 
 V = Amplitude of the applied trapping voltage 
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 a = Distance between the trapping plates 
 B = Magnetic field strength 
 
If multiple ion packets of different m/z values are detected, the signal that is 
produced is an overlay of sinusoidal waves of different frequencies and 
amplitudes (Figure 1.23).130  This complex signal is referred to as a transient, 
and is in the time domain.  The complexity of the signal prevents simple 
mathematical treatment to derive the m/z value of the ions from the calibration 
line because it is a composite of a number of signals.  However, frequency 
components from the time domain transient can be derived by applying a fast 
Fourier transform.  This deconvolutes the signal and generates a frequency 
spectrum, which can be converted to a mass spectrum using the previously 
determined calibration line.133  
 
 
Figure 1.23 A time domain transient 
Reproduced from reference 133 with kind permission from John 
Wiley & Sons Ltd. 
 
Improved signal-to-noise ratio and mass resolving power is obtained with 
transients of increasing lengths of time, as detailed by the relationships in 
Equations 1.20 and 1.21.  Acquisition of long transients is possible because the 
detection process is non-destructive.  Thus, the ions can be remeasured on a 
number of occasions.  To prevent ion loss, and thus enable remeasurement, an 
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ultra-high vacuum is used to maintain pressures of 1 x 10-8 – 1x10-9 mbar inside 
the cell.  This minimises the numbers of neutrals present that can collide with 
the ions, thus causing their neutralisation.  Transient lengths are not infinite 
however, with residual neutral molecules eventually causing loss of coherence 
of the ion packets.  The longest transients are of the order of a minute in 
length.133  
 
Equation 1.20  nN:S  where: n = number of scans 
 
Equation 1.21  
2
Tf
R c  where: fc = cyclotron motion frequency 
      T = duration of transient 
 
Although both “in-time” MS/MS trapping instruments, low-energy CID is 
performed in a slightly different manner in the FT-ICR mass spectrometer 
compared to the QIT mass spectrometer.  Firstly, the collision gas is pumped 
into the FT-ICR cell in a pulsing fashion.  This briefly increases the pressure 
inside the cell to facilitate low-energy CID, but can not be maintained there due 
to its hindering effect on detection and is thus rapidly pumped away c.f. QIT 
where the helium gas is present in the mass analyser throughout the 
experiment.  This process can take several seconds (s), meaning that low-energy 
CID-MS/MS experiments using FT-ICR mass spectrometers have a low duty 
cycle.138  The second key difference is that there is no LMCO, meaning that all 
product ions can be trapped and mass analysed.139  Like the QIT, the trapping 
capability of the FT-ICR mass spectrometer facilitates MSn experiments.138  
 
Isolation of the precursor ion of interest is most commonly performed using the 
stored-waveform inverse Fourier transform (SWIFT) technique.140  This 
waveform excites all ions present in the cell to orbits of larger radii.  The energy 
imparted to the undesired ions is sufficient to increase the radii such that they 
collide with the walls of the cell, thus leading to their neutralisation and 
subsequent removal by the vacuum system.136  Concurrently, the ion of interest 
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is also excited to a larger cyclotron motion radius, leading to an increase in its 
kinetic energy.  However, only half the energy imparted to the undesired ions is 
applied to the ion of interest so that its cyclotron motion radius is not increased 
to such an extent that it strikes the walls of the cell.133  The excited ions of 
interest then undergo collisions with the gas that is pumped into the cell, which 
increases their internal energy and facilitates dissociation. 
 
The excitation frequency used to excite the precursor ions of interest to a larger 
cyclotron motion radius is “off-resonance” i.e. not equal to the frequency of the 
ion’s cyclotron motion.  Hence, the activation technique is referred to as 
sustained off-resonance excitation (SORI)-CID.141  This approach is used to 
enable more efficient detection of the product ions than is possible with an “on-
resonance” excitation frequency like the one used in the QIT.133  Using an on-
resonance excitation frequency, the product ions are a significant distance from 
the centre of the cell when they are produced, which means that they cannot 
be formed into as coherent a packet for detection.  This has an adverse effect 
on the mass resolution of the resulting mass spectrum.133  Low-energy SORI-CID 
overcomes this by applying an excitation frequency that is slightly off-resonance 
of the cyclotron frequency of the precursor ions of interest.  This results in the 
precursor ions being alternately in-phase and out-of-phase with the applied 
frequency.133  Hence, the precursor ions experience periodic increases and 
decreases in their cyclotron motion radii, and therefore their kinetic energy.136  
The amplitude of the applied frequency is maintained at a low value so that the 
precursor ions do not travel far from the centre of the cell.133  This, in 
combination with their intermittent decrease in radii towards the centre of the 
cell, means that the product ions formed from dissociation of the precursor ion 
are also located at the centre of the cell.  This then allows them to be excited as 
a coherent packet for detection.  Thus, low-energy SORI-CID improves the 
efficiency and mass resolution with which the product ions can be detected.133  
 
 
Chapter 2 
42 
Chapter 2 
 
The use of mass spectrometry in pharmaceutical 
drug metabolite identification and characterisation 
 
2.1 Introduction to pharmaceutical drug metabolism 
The term metabolism describes a reaction, or series of reactions, in a biological 
system that converts a given molecule into a different compound or 
compounds.142  The intermediates and products of these reactions are called 
metabolites.143  Metabolites are produced from compounds that have essential 
biological functions e.g. carbohydrates, lipids, vitamins etc., and also 
xenobiotics.  A xenobiotic is defined as any compound that is not ordinarily 
present in a biological organism or is present at a concentration much higher 
than usual due to uptake from an external source.144  A pharmaceutical 
compound is therefore classed as a xenobiotic. 
 
Pharmaceutical compounds are metabolised because the biological organism 
(either human or animal) recognises it as a xenobiotic.  As a defence mechanism 
to prevent accumulation of xenobiotics, the organism reacts by attempting to 
eliminate the compound through a combination of physical and chemical 
means.  Physical elimination takes place by means of excretion, primarily via 
urine or faeces.144  To expedite the drug’s excretion, chemical changes are made 
to the compound, which constitutes its metabolism.  The urinary excretion of 
the lipophilic parent drug compound is an inefficient process due its limited 
solubility in water.  Therefore, the organism metabolises the compound, 
typically converting the lipid-soluble parent drug compound into a more 
hydrophilic metabolite.145  The increased hydrophilicity of the metabolite 
compared to the parent compound makes it more water-soluble, and hence 
easier to excrete via the kidneys.  Thus, metabolism increases the rate of a 
drug’s excretion from the body.146  
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Metabolism of pharmaceutical drugs consists of two stages of reactions; phase I 
metabolism and phase II metabolism.  Phase I metabolism involves 
functionalisation reactions that either produce or uncover a functional group 
through oxidation, reduction or hydrolysis.  Phase II metabolism involves the 
conjugation of an endogenous polar molecule, such as glucuronic acid, to a 
functional group either produced by phase I metabolism147 or already present in 
the parent compound.144  The phase II reactions are those that generally cause a 
significant increase in the hydrophilicity of the drug.  This facilitates its excretion 
from the body, and also decreases its volume of distribution.148  Thus, phase II 
metabolism is deemed to be the detoxifying process.  The phase I reactions do 
not deactivate the drug, and in some cases can create a metabolite that itself 
has pharmacological activity.  This behaviour can be used to positive effect in 
the case of prodrugs, which become pharmacologically active upon 
metabolism.147  
 
The focus of the presented study was to identify structurally dependent 
dissociation pathways that could be used to characterise oxidised metabolites 
formed during phase I metabolism.  The major enzymes involved in the 
oxidation of xenobiotics, including pharmaceutical drugs, are cytochrome P450s 
(CYP450s), which account for more than 90% of all oxidative reactions of this 
type.149  CYP450s are a superfamily of haem-containing enzymes with many 
different forms, which are present in all eukaryotic organisms and some 
prokaryotes.150  The different forms are divided into families based upon the 
similarity in their DNA sequences, with a 40% overlap indicating that two 
CYP450s are in the same family.  Further subdivision within a family can be 
obtained if the sequence similarity reaches 55%.  Each family has a number, and 
subfamilies are denoted by a letter in alphabetical order e.g. CYP3A, CYP3B.  
Individual family members, which must differ in DNA sequence by greater than 
3% compared to the other family members, are denoted by a number after the 
subfamily letter e.g. CYP3A4.151  A total of fifty-seven CYP450 genes belonging 
to different families have been identified in humans.152  Although structurally 
different, all CYP450s are mono-oxygenases that metabolise xenobiotics via a
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redox reaction.153  The generalised reaction is shown below;154 
  
Drug + NADPH + O2 + H
+          →        Drug-O + NADP+ + H2O 
 
Briefly, the mechanism of the redox reaction initially involves binding of the 
drug molecule to the active site of the CYP450 (Figure 2.1, step 1).  An electron 
is then transferred from reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) to the haem portion of the CYP450, which is in the ferric (Fe3+) state.  
This causes its reduction to a ferrous (Fe2+) enzyme (Figure 2.1, step 2).155  The 
reaction is mediated by a second enzyme; NADPH-CYP450 reductase.156  The 
reduced haem then binds a molecule of oxygen (Figure 2.1, step 3).  Addition of 
a second electron to the complex, donated by NADPH, in conjunction with a 
proton creates an iron-hydroperoxo intermediate i.e. Fe(II)-OOH (Figure 2.1, 
steps 4 and 5).155  Cleavage of the oxygen-oxygen bond, with concomitant 
addition of a second proton, releases a molecule of water (Figure 2.1, step 6).154  
This leaves an electron-deficient FeO3+ complex, which abstracts either a 
hydrogen atom or an electron from the drug compound depending upon 
whether a carbon atom or heteroatom is being oxidised (Figure 2.1, step 7).157  
The radical drug molecule then reacts with the hydroxyl group or the radical 
oxygen atom in the complex.  This results in the insertion of the oxygen atom 
into the molecular structure of the drug to form the metabolite (Figure 2.1, step 
8).154  The change in the drug’s molecular structure and physicochemical 
properties are such that the complex separates to release the metabolite.  This 
final step converts the CYP450 back to its original form and allows it to catalyse 
the biotransformation of another substrate molecule.157  
 
The variation in structure between CYP450s leads to different active site shapes, 
which lends a degree of substrate specificity to different isozymes.158  As a 
result, five forms of CYP450 are responsible for the oxidation of a vast majority 
of drug molecules; CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.159  In 
particular, CYP3A4 is very prominent in the metabolism of pharmaceutical 
compounds, catalysing the oxidation of greater than 50% of commonly used
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Figure 2.1 Generalised catalytic cycle of the oxidation of xenobiotics by 
CYP450s 
 Reproduced from reference 154 with kind permission from the 
American Chemical Society 
 
clinical drugs.160  These forms are predominately found in the liver, which is thus 
the primary site of pharmaceutical drug metabolism,161 although CYP450s can 
be found throughout the human body.151, 162  In the liver, CYP450s are situated 
on the membranes of mitochondria or endoplasmic reticula.150  
 
Understanding the metabolism of a NCE is of key importance to the 
pharmaceutical industry.  Metabolite identification studies are performed 
throughout the drug discovery and development process to detect, structurally 
characterise and quantify metabolites of pharmaceutical compounds.163  In 
early drug discovery, these studies provide many pieces of information that 
indicate whether a given NCE is suitable to proceed further along the discovery 
stage and into development.  The structural characterisation of the metabolites 
of a NCE can indicate those parts of the molecule that are prone to alteration by 
the metabolising enzymes.  This information, in conjunction with quantitative 
data gained from clearance studies, can allow medicinal chemists to synthesise 
more or less stable analogues of the NCE.  This can allow tailoring of the 
pharmacokinetics of the compound by altering its metabolic stability.164  
Another aim of metabolite identification studies is to identify those metabolites 
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that are not inactivated as a result of their structural change.  This can lead to 
the formation of active metabolites i.e. those that have pharmacological 
activity.  This activity can either be synergistic or inhibitory to the parent 
compound, which would affect the organism’s response to a specific dosage.  In 
contrast, the active metabolite may elicit a different pharmacological response 
than that intended by the drug as a result of acting on a different target.147  
Therefore, the identification of active metabolites can enable pharmacodynamic 
results to be rationalised.165  Finally, metabolite identification studies need to 
determine whether any reactive metabolites are formed, which can result in 
drug-induced toxicity.166  Identification of NCEs that form reactive metabolites 
in the early drug discovery stage allows a judicious selection of candidates to 
proceed to the more costly development stage.167  The identification of active 
and reactive metabolites is of particular interest in the pharmaceutical industry 
at this current time due to the recent publication of the “Metabolites in Safety 
Testing” (MIST) guidelines by the Food and Drug Administration (FDA).168  The 
MIST guidelines propose that additional safety assessments should be 
performed for compounds that produce metabolites that are only detectable in 
human plasma, or are present at much greater levels in man compared to the 
other species used to test the safety of the NCE.169  Additional safety tests are 
required in this circumstance because the effect of the metabolite in man can 
not be extrapolated from the results in animals at these greater levels of 
production.  Further, any metabolite that has a systemic exposure of greater 
than 10% of the parent compound at steady state should raise a safety 
concern.169  If this metabolite is active and present at greater than 10% of the 
parent compound, then the body may be unable to tolerate the extra burden in 
pharmacological terms if both compounds have a similar effect.  Therefore, 
additional safety assessments should be conducted before the drug is used in 
further clinical studies. 
 
To obtain an understanding of how a compound is metabolised, a combination 
of in vitro and in vivo studies are utilised in drug discovery and development.170  
Oxidised metabolites, which are the focus of the presented study, are 
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investigated in the early drug discovery process using in vitro assays that allow 
phase I metabolites to be formed.   The most commonly used in vitro test 
systems are liver microsomes and hepatocytes, with liver slices also being used 
on occasion.171  Liver microsomes, either from human or animals, offer a simple 
system to assess phase I metabolism.  Microsomes are artifactual vesicles 
formed through disruption of endoplasmic reticula, which retain the activity of 
the key enzymes involved in phase I metabolism, including CYP450s.170, 172  A 
group of enzymes involved in phase II metabolism, the uridine diphosphate 
(UDP) glucuronyl transferases, are also microsomal.  However, the cofactor 
required for glucuronidation, UDP-glucuronic acid (GA), is cystolic and thus is 
not present.  Addition of the cofactor to the test system facilitates phase II 
metabolism in vitro.  Other enzymes involved in phase II metabolism, for 
instance sulfotransferases, are not present in microsomes.173  Thus, microsomes 
do not provide a complete representation of the metabolism of a NCE.  Further, 
cofactors required for metabolism, such as NADPH are not present and their 
addition to the system is required to activate it.173  These limitations are offset 
by the accessibility of microsomes, which are commercially available, and their 
retention of activity even after long-term freezing.171, 174  This makes 
microsomes a suitable in vitro test system for the high-throughput analyses 
required by the pharmaceutical industry.  Hepatocytes are whole-cell systems 
which offer the advantage of containing all of the metabolising enzymes and 
associated cofactors at physiologically relevant concentrations.175  This means 
that both phase I and phase II metabolism can be investigated in a single test 
system.  However, hepatocytes quickly lose their activity, meaning that fresh 
cultures are favoured to provide accurate and robust results.  Thus, the 
availability of fresh hepatocytes are a restriction to their usage in metabolite 
identification studies.176  Further, isolated hepatocytes can show different 
enzymatic activity to those in a biological environment, limiting the in vitro-in 
vivo correlation that can be deduced.175  Liver slices represent the most 
complete in vitro model.171  These systems closely replicate metabolism in vivo 
because all of the relevant enzymes and cofactors are present at physiological 
relevant concentrations and retain their activity.170  However, liver slices are 
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more expensive and difficult to prepare than microsomes and hepatocytes, and 
are thus seldom used. 
 
2.2 Analytical approaches for the identification of 
pharmaceutical drug metabolites 
A range of analytical approaches are used in metabolite identification studies to 
detect, characterise and quantify the metabolites of a NCE during drug 
discovery and development.  These include nuclear magnetic resonance (NMR) 
spectroscopy,148 ultra-violet (UV) spectroscopy176 and HPLC with radioactivity 
detectors.177  The primary analytical approach utilised in early drug discovery 
metabolite identification studies is MS (see Chapter 1).178  This is because only 
small amounts of NCEs are typically available for metabolite identification 
studies.  Thus, the analytical techniques used must be capable of a low limit of 
detection to facilitate the analysis of all of the metabolites formed.  MS is 
capable of very low limits of detection, and this characteristic, in addition to its 
high selectivity when the MS/MS experiment is utilised, means that it has 
become the technique of choice for early drug discovery metabolite 
identification studies.  The ability of MS to rapidly provide structural 
information about the metabolites using MS/MS experiments also means that 
its use is favoured.148  Finally, MS is easily interfaced to HPLC.  A separation 
science is required because the matrices in which metabolites are present are 
complex mixtures containing biological molecules, such as proteins and lipids, 
salts and other endogenous compounds.145  Reversed phase (RP)-HPLC is 
favoured in pharmaceutical analyses because most drugs and metabolites are 
amenable to ionisation by ESI, which necessitates delivery of the sample in the 
solution phase using a polar solvent.178  RP-HPLC can separate the mixture of 
compounds such that they enter the mass spectrometer at different times.  The 
separation of the metabolites from the matrix components is critical to the 
success of metabolite identification studies for two reasons.  Firstly, metabolism 
of a NCE can result in the formation of isomeric metabolites e.g. two 
metabolites that have both been oxidised but at different locations.145  If these 
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two species are ionised and enter the mass spectrometer at the same time e.g. 
introduction by direct infusion, the peak due to the protonated parent 
compound plus 16 m/z units would be a composite of the two species.  Thus, 
the tandem mass spectrum would also be a composite, which could make the 
structural characterisation of the metabolites a more time-consuming and 
difficult task than if the species were separated in time.  Secondly, and arguably 
more importantly, separation helps to alleviate the problems related to matrix 
effects.  The term matrix effects refers to either enhancement or suppression of 
the mass spectrometric signal of an analyte of interest by a co-eluting 
compound that is present in the sample matrix.179  Ion suppression is the most 
problematic matrix effect in the context of metabolite identification studies.  
This is because a metabolite present in the sample may not be ionised, hence 
meaning that it is not detected nor identified i.e. a false negative result would 
be obtained.  King and co-workers conducted an in-depth comparative study to 
investigate whether solution or gas phase processes have a greater effect on 
the suppression of an analyte’s ionisation.180  This was achieved by comparing 
the suppression of the ionisation of caffeine, phenacetin and urapidil, as well as 
two proprietary compounds, using both ESI and APCI.  They concluded that, 
although gas phase processes contribute to ion suppression, solution phase 
processes predominate.  Their findings suggested that ESI is more sensitive to 
matrix effects than APCI, and thus greater ion suppression will be encountered 
using the former.  This conclusion has been supported by the research of other 
groups.181-184  However, reports of ion suppression in bioanalytical assays using 
APCI exist in the literature.184-186  This indicates that approaches towards 
eliminating, or at least minimising, matrix effects must be taken regardless of 
the ionisation technique utilised when performing metabolite identification 
studies by API-MS/MS.  Separation of the matrix components from the analytes 
of interest in time using RP-HPLC, along with the removal of interferences using 
sample preparation techniques, are the most commonly used methods of 
eliminating or reducing matrix effects.187, 188 
 
The causes and mechanisms of ion suppression differ depending upon whether
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ESI or APCI is being considered.189  In ESI, interferences that increase the surface 
tension of the charged droplets prevent solvent evaporation.190  This leads to 
fewer desolvated ions reaching the mass analyser, thus leading to a suppression 
of the signal compared to that obtained for a single component sample solely 
containing the analyte.  Matrix components that typically suppress ions by this 
mechanism are endogenous phospholipids, which are thought to coat the 
surface of the charged droplet, preventing evaporation of the solvent and hence 
droplet fission.  Phosphotidylcholines, which are zwitterions, are a major cause 
of ion suppression because of their ability to ionise using both positive ion and 
negative ion ESI.191  Non-polar analytes, such as phospholipids, are more 
difficult to separate from analytes of interest using RP-HPLC, and thus are more 
likely to co-elute and cause ion suppression.192  The presence of non-volatile 
compounds, such as salts, is proposed to have numerous ion suppressing 
effects.180  Firstly, the non-volatile compound may increase the boiling point 
and surface tension of the charged droplet.  This would slow the rate of solvent 
evaporation, potentially to the extent that the ions do not reach a radius of 
around 10 nm, which prevents field desorption as described by the IEM.189  
Further, the non-volatile compound will precipitate as the solvent evaporates 
from the charged droplet.  The analyte may co-precipitate with the non-volatile 
compound, leading to a reduction in the number of molecules which form gas-
phase ions.180  A further posited mechanism of ion suppression in ESI is the 
competition between analytes for space at the surface of the charged droplet, 
as described by Enke’s equilibrium partitioning model for singly charged ions.193  
Saturation of the surface with analyte is thought to occur at high concentrations 
of the order of greater than 10-5 molar (M), which is when the ESI response 
typically becomes non-linear.194  The competition between analytes leads to 
preferential ionisation of those at the surface, which have greater likelihood of 
entering the gas phase.15  The analytes that are more solvated and positioned in 
the bulk of the charged droplet are prevented from being desorbed.  Thus, they 
fail to form gas-phase ions.189  This form of ion suppression is proposed to affect 
polar analytes, which are more likely to be positioned in the bulk of the charged 
droplet.195  A study by Cech and Enke demonstrated this by using a series of 
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peptides, as well as surface active analytes.196  Their work showed that ESI 
response was related to the non-polar character of the peptide.  Further, it 
demonstrated that the ESI response of surface active analytes is not affected by 
a high concentration of solvated species.  Conversely, a suppression of the ESI 
response of solvated compounds was observed as the concentration of surface 
active analytes increased.  The final mechanism postulated for ion suppression 
using ESI is neutralisation of the analytes caused by reactions with interfering 
compounds after desolvation e.g. deprotonation of positively charged ions.190  
This is a gas-phase mechanism as opposed to the solution-phase processes 
detailed above.  This mechanism is proposed to occur when the interferences 
have high gas-phase basicities or acidities, to effect deprotonation or 
protonation respectively, and concentrations are sufficiently high to facilitate 
ion-molecule reactions.189  
 
The mechanisms of ion suppression using APCI are different to those when ESI is 
employed because there is no competition between analytes and interferences 
to enter the gas phase, and much less competition to become charged.  
Entrance into the gas phase is not competitive because all of the thermally 
stable neutral species are transferred from the solution phase by the heated gas 
stream in the source.189  The competition to become charged occurs at higher 
concentrations than in ESI because an excess of reagent ions is typically formed.  
Thus, more interfering compounds can be tolerated before ion suppression 
occurs.197  Gas-phase reactions are a major source of ion suppression in APCI, as 
the ionisation technique is ideally suited to facilitating ion-molecule reactions.  
Therefore, as with ESI, suppression can occur via gas-phase reactions with 
interferences possessing high gas-phase basicities or acidities.189  A related 
mechanism is the change in the efficiency of charge transfer from the corona 
discharge needle as a result of the matrix components.185  Finally, because APCI 
is a gas-phase ionisation technique, the precipitation of non-volatile interfering 
compounds as the solution evaporates may cause co-precipitation of analyte 
molecules, leading to their loss and thus suppression of the ion signal.180 
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Once a metabolite has successfully formed a gas-phase ion and been sampled 
into the mass analyser, the typical protocol to identify and characterise it by MS 
is to first acquire a full scan spectrum i.e. no ion activation technique is utilised 
to induce dissociation.  From the protonated molecule observed, the structural 
change can be deduced.  For example, a mass shift of +16 m/z units for a 
metabolite compared to the parent compound would suggest that oxidation has 
taken place, whilst a mass shift of -14 m/z units would indicate that 
demethylation has occurred.  The metabolite is then dissociated, routinely by 
low-energy CID, so as to facilitate its structural characterisation.  The 
interpretation approach most commonly used to localise the site of metabolism 
is the “Shift technique”.198  This involves comparing the low-energy CID product 
ion spectra of the parent compound and the metabolite and looking for major 
product ions that are mass shifted.  Based upon the assumption that the 
dissociation of the two ions are very similar as only a small modification has 
been made, the product ions of the metabolite that are mass shifted compared 
to the parent compound are those that have been structurally altered during 
metabolism (Figure 2.2).  The schematic shows a parent drug compound that 
dissociates to form three product ions; A, B and C (Figure 2.2a).  Upon oxidation 
of the portion of the molecule that forms product ion C, the metabolite 
dissociates to form product ions A and B at the same m/z values as for the 
parent compound (Figure 2.2b).  However, as the result of the addition of an 
oxygen atom, the product ion due to the C part of the molecule is mass shifted 
by +16 m/z units compared to that observed for the parent compound (Figure 
2.2b).  The peak denoted in red represents that originally observed in the low-
energy CID product ion spectrum for the parent compound, which is mass 
shifted to the m/z value equal to “C + O” in the low-energy CID product ion 
spectrum of the oxidised metabolite. 
 
The limitation of the Shift technique is that unambiguous assignments are 
frequently not possible.  This is particularly true for oxidised metabolites.  For 
example, a product ion mass shifted by +16 m/z units in the low-energy CID 
product ion spectrum of the metabolite compared to the parent compound
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Figure 2.2 Schematic of the Shift technique approach to the identification 
of the site of metabolism of a NCE using low-energy CID-MS/MS 
 
would lead to the deduction that oxidation has taken place on the portion of 
the molecule represented by that ion.  However, oxidation can take place at 
carbon, nitrogen and sulfur atoms; all common constituents of small molecule 
NCEs.  Thus, the product ion may contain more than one atom that can be 
oxidised, precluding the definitive identification of the site of oxidation.  A 
recent example of this ambiguity was observed in the investigation of the in 
vitro metabolism of dasatinib in rat, monkey and human (Figure 2.3).199  In this 
study, the authors were only able to localise oxidations to the N-(2-chloro-6-
methylphenyl)formamide and the 2-(piperazin-1-yl)ethanol substructures.  
Many other such examples of ambiguity in the characterisation of oxidised 
metabolites formed both in vitro and in vivo exist in the literature.175, 200-203 
 
 
Figure 2.3 Molecular structure of dasatinib 
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Being able to specify the portion of a NCE that is metabolised is useful 
information to medicinal chemists in their endeavours to improve its metabolic 
stability.  However, faster and more efficient production of metabolically stable 
analogues could be achieved if the specific atom that has been oxidised could 
be identified. 
 
A number of approaches have been reported in the literature to discriminate 
between C-, N- and S-oxides, many of which can be achieved rapidly.  Further, 
some of the methods also facilitate the definitive localisation of the site of 
oxidation.  The approaches for the identification and characterisation of C-. N- 
and S-oxides will be considered in turn. 
 
A number of wet chemistry approaches have been reported for identifying C-
oxidised metabolites, one of the most commonly applied being the use of 
solution-phase hydrogen/deuterium (H/D) exchange experiments.  These can be 
conducted either off-line204 or on-line using HPLC.205, 206 Further, gas-phase H/D 
exchange has also been demonstrated.207, 208  Oxidation of a carbon atom 
creates a hydroxyl group, whilst oxidation at nitrogen and sulfur atoms forms 
N+-O- and S+-O- bonds respectively.  Thus, only C-oxidation creates a functional 
group with an exchangeable hydrogen atom.171  This can be exchanged for a 
deuterium atom in solution when the metabolite is dissolved in a solvent 
containing acidic deuterons e.g. deuterium oxide (D2O).  Therefore, if the 
oxidised metabolite has been hydroxylated, its recorded m/z value will mass 
shift according to the number of deuterium atoms incorporated into its 
structure e.g. 1 m/z units for a mono-oxidised metabolite, 2 m/z units for a di-
oxidised metabolite etc., plus an equal number of m/z units to the number of 
exchangeable hydrogen atoms in the parent compound’s ion structure.  The 
absence of any additional exchangeable hydrogen atoms in a N- or S-oxide 
compared to the parent compound means that both the parent compound and 
the metabolite will be mass shifted by the same number of m/z units.  Thus, a C-
oxide can be discriminated from an N- or S-oxide.  The drawback of this method 
is that it can not always determine which carbon atom has been oxidised.  
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Instead, it can only provide information on the portion of the molecule that has 
been biotransformed.  Further, the cost of deuterated solvents is high, meaning 
that routine application may be precluded.  Derivatisation reagents can also be 
used to selectively react with hydroxyl groups to identify their presence.  The 
use of derivatisation in metabolite identification studies has been reviewed by 
Liu and Hop.209  Many derivatisation reagents will not only show selectivity for 
hydroxyl functionalities, thus discriminating between and C-oxides and N- and S-
oxides, but will also demonstrate selectivity towards either aliphatic or aromatic 
hydroxyl groups.  This can aid in determining the site of oxidation.  For example, 
discrimination between aliphatic and aromatic hydroxyl groups can be achieved 
using acetic anhydride in water.  This reagent will selectively acetylate aromatic 
hydroxyl groups whilst being unreactive towards aliphatic hydroxyl 
functionalities.  The drawback of this approach is that partial or complete 
acetylation of amine groups can also occur.171  This is particularly true under 
aqueous conditions, whereby the more nucleophilic amine groups are readily 
acetylated whilst the hydroxyl groups are prohibited from reacting due to the 
presence of water.209  Therefore, more stringent control of reaction conditions 
is required for this method to be successful.  Diazomethane and diazoethane 
can also be used to selectively react with aromatic hydroxyl groups.  However, 
these reagents can also react with other functionalities, in this case carboxylic 
acids, which may complicate data interpretation.209  The use of Jones reagent 
(chromium trioxide in concentrated sulfuric acid) can allow discrimination 
between primary and secondary alcohols, because the former produces a 
carboxylic acid upon oxidation whilst the latter forms a ketone.210  A reported 
example is the discrimination of two hydroxylated metabolites of pioglitazone 
(Figure 2.4).211  
 
 
Figure 2.4 Molecular structure of pioglitazone 
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In this study, a previously unreported oxidised metabolite was identified.  The 
MS/MS dissociation pattern was used to identify the oxidation product as a 
hydroxylated compound, due to the loss of water, and localise the site of 
oxidation to the 2-(5-ethyl-2-pyridyl)ethyl substructure.  However, it was not 
possible to determine whether the hydroxylation site was a primary, secondary 
or aromatic carbon atom.  A known oxidised metabolite of pioglitazone (Figure 
2.5), which has a hydroxyl group on the α-carbon of the ethyl group, also has 
the same MS/MS dissociation pattern but a different retention time in the HPLC 
chromatogram. 
 
 
Figure 2.5 Molecular structure of known hydroxylated pioglitazone 
metabolite 
 
Treatment of the crude sample with Jones reagent produced two different 
products.  The known metabolite formed a keto-product as expected, and thus 
formed a compound that gave a signal 2 m/z units lower than the precursor.  
The unknown metabolite formed a product that was 16 m/z units greater in 
mass than the precursor.  This indicated that a carboxylic acid-containing 
species had been formed.  From this conclusion, it was deduced that the 
precursor must contain a primary alcohol and hence the metabolite was 
definitively structurally characterised as shown in Figure 2.6. 
 
 
Figure 2.6 Molecular structure of unknown hydroxylated pioglitazone 
metabolite deduced using derivatisation with Jones reagent and 
HPLC-MS/MS 
 
The limitations of all of these derivatisation methods are that extra analysis
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time is required,212 which also increases costs, and that losses of trace 
metabolites can occur during the reaction.  In many cases, definitive localisation 
of the site of oxidation is also not possible.  A faster approach to derivatisation 
that minimises the possibility of sample degradation is the use of ion-molecule 
reactions in the gas phase between a protonated analyte and neutral reagent 
gas; a process which can be automated.  The use of dimethylethoxyborane 
(DEMB) facilitates a reaction with primary, secondary and tertiary hydroxyl 
groups, resulting in the formation of an adduct minus a molecule of 
methanol.213  However, DEMB is not selective and will also react with 
aldehydes, esters, ethers and ketones in the same manner.  This was overcome 
in the reported study by using gas-phase H/D exchange experiments after the 
derivatisation reaction.  The hydroxyl derivatives contain a single exchangeable 
hydrogen atom; a structural feature that is not found in any of the other 
derivatives.  Hence, hydroxyl-containing precursors could be distinguished.213  
The number of hydroxyl groups in a polyol can also be determined using ion-
molecule reactions with either DEMB214 or trimethylborate (TMB).215  This can 
discriminate a C-oxide from N- and S-oxides because the former will have one 
greater number of hydroxyl groups than the parent compound, whilst the other 
two types of metabolite will have the same number.  The study using DEMB was 
demonstrated to be compatible with HPLC, which is crucial in metabolite 
identification studies.  However, the limitation of ion-molecule reactions, as 
with condensed-phase derivatisation, is that definitive identification of the 
carbon atom that has been oxidised is frequently not possible.  Further, the 
cited studies were all performed on FT-ICR mass spectrometers, which are 
expensive and thus not readily available.  Hence, implementation as a routine 
application is unlikely.  An analytical approach that can allow the discrimination 
of aliphatic and aromatic hydroxylation is through the use of diagnostic 
dissociation behaviour.  The loss of water under low-energy CID conditions has 
been suggested as being an indicator of aliphatic hydroxylation.216  In a study of 
loratadine metabolism, the loss of water was favoured from the aliphatic 
hydroxylated metabolite compared to the aromatic hydroxylated desloratadine 
metabolite.  This allowed discrimination between the two metabolites in this 
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study.  However, a comprehensive study assessing whether aliphatic 
hydroxylation always leads to a more favourable loss of water than aromatic 
hydroxylation has yet to be conducted.  Further, the robustness of this 
approach to discriminate between C-oxides and N- and S-oxides is questionable.  
This is because in the same study, the piperidine-N-oxide and pyridine-N-oxide 
metabolites of loratadine, neither of which contained hydroxyl groups, also
showed losses of 18 m/z units, which corresponds to a molecule of water, in 
their low-energy CID product ion spectra.216  
 
Both analytical and wet chemistry approaches have also been demonstrated to 
identify N-oxides.  Ramanathan and co-workers showed that N-oxides undergo 
thermally-induced deoxygenation when using APCI; a trait not reported for C- 
and S-oxides.216  Subsequent work observed similar behaviour using an ESI ion 
source with a heated transport capillary and proved that the loss of oxygen was 
not due to in-source CID.217  The abundance of the loss of oxygen was also 
shown to be independent of the length of the heated capillary/ion transfer 
tube, indicating that the kinetics of the reaction are fast.218  The same loss has 
also been observed using APPI.219  Another analytical approach utilises the 
chromatographic behaviour of N-oxides using RP-HPLC.  Under these conditions, 
N-oxidised metabolites have been observed to elute after the parent 
compound, despite being of greater polarity.165, 199, 220-222  However, this is not 
generic behaviour, and examples of N-oxidised metabolites that elute prior to 
the parent compound are also reported in the literature.216, 223  Wet chemistry 
approaches are also evident in the literature for the identification of N-oxides.  
Selective reduction of N-oxides back to their amine parent compounds has been 
achieved by adding titanium chloride (TiCl3) directly to plasma and urine 
matrices.224  The identification of an N-oxide was demonstrated for a 
proprietary compound where the low-energy CID product ion spectrum was 
ambiguous and suggested the formation of either a C- or N-oxide.  Further, TiCl3 
was able to quantitatively reduce the N-oxide group in a di-oxidised metabolite 
containing both an oxidised piperidine nitrogen and an oxidised thioether 
sulfur, thus demonstrating the selectivity of the reagent.  The drawback of the 
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method is the long reaction time (60-90 minutes), thus limiting its usage in a 
high-throughput environment.  The Kenttämaa group has published a number 
of papers detailing functional group selective ion-molecule reactions between 
protonated analytes and neutral reagent gases.  Reagents have been identified 
that can characterise monofunctional primary amine-N-oxides,225 aromatic 
tertiary amine-N-oxides226, 227 and aliphatic tertiary amine-N-oxide.227  The 
adduct-forming reactions with dimethyl disulfide,225 2-methoxypropene,226 
tri(dimethylamino)borane227 have potential application in metabolite 
identification studies because the reagents selectively react with N-oxides but 
not amine functionalities.  However, as with the ion-molecule reactions used to 
identify hydroxyl-containing compounds, all of the studies were performed on 
instruments with limited availability; either FT-ICR or modified QqQ mass 
spectrometers.  Thus, the experiments may not be possible in all laboratories.  
Further, the reactions occur on an extended time-scale; generally in the region 
of seconds.  Therefore, the duty cycle of the experiment i.e. the time taken for 
the gas-phase ion-molecule reaction to take place and the products to be 
detected by the mass spectrometer, may not be compatible with the time-scale 
of the chromatographic separations used in metabolite identification studies.  
Indeed, none of the cited studies used HPLC as a method to introduce the 
samples into the mass spectrometer.  Reaction times of the order of 500 ms 
have been suggested as being suitable for HPLC-MS applications.228  A limitation 
common to all of the discussed approaches for N-oxide identification is that 
they give no indication of the site of oxidation, except for the ion-molecule 
reaction between protonated primary N-oxides and dimethyl disulfide.225  Two 
examples of definitive localisation of the site of oxidation for N-oxides involve 
structurally dependent dissociation pathways.  Ma and co-workers elucidated a 
thermally induced structurally dependent dissociation pathway that definitively 
identified the oxidised nitrogen atom in a series of model N-oxide 
metabolites.219  They showed that a Meisenheimer rearrangement preceded 
the loss of an aldehyde or a ketone, which took place at a tertiary amine-N-
oxide containing an alkyl or benzyl group.  This structural specificity allowed the 
nitrogen atoms in the analysed compounds (both pharmaceuticals and other 
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small molecules) to be discriminated.  The rearrangement and thermally 
induced dissociation was shown to be specific for the tertiary amines analysed 
because the analogous loss was not observed for the aromatic N-oxide 
metabolite of 2-(methylsulfonylmethyl)-pyridine-N-oxide.  Lay and co-workers 
utilised high-energy FAB-MS and FAB-CID-MS/MS to show that the losses of 
dimethylamine and N,N-dimethylhydroxylamine were observed for a series of 
ethylenediamine, ethanolamine and propylamine antihistamine drugs and their 
tertiary amine-N-oxides respectively.229  These diagnostic losses provided an 
approach to localise the site of oxidation to the tertiary amine substructure.  
However, equivalent data under low-energy CID conditions has never been 
reported.   
 
Of the three types of oxidised metabolite, S-oxides have the fewest reported 
rapid and definitive identification approaches in the literature.  No examples of 
derivatisation reagents that are selective towards S-oxide functionalities are 
evident in the literature.148, 209  Further, no details of ion-molecule reactions 
that facilitate their identification could be sourced.  Thus, the only reported 
method for rapid and definitive identification of sulfoxides is based on their 
diagnostic dissociation behaviour.230  This study showed that the group bonded 
to the sulfoxide functionality is lost as a radical using low-energy CID-MS/MS.  
The corresponding radical loss was not observed for the parent compound.  
Thus, a radical loss in the low-energy CID product ion spectrum of an oxidised 
metabolite could be indicative of an S-oxide.  Further, the site of oxidation could 
be inferred by characterising the radical loss, as the leaving group was originally 
bonded to the sulfoxide functionality. 
 
In summary, the existing approaches for identifying and discriminating between 
oxidised metabolites often do not provide definitive localisation of the site of 
oxidation.  Further, those that can are often not applicable to routine 
application.  The inability to localise the specific site of oxidation on a 
pharmaceutical compound is problematic if there are two or more potential 
oxidation sites for which a given approach is diagnostic e.g. two nitrogen atoms 
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that could be oxidised and then identified following reduction using TiCl3.  In 
this circumstance, the analyst must rigorously interrogate the low-energy CID 
product ion spectrum of the metabolite to assign the site of oxidation.  
However, this approach may still result in an ambiguous assignment, as 
demonstrated in the case of dasantinib.199  The work of Wright and co-workers, 
in conjunction with that performed by the groups of Ma and Lay, suggest that 
the elucidation of structurally dependent dissociation pathways could provide a 
means to definitively localise the site of oxidation in oxidised metabolites.  This 
is supported by the work of the Desaire and Langley groups, who have shown 
diagnostic losses for the identification and localisation of other functional 
groups in small molecules using low-energy CID-MS/MS.  The Desaire group 
have demonstrated that the loss of carbon dioxide (44 m/z units) in a negative 
ion low-energy CID-MS/MS product ion spectrum is indicative of a carboxylic 
acid.231  The observation of the loss also provides structural information about 
the chemical environment in which the carboxylic acid functionality is 
positioned, with certain substructures precluding the loss of carbon dioxide e.g. 
dicarboxylic acids where the acid groups are separated by three carbon atoms 
do not lose carbon dioxide under low-energy CID conditions.  A further paper 
showed that carboxylic acid-containing metabolites formed through hydrolysis 
of lactones can be differentiated from their parent compounds through 
diagnostic neutral losses from both the parent molecule and the metabolite.232  
Finally, the localisation of the site of sulfation in phase II metabolism was 
achieved, with diagnostic product ions and losses used to classify the sulfation 
site as one of four possibilities.233  This enabled prediction of the metabolite’s 
biological effect, which is important as conjugation of the sulfate group to 
benzylic alcohol, allylic alcohol or aromatic hydroxylamine functionalities gives 
rise to carcinogenic species.  The Langley group have also conducted work into 
the elucidation of structural motifs that drive dissociation pathways.234, 235  Their 
studies showed that class-specific product ions and losses could be identified for 
a number of groups of small molecules.  Further, they demonstrated that the 
different classes of compounds would cluster using principal component 
analysis (PCA) based upon the ions observed in their low-energy CID product ion 
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spectra.  This therefore indicated that the structure of the molecule drives its 
dissociation under low-energy CID conditions.  The information in the literature 
therefore suggested that there was scope to elucidate structurally dependent 
dissociation pathways using low-energy CID-MS/MS that would allow 
discrimination and characterisation of oxidised pharmaceutical drug 
metabolites.  It was envisaged that such information could have immediate 
benefit to the metabolite identification community by enabling faster 
interpretation of data; a recognised bottleneck in metabolite identification 
studies.178  This is because an analyst would, as a first approach, be able to just 
look for key diagnostic information in a low-energy CID product ion spectrum of 
an unknown metabolite, rather than rigorously interrogating the data.  Thus, 
faster throughput would be possible using such a protocol, and hence the 
presented study was conducted. 
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Chapter 3 
 
Experimental 
 
3.1 Introduction 
The experimental conditions detailed below are the generic protocols used for a 
majority of the work in the presented study.  Deviations from the generic 
protocol, or specific experiments not conducted throughout the study, are 
detailed in the relevant chapters. 
 
3.2 Chemicals 
Solutions were prepared in LC-MS grade methanol and analytical grade 
methanoic acid [99.9:0.1, volume by volume (v/v)] (Fisher Scientific UK Ltd., 
Loughborough, UK) for QIT-MS and FT-ICR-MS experiments.  The concentrations 
were 10 micrograms per millilitre (μg mL-1) for the QIT-MS experiments and 
1 μg mL-1 for the FT-ICR-MS experiments.  QqTOF-MS experiments were 
performed using solutions prepared at 1 μg mL-1 in LC-MS Chromasolv® 
acetonitrile [1:1, v/v] (Sigma-Aldrich Company Ltd., Gillingham, UK) and HPLC 
grade water (Millipore, Bedford, MA, USA).  Solution-phase H/D exchange 
experiments were performed by preparing the compound in >99.5% deuterated 
methanol with either 99.5% methanoic acid [99.9:0.1, v/v] or 99.5% ethanoic 
acid [99:1, v/v] (Apollo Scientific Ltd., Stockport, UK).  The concentration of the 
solutions for the solution-phase H/D exchange experiments were 10 μg mL-1.  
Reserpine (Sigma-Aldrich Company Ltd., Gillingham, UK) was prepared at 100 
nanogram per millilitre (ng mL-1) in LC-MS grade methanol and analytical grade 
methanoic acid [99.9:0.1, v/v] for calibration of the FT-ICR mass spectrometer.  
All chemicals were used without further purification. 
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3.3 Instrumental 
“In-time” low-energy CID product ion spectra were acquired using a LCQ Classic 
QIT mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA).  Positive 
ion ESI-MS/MS was performed by infusing the solutions directly into the ion 
source at a constant flow rate of 3 microlitres per minute (μL min-1).  Nitrogen 
was used as the sheath and auxiliary gas.  The ion source conditions varied 
between experiments and will be detailed in the individual chapters.  Low-
energy CID product ion spectra were acquired using an isolation width of 6 m/z 
units (1 m/z unit for solution-phase H/D exchange experiments), an activation Q 
of 0.250 and an activation time of 30 ms.  Acquisitions were performed for 
twenty scans.  Helium was used as the buffer gas.  The value of the normalised 
collision energy and the WideBand activation setting were varied between 
experiments and will be detailed in the individual chapters.  Data acquisition 
was performed using XCalibur version 1.2 (Thermo Fisher Scientific, San Jose, 
CA, USA). 
 
“In-space” low-energy CID product ion spectra were acquired using a Premier 
QqTOF mass spectrometer (Waters Ltd., Elstree, UK) coupled to an Acquity ultra 
performance liquid chromatography (UPLC) instrument (Waters Ltd., Elstree, 
UK).  Separation was achieved using a Sunfire C18 column, 50 millimetre (mm) x 
2.1 mm internal diameter (i.d.), 3.5 μm particle size (Waters Ltd., Elstree, UK).  
The column oven temperature was set to 40oC.  The mobile phases were; (A) 
HPLC grade water and LC-MS Chromasolv® acetonitrile [95:5, v/v] containing 
0.1% analytical grade methanoic acid and (B) LC-MS Chromasolv® acetonitrile 
containing 0.1% analytical grade methanoic acid.  The gradient conditions are 
shown in Table 3.1.  The eluent flow rate was 200 μL min-1 and the injection 
volume was 5 μL. 
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Table 3.1 Gradient conditions for the UPLC-QqTOF-MS/MS analyses 
 
Time / min % A % B 
0 95 5 
1 95 5 
8 2 98 
9 2 98 
9.1 95 5 
13 95 5 
 
Positive ion ESI-MS/MS was performed using the following ion source 
conditions; cone gas flow, 40 litres per hour (L hr-1); desolvation gas flow, 
650 L hr-1; capillary voltage, 3.2 kV; sampling cone, 25 V; extraction cone, 4 V; 
ion guide, 2.5 V; source temperature, 120 degrees Celsius (oC); desolvation 
temperature, 350oC.  Nitrogen was used as the cone and desolvation gas.  Low-
energy CID product ion spectra were acquired at collision energies of 15, 20 and 
25 electron volts (eV) using argon as the collision gas.  The mass spectrometer 
was operated in the “V” mode.  The scan time was 0.2 s and the interscan time 
was 0.05 s.  Data acquisition was performed using MassLynx version 4.1 (Waters 
Ltd., Elstree, Herts., UK). 
 
AMM “in-time” low-energy SORI-CID product ion spectra were acquired using 
an Apex III FT-ICR mass spectrometer (Bruker, Billerica, MA, USA) equipped with 
a 4.7 Tesla actively shielded superconducting magnet, an Infinity cylindrical 
analyser cell and an Apollo ESI ion source.  Positive ion ESI-MS/MS was 
performed by infusing the solutions directly into the ion source at a constant 
flow rate of 3 μL min-1.  Nitrogen was used as the drying gas.  The ion source 
conditions and excitation amplitude varied between experiments and will be 
detailed in the individual chapters.  Positive ions were accumulated in the 
hexapole ion guide for 0.2 s prior to transfer into the ICR cell.  The conditions for 
the acquisition of “in-time” low-energy SORI-CID product ion spectra varied 
between experiments and will be detailed in the individual chapters.  However, 
argon was always used as the collision gas.  The instrument was calibrated using 
the first-generation low-energy SORI-CID product ion spectrum of reserpine.  
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Data acquisition was performed using XMass version 7.0.8 (Bruker, Billerica, 
MA, USA). 
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Chapter 4 
 
Evidence for an ortho-effect on the fragmentation 
of 4-benzenesulfinyl-3-methylphenylamine 
 
4.1 Introduction 
Herein, an ortho-effect on the fragmentation of a model S-oxide leading to a 
50 m/z unit loss is described.  Ortho-effects are common observations in EI-MS 
and have been extensively investigated.236-239  They are less frequent under low-
energy CID conditions, although reports do exist for protonated,240, 241 
deprotonated242-244 and adduct molecules.241, 245  Further, Mendes and co-
workers demonstrated an ortho-effect in both the EI and low-energy CID mass 
spectra of ortho-N-chlorophenyl- and ortho-N-bromophenyl-2-
aminobenzamidine.246  The 50 m/z unit loss discussed below is of interest as a 
potential tool for metabolite identification because oxidation at a sulfur atom is 
a common phase I biotransformation, both in vitro and in vivo.247  The 
dissociation behaviour discussed could possibly be of use during drug discovery 
for definitively identifying the sulfur atom in a pharmaceutical compound that 
has undergone S-oxidation. 
 
4.2 Experimental 
 
4.2.1 Chemicals 
4-Benzenesulfinyl-3-methylphenylamine (Compound 4.1), 4-
benzenesulfinylphenylamine (Compound 4.2), 3-methyl-4-
phenylsulfanylphenylamine (Compound 4.4), (4-methanesulfinyl-3-
methylphenoxy)acetic acid (Compound 4.5) and 3-dimethylaminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide (Compound 4.6) were 
provided by Pfizer Global Research and Development (Sandwich, UK).  2-
Aminofluorene (Compound 4.3) was purchased from Alfa Aesar (Heysham, UK).  
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Solutions of Compounds 4.1-4.6 were prepared for QIT-MS experiments as 
detailed in Chapter 3.  Further solutions of Compound 4.1 were prepared for 
FT-ICR-MS, QqTOF-MS and solution-phase H/D exchange experiments as 
detailed in Chapter 3 and at 20 µg mL-1 in LC-MS grade methanol and analytical 
grade methanoic acid [99.9:0.1, v/v] for the MS4 experiment using QIT-MS. 
 
4.2.2 Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.  The ion source conditions were; 
sheath gas, 30 arbitrary units; auxiliary gas, 5 arbitrary units (45 arbitrary units 
for the solution-phase H/D exchange experiment); spray voltage, 4 kV; capillary 
voltage, 17 V; capillary temperature, 140oC; tube lens offset, 10 V.  The 
experiments performed, the setting of the WideBand activation parameter and 
the normalised collision energy value are shown in Table 4.1. 
 
Table 4.1 Experiment performed, WideBand activation parameter setting 
and normalised collision energy value for the QIT-MS analyses 
of Compounds 4.1-4.6 
 
Compound Experiment WideBand 
activation on/off 
Normalised 
collision energy 
/ % 
4.1 MS/MS On 50 
4.1 MS/MS Off 30 
4.1 MS3 Off 35, 35 
4.1 MS4 Off 40, 40, 30 
4.2 MS/MS On 55 
4.3 MS/MS Off 35 
4.4 MS/MS On 60 
4.5 MS/MS On 50 
4.6 MS/MS On 50 
 
QqTOF-MS experiments were performed as detailed in Chapter 3 to acquire “in-
space” low-energy CID product ion spectra of Compound 4.1. 
 
FT-ICR-MS experiments were performed as detailed in Chapter 3 to acquire an 
AMM “in-time” low-energy SORI-CID product ion spectrum of Compound 4.1.  
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The ion source conditions were; capillary voltage, -4.5 kV; end plate voltage, -
3.8 kV; capillary exit voltage, 100 V; skimmer 1, 11 V; skimmer 2, 6 V; offset, 
1.25; RF amplitude, 600 Hertz (Hz); dry gas temperature, 250oC; dry gas flow 
rate, 30 arbitrary units; nebulising gas pressure, 50 pounds-per-square-inch 
(psi).  The excitation amplitude was 3.7 decibels (dB).  A low-energy SORI-CID 
product ion spectrum was acquired for eight scans using 512K data points.  The 
MS/MS parameters were; corr sweep pulse length, 1000 µs; corr sweep 
attenuation, 28.5 dB; ejection safety belt, 3000 Hz; user pulse length, 1000 µs; 
ion activation pulse length, 250000 µs; ion activation attenuation, 38.9 dB; 
frequency offset from activation mass, - 500 Hz; user delay length, 3 s. 
 
4.2.3 Molecular modelling 
The gas-phase proton affinity of Compound 4.1 was calculated using Spartan 
’02 (Wavefunction, Inc, CA, USA).  The gas-phase proton affinity is defined as 
the negative of the enthalpy change at 298 Kelvin (K) for the protonation 
reaction (Equation 4.1):1 
 
Equation 4.1   
 
Four different conformers of the molecule were modelled.  For each of these 
models, one conformer protonated at the amine nitrogen and four conformers 
protonated at the sulfoxide oxygen were modelled through the addition of a 
proton at the relevant site.  Four different conformers of the protonated 
sulfoxide oxygen were modelled from each neutral species to account for 
different spatial orientations that the proton can assume in the gas phase when 
protonation occurs at this functional group. 
 
The structures were minimised and the energies calculated at the density 
functional theory (DFT) level (B3LYP) using the 6-31G** basis set.  The 
equilibrium geometry was calculated at the ground state starting from AM1 
geometry.  The total charge was set to cation for the protonated species and 
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neutral for the molecule.  The calculated energies were converted from atomic 
units to kilocalories per mole (kcal mol-1) using the conversion factor of 627.5.248  
The enthalpy change was calculated by subtracting the energy of the molecule 
from the energy of each protonated species.  The obtained values corresponded 
to the ΔH value and were converted to proton affinities by multiplying by -1 (see 
Equation 4.1). 
 
4.3 Results and discussion 
The fragmentation of protonated 4-benzenesulfinyl-3-methylphenylamine 
(Compound 4.1) (Figure 4.1a) was investigated.  A 50 m/z unit loss was 
observed in the first-generation low-energy CID product ion spectrum acquired 
with WideBand activation on (Figure 4.2).110  It was proposed that this loss is 
the result of an ortho-effect due to the presence of the methyl group on the 
phenylamine ring.  This hypothesis was suggested because the des-methyl 
homologue, protonated 4-benzenesulfinylphenylamine (Compound 4.2) (Figure 
4.1b), did not display a 50 m/z unit loss in the first-generation low-energy CID 
product ion spectrum acquired with WideBand activation on.  Instead, a 48 m/z 
unit loss was observed, which corresponded to the loss of sulfur monoxide 
(Figure 4.3).  Thus, the 50 m/z unit loss from protonated Compound 4.1 was 
proposed to be a loss with the elemental formula H2SO.  Further experiments 
were conducted to confirm this loss and investigate the fragmentation. 
 
 
Figure 4.1 Molecular structures of a) 4-benzenesulfinyl-3-
methylphenylamine (Compound 4.1) and b) 4-
benzenesulfinylphenylamine (Compound 4.2) 
 
It was noted that the 50 m/z unit loss from protonated Compound 4.1 was only 
observed when the low-energy CID product ion spectrum was acquired with 
WideBand activation on.  With the parameter switched off, no signal was
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Figure 4.2 First-generation low-energy CID product ion spectrum of 
protonated Compound 4.1 (m/z 232) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
observed at m/z 182 (Figure 4.4).  This is consistent with the suggestion that the 
product ion is not formed directly from protonated Compound 4.1.  It appeared 
that the 20 m/z unit activation window created with WideBand activation on 
was required to form the product ion.  Thus, it was hypothesised that the 
product ion at m/z 182 is formed through a two-step fragmentation process via 
the other major ion in the activation window, namely m/z 215. To test this 
hypothesis, an MS3 experiment was performed with WideBand activation off 
using the ion at m/z 215 as the precursor ion for the second stage of mass 
analysis.  The second-generation low-energy CID product ion spectrum of 
protonated Compound 4.1 displays an ion at m/z 182 (Figure 4.5).  This proves 
that the product ion at m/z 182 is formed by fragmentation of the ion at 
m/z 215 and not directly through dissociation of the protonated molecule.  
Thus, the loss of 50 m/z units from protonated Compound 4.1 occurs in a two-
step process through sequential losses of 17 and 33 m/z units.  As a loss with 
the elemental formula H2SO had been proposed previously, the identities of the 
sequential losses were thought to be a hydroxyl radical and a thiol radical.  
However, this could not be determined by means of the preservation or
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Figure 4.3 First-generation low-energy CID product ion spectrum of 
protonated Compound 4.2 (m/z 218) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 4.4 First-generation low-energy CID product ion spectrum of 
protonated Compound 4.1 (m/z 232) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation off 
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Figure 4.5 Second-generation low-energy CID product ion spectrum of 
protonated Compound 4.1 (m/z 232) using the ion at m/z 215 as 
the precursor ion for the second stage of mass analysis acquired 
using a LCQ Classic QIT mass spectrometer with WideBand 
activation off 
 
disappearance of the 34S isotope pattern for the peaks of interest due to the 
difficulties associated with observing the true isotope pattern using a QIT mass 
spectrometer.  An alternative identity for the loss of 17 m/z units could have 
been ammonia, particularly if Compound 4.1 protonated at the amine nitrogen.  
Further experiments were utilised to investigate the identity of the losses. 
 
Molecular modelling calculations were utilised to support the proposed loss of a 
hydroxyl radical during the first stage of mass analysis.  The gas-phase proton 
affinities for the two most likely sites of protonation on Compound 4.1, the 
sulfoxide oxygen and the amine nitrogen, were calculated.  A number of 
conformers of Compound 4.1 were modelled to represent some of the spatial 
orientations that the molecule can assume in the gas phase.  Using the neutral 
species, the protonated molecules were modelled by adding a proton at the 
relevant site.  Four different conformers protonated at the sulfoxide oxygen 
were modelled for each neutral species.  This is because rotation of the S-O 
bond alters the spatial orientation of the proton, which could affect the overall 
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energy of the ion.  Only a single protonated amine nitrogen species was 
modelled for each neutral conformer due to rotation of the C-N bond having no 
effect on the overall structure of the ion.  A number of conformers were 
investigated for the molecules, and the corresponding protonated species, to 
verify that the same site of protonation was favoured regardless of the spatial 
orientation.  However, it must be noted that this approach does not define the 
absolute site of protonation; the conformers investigated were not exhaustive 
of all of those that can exist in the gas phase.  The energies of the protonated 
species were compared to the relevant neutral conformer to determine the 
most likely site of protonation.  The lower the energy of the protonated species 
then the more likely it is to occur in the gas phase due to the ion being more 
energetically stable.  The calculations showed that the protonated sulfoxide 
oxygen species were lower in energy by between 21.9 and 24.7 kcal mol-1 
compared to the protonated amine nitrogen species across the investigated 
conformers.  These values are comparable to those used to assign the sulfoxide 
oxygen as the site of protonation in a previous study.230  Hence, it can be 
concluded that the most energetically favourable site of protonation for 
Compound 4.1 is the sulfoxide oxygen.  This finding suggested that the 17 m/z 
unit loss from protonated Compound 4.1 was more likely to be a hydroxyl 
radical than the alternative, a molecule of ammonia.  This is because 
protonation at the sulfoxide oxygen facilitates the loss of a hydroxyl radical.  To 
support the molecular modelling calculations and determine the number of 
exchangeable hydrogen atoms in the overall 50 m/z unit loss, solution-phase 
H/D exchange experiments were performed.  The 18 m/z unit loss indicated that 
a deuterohydroxyl radical was lost from the fully exchanged, deuterated 
molecule, [M + D]+ (Figure 4.6).  This definitively proved that Compound 4.1 
protonates at the sulfoxide oxygen.  The experiment also showed that one 
exchangeable hydrogen atom was involved in the overall 50 m/z unit loss due to 
the mass difference between the precursor ion and the product ion of interest 
being 51 m/z units under deuterated conditions.  Isomerisation prior to 
dissociation i.e. scrambling of the deuterium label, prior to dissociation can be 
excluded because the relative abundance of the ion at m/z 185 is insufficient to
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Figure 4.6 First-generation low-energy CID product ion spectrum of fully 
exchanged, deuterated Compound 4.1 (m/z 235) acquired using 
a LCQ Classic QIT mass spectrometer with Wideband activation 
on 
 
suggest that a combination of 50 and 51 m/z unit losses have occurred 
concurrently. 
 
The single exchangeable hydrogen atom is accounted for in the first stage of 
fragmentation through the loss of the hydroxyl radical.  Thus, the 33 m/z unit 
loss during the second stage of fragmentation is likely to be accounted for by a 
thiol radical involving a non-exchangeable hydrogen atom.  As an ortho-effect 
had been postulated, the source of this non-exchangeable hydrogen atom was 
proposed to be the methyl group bonded to the phenylamine ring.  To confirm 
the elemental formulae of the losses, AMMs were performed using a FT-ICR 
mass spectrometer.  The elemental formulae with the lowest mass 
measurement error (MME) values were consistent with the loss of a hydroxyl 
radical and a thiol radical (Figure 4.7).  The rings plus double bond equivalents 
values were 8 for the product ion at m/z 215.0762 and 8.5 for the product ion at 
m/z 182.0965.  These values indicate that the structures were odd- and even-
electron ions respectively,249 supporting the hypothesis of sequential radical
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Figure 4.7 First-generation low-energy SORI-CID product ion spectrum of 
protonated Compound 4.1 (m/z 232) acquired using an Apex III 
FT-ICR mass spectrometer 
 
losses.  Because of the deficiency of the even-electron ion value by 0.5 due to 
the addition of a proton to the molecule,250 it was deduced that the number of 
rings and double bond equivalents in the product ion was 9.  This is consistent 
with a protonated aminofluorene, which was proposed as the structure of the 
product ion at m/z 182 (Figure 4.8).  To verify this conclusion, a commercially 
available sample of 2-aminofluorene (Compound 4.3) was used to acquire the 
first-generation low-energy CID product ion spectrum of the protonated 
molecule, m/z 182 (Figure 4.9).  The spectrum was compared to the third-
generation low-energy CID product ion spectrum of protonated Compound 4.1 
i.e. acquired using m/z 182 as the precursor ion (Figure 4.10).  Both spectra 
displayed a loss of 17 m/z units.  For protonated Compound 4.3, this correlated 
to the loss of a molecule of ammonia.  It is expected that, regardless of the 
position of the amine group on the fluorene substructure, the dissociations of 
the different protonated aminofluorenes will be the same i.e. loss of a single 
molecule of ammonia.  It has been shown previously that the hydroxyl group is 
lost during the first stage of mass analysis for protonated Compound 4.1.  
Therefore, it was concluded that the further loss of 17 m/z units was the loss of 
a molecule of ammonia.  Hence, the results are consistent with a protonated 
aminofluorene being the structure of the product ion at m/z 182. 
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Figure 4.8 Proposed structure of the product ion at m/z 182, a protonated 
aminofluorene 
 
 
Figure 4.9 First-generation low-energy CID product ion spectrum of 
protonated Compound 4.3 (m/z 182) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation off 
 
 
Figure 4.10 Third-generation low-energy CID product ion spectrum of 
protonated Compound 4.1 (m/z 232) using the ions at m/z 215 
and 182 as the precursor ions for the second and third stages of 
mass analysis acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation off 
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A dissociation mechanism for the formation of protonated Compound 4.3 from 
protonated Compound 4.1 is proposed (Figure 4.11).  The production of 
protonated 4-aminofluorene can not be precluded and a mechanism for this 
dissociation is also suggested (Figure 4.12).  However, this could not be verified 
because 4-aminofluorene was not commercially available. 
 
 
Figure 4.11 Proposed dissociation mechanism for the formation of 
protonated Compound 4.3 by dissociation of protonated 
Compound 4.1 through sequential losses of a hydroxyl radical 
and a thiol radical 
 
 
 
Figure 4.12 Proposed dissociation mechanism for the formation of 
protonated 4-aminofluorene by dissociation of protonated 
Compound 4.1 through sequential losses of a hydroxyl and a 
thiol radical 
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In both cases, the driving force for the dissociation appears to be product ion 
stability, with the planar structures likely to make the transitions energetically 
favourable (Figure 4.13). 
 
 
Figure 4.13 Molecular model of protonated Compound 4.3 demonstrating 
the planar structure of the ion 
 
The discussed dissociation behaviour has potential as a tool for identifying the 
site of oxidation of a NCE during the drug discovery process.  This is because the 
loss was not observed for protonated 3-methyl-4-phenylsulfanylphenylamine 
(4), the unoxidised analogue of the model S-oxide i.e. equivalent to the parent 
compound (Figure 4.14).  The hydroxyl radical can not be lost without prior 
oxidation of the sulfur atom.  Therefore, a 50 m/z unit loss in the low-energy 
CID product ion spectrum of a drug metabolite may suggest oxidation at a sulfur 
atom that is positioned ortho to a methyl group.  This may rule out other sulfur 
atoms in the molecule as sites of oxidation because they lack the required 
chemical environment.  Thus, rapid and definitive assignment of the site of S-
oxidation could be achieved based upon a single loss in the low-energy CID 
product ion spectrum.  The observed loss could be used as a tool to identify S-
oxidised metabolites using both “in-time” and “in-space” MS/MS platforms.  
This is because the same dissociation was recorded using a QqTOF mass 
spectrometer operated over a range of collision energies (Figure 4.15).  
However, the investigation of the observed loss and the understanding of the 
mechanism were more effectively achieved using the QIT mass spectrometer.
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Figure 4.14 First-generation low-energy CID product ion spectrum of 
protonated Compound 4.4 (m/z 216) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 4.15 First-generation low-energy CID product ion spectra of 
protonated Compound 4.1 (m/z 232) acquired using a Premier 
QqTOF mass spectrometer operated at collision energies of a) 
15 eV, b) 20 eV and c) 25 eV 
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The inability of the QqTOF mass spectrometer to perform MSn experiments, in 
addition to the assumption that even-electron precursor ions dissociate to form 
even-electron product ions,251 could result in an analyst proposing that the loss 
of 50 m/z units takes place in a single step.  It is unlikely that sequential radical 
losses from even-electron precursor ions would be postulated under low-energy 
CID conditions, as a rationalisation based upon a neutral molecule loss would be 
sought in agreement with extensive experimental observations.252  However, 
the ability of the QIT mass spectrometer to acquire MS3 data allowed the 
elucidation of the sequential radical losses that constitute the loss of 50 m/z 
units. 
 
It is hypothesised that two aromatic substructures bonded to the sulfoxide 
group, as well as the ortho methyl group, are required for the 50 m/z unit loss 
to be observed.  This is because the loss was not observed for two compounds 
with sulfoxide functionalities bonded to a single aromatic ring and a methyl 
group; (4-methanesulfinyl-3-methylphenoxy)acetic acid (Compound 4.5) and 3-
dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide (Compound 4.6) (Figures 4.16a and 
4.16b). 
 
 
Figure 4.16 Molecular structures of a) (4-methanesulfinyl-3-
methylphenoxy)acetic acid (Compound 4.5) and b) 3-
dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide (Compound 4.6) 
 
The absence of a 50 m/z unit loss in their first-generation low-energy CID 
product ion spectra, acquired with WideBand activation on, (Figures 4.17 and 
Figure 4.18) suggests that the loss of a hydroxyl radical and a thiol radical is not
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Figure 4.17 First-generation low-energy CID product ion spectrum of 
protonated Compound 4.5 (m/z 229) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 4.18 First-generation low-energy CID product ion spectrum of 
protonated Compound 4.6 (m/z 383) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
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energetically favourable without a second aromatic ring bonded to the sulfoxide 
group.  Without two aromatic groups, a planar fluorene product ion-type 
structure can not be formed.  Hence, it is hypothesised that the planar structure 
of the product ion is the driving force for the dissociation in this case.  A further 
proposal concerning the dissociation is that the identity of the functional group 
positioned ortho to the sulfoxide functionality that facilitates the 50 m/z unit 
loss may not be restricted to a methyl group.  However, suitable compounds to 
test these hypotheses were not available for this study. 
 
4.4 Conclusions 
 
The experimental investigation of the loss of 50 m/z unit loss from protonated 
Compound 4.1 has been presented.  Comparison of the low-energy CID product 
ion spectrum with that of the homologue lacking a methyl group on the 
phenylamine ring, Compound 4.2, led to the proposal of an ortho-effect on the 
dissociation.  The findings indicated that the dissociation was a two-step 
process involving sequential losses of a hydroxyl radical followed by a thiol 
radical; a rare observation under low-energy CID conditions when even-electron 
precursor ions are fragmented.  Solution-phase H/D exchange experiments 
showed that only one exchangeable hydrogen atom was involved in the 
fragmentation and that it was located on the hydroxyl group formed during 
protonation.  Thus, definitive assignment of the site of protonation was 
achieved using the solution-phase H/D exchange approach.  The involvement of 
a non-exchangeable hydrogen atom during the loss of the thiol radical 
supported the hypothesis of an ortho-effect due to the methyl group.  
Molecular modelling calculations complemented these findings by 
demonstrating that the most likely site of protonation was the sulfoxide oxygen, 
thus facilitating the loss of the hydroxyl radical.  Accurate mass FT-ICR-MS 
product ion data confirmed the elemental formulae of the two radical losses.  
The elemental formula derived from the AMM of the resultant product ion was 
consistent with the calculated rings plus double bond equivalents for a 
protonated aminofluorene.  The hypothesised product ion structure was 
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verified by comparison of the low-energy CID product ion spectrum of 
commercially available protonated Compound 4.3 with that acquired by 
dissociation of the product ion derived through the loss of 50 m/z units from 
protonated Compound 4.1.  Possible dissociation mechanisms are proposed. 
 
The loss of H2SO has potential application in fields where structural elucidation 
is of interest, particularly the pharmaceutical industry.  In this area, a 50 m/z 
unit loss in the low-energy CID product ion spectrum of a drug metabolite may 
indicate that S-oxidation has taken place at a sulfur atom bonded to two 
aromatic rings with a methyl group positioned ortho to it.  During drug 
discovery, this could facilitate rapid and definitive identification of S-oxidation.  
Further, it could discriminate between multiple sulfur atoms in a compound as 
the site of oxidation based upon the chemical environment required for the loss 
to take place. 
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Chapter 5 
 
An example of how unexpected dissociation 
behaviour could preclude correct assignment of 
sites of metabolism 
 
5.1 Introduction 
The principal method of assigning the site of metabolism of a NCE using MS/MS 
involves comparing the low-energy CID product ion spectrum of the parent 
compound with that of the metabolite.  The analyst interrogates the spectra for 
mass shifts of the major peaks to determine which part of the molecule has 
been altered i.e. the Shift technique.198  However, unambiguous assignments by 
this approach are frequently not possible (see Chapter 2).  Furthermore, the 
high-throughput nature of modern drug discovery means that multiple mass 
spectrometric-related structural elucidation experiments e.g. isotopic labelling, 
derivatisation etc., which could assist in definitively identifying the site of 
metabolism, may not be performed.  Thus, there is a risk that incorrect 
assignment of sites of metabolism could arise, which is restrictive on timely 
completion of metabolite identification studies.  This is a particular likelihood 
given that fragmentation under low-energy CID conditions is still not fully 
understood, with unexpected rearrangements being previously reported in the 
literature for both peptidic and small molecules.253-256  Herein, a further 
example of unanticipated dissociation behaviour, observed for the model 
sulfoxide metabolite 3-dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide, demonstrates how incorrect assignment 
of the sites of metabolism of a NCE could occur if a rigorous analytical approach 
is not applied. 
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5.2 Experimental 
 
5.2.1 Chemicals 
3-Dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide (Compound 5.1) and 3-dimethyl-2H6-
aminomethyl-4-(4-methanesulfinyl-3-methylphenoxy)benzenesulfonamide 
(Compound 5.2) were provided by Pfizer Global Research and Development 
(Sandwich, UK).  Solutions of both compounds were prepared for QIT-MS 
experiments as detailed in Chapter 3.  Further solutions of Compound 5.1 were 
prepared for FT-ICR-MS, QqTOF-MS and solution-phase H/D exchange 
experiments as detailed in Chapter 3. 
 
5.2.2 Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.  The ion source conditions were; 
sheath gas, 35 arbitrary units; auxiliary gas, 5 arbitrary units; spray voltage, 4.5 
kV; capillary voltage, 11 V; capillary temperature, 220oC; tube lens offset, 35 V.  
For both MS/MS and MS3 experiments, the normalised collision energy was set 
to 50% and WideBand activation was switched on. 
 
QqTOF-MS experiments were performed as detailed in Chapter 3 to acquire “in-
space” low-energy CID product ion spectra of Compound 5.1. 
 
FT-ICR-MS experiments were performed as detailed in Chapter 3 to acquire an 
AMM “in-time” low-energy SORI-CID product ion spectrum of Compound 5.1.  
The ion source conditions were; capillary voltage, -4.5 kV; end plate voltage, -
3.8 kV; capillary exit voltage, 100 V; skimmer 1, 11 V; skimmer 2, 6 V; Offset, 
1.25; RF amplitude, 600 Hz; dry gas temperature, 250oC; dry gas flow rate, 
30 arbitrary units; nebulising gas pressure, 50 psi.  The excitation amplitude was 
3.7 dB.  A low-energy SORI-CID product ion spectrum was acquired for eight 
scans using 1024K data points.  The MS/MS parameters were; corr sweep pulse 
length, 1000 µs; corr sweep attenuation, 37.5 dB; ejection safety belt, 3000 Hz; 
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user pulse length, 1000 µs; ion activation pulse length, 250000 µs; ion activation 
attenuation, 37.2 dB; frequency offset from activation mass, - 500 Hz; user 
delay length, 3 s. 
 
5.3 Results and discussion 
As part of the presented study, a series of pharmaceutical compounds and 
model metabolites were analysed using QIT-MS to identify product ions and 
losses that could facilitate rapid and definitive identification of pharmaceutical 
drug metabolites.  During these studies, the dissociation of a model S-oxidised 
metabolite, 3-dimethylaminomethyl-4-(4-methanesulfinyl-3-
methylphenoxy)benzenesulfonamide (Compound 5.1) (Figure 5.1), was 
investigated. 
 
 
Figure 5.1 Molecular structure of 3-dimethylaminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide 
(Compound 5.1) 
 
The first-generation low-energy CID product ion spectrum of the protonated 
molecule is shown in Figure 5.2.  A loss of 62 m/z units was observed, forming 
the product ion at m/z 321.  The same loss was not seen for the parent 
compound (data not shown).  The dissociation thus appeared dependent upon 
the biotransformation i.e. oxidation.  Hence, the loss was thought to be of 
potential use in metabolite identification.  This proposal was supported by the 
observation of the same loss using a QqTOF mass spectrometer (Figure 5.3).  
This demonstrated that the dissociation could be recorded using both “in-
space” and “in-time” MS/MS platforms i.e. the dissociation was instrument-
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Figure 5.2 First-generation low-energy CID product ion spectrum of 
protonated Compound 5.1 (m/z 383) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 5.3 First-generation low-energy CID product ion spectra of 
protonated Compound 5.1 (m/z 383) acquired using a Premier 
QqTOF mass spectrometer operated at collision energies of a) 
15 eV, b) 20 eV and c) 25 eV 
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configuration independent.  This was important to establish because mass 
spectrometers with many different mass analysers are employed for the 
purpose of metabolite identification.175, 257-261   
 
Involvement of the oxygen atom was inferred and the loss was assigned as 
methanethial, S-oxide (CH2SO).  This hypothesis was attractive because S-
oxidation of the parent compound produces an ideal candidate for the loss of 
62 m/z units through the well-documented processes of charge-remote 
fragmentation262 and 1,3-proton shifts263 via four-centred rearrangements 
(Figure 5.4).  The dissociation was thought to be energetically favourable due to 
the conformance of the proposed product ion with the even-electron rule.251  
However, the loss could not be confirmed by a change in the 34S isotope pattern 
for the product ion compared to the precursor ion due to the difficulties 
associated with observing the true isotope pattern using a QIT mass 
spectrometer.  The overlapping of the second isotope peak of the product ion at 
m/z 321 with the monoisotopic peak of the product ion at m/z 323 further 
precluded this approach to structural elucidation. 
 
 
Figure 5.4 Proposed mechanism for the loss of methanethial, S-oxide from 
protonated Compound 5.1 via a four-centred rearrangement 
 
It was noted that the proposed 62 m/z unit loss did not involve any of the three 
exchangeable hydrogen atoms on the precursor ion.  Thus, if the assignment of 
the loss were correct, the m/z of the product ion for the loss of methanethial, S-
oxide would mass shift by 3 m/z units to m/z 324 in the low-energy CID product 
ion spectrum of the fully exchanged, deuterated species (Figure 5.5).  The
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Figure 5.5 First-generation low-energy CID product ion spectrum of fully 
exchanged, deuterated Compound 5.1 (m/z 386) acquired using 
a LCQ Classic QIT mass spectrometer with WideBand activation 
on 
 
absence of a peak at m/z 324 under deuterated conditions indicated that the 
initially posited loss was incorrect.  Further, an additional peak was observed at 
m/z 323 in the low-energy CID product ion spectrum of the fully exchanged, 
deuterated species that was not seen for the protonated molecule.  It should be 
noted that this product ion was different to that seen at m/z 323 in the low-
energy CID product ion spectrum of the protonated molecule, which is mass 
shifted to m/z 325 under deuterated conditions.  The observation of an 
additional peak led to the deduction that two nominally isobaric product ions 
were formed through dissociation of the protonated molecule.  The product 
ions only became mass-resolved when the fully exchanged, deuterated 
molecule was dissociated due to the retention of different numbers of 
deuterium atoms by the two product ions.  Thus, the solution-phase H/D 
exchange experiment showed that two losses of 62 m/z units took place, 
neither of which being that initially postulated.  The loss of all of the deuterium 
atoms to form the product ion at m/z 321 indicated that the primary amine 
group had been lost during the dissociation.  This was because exchange of the 
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two hydrogen atoms in the primary amine group for two deuterium atoms 
would have occurred in solution.  The peak at m/z 323, formed through a loss 
involving one deuterium atom, indicated that this product ion retained the 
primary amine.  Further, it suggested that the ionising deuteron was lost during 
the dissociation, and hence the loss included a site of ionisation. 
 
Further experimentation was undertaken to characterise the two losses of 62 
m/z units.  To this end, the first-generation low-energy CID product ion 
spectrum of a deuterium-labelled analogue, 3-dimethyl-2H6-aminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide (Compound 5.2) 
(Figure 5.6), was acquired (Figure 5.7). 
 
 
Figure 5.6 Molecular structure of 3-dimethyl-2H6-aminomethyl-4-(4-
methanesulfinyl-3-methylphenoxy)benzenesulfonamide 
(Compound 5.2) 
 
In the mass range of interest, the low-energy CID product ion spectrum 
resembled that of protonated Compound 5.1, with only two peaks being 
observed.  This indicated that the product ions were nominally isobaric again 
and neither product ion retained the six deuterium labels.  Thus, both losses of 
62 m/z units in Figure 5.2 involved the tertiary amine group.  The solution-phase 
H/D exchange experiment had shown that one product ion also lost the primary 
amine group; thus, the overall loss was postulated to be C2H10N2.  The same 
experiment had also shown that one product ion retained the primary amine 
and lost the ionising deuteron.  From this information, it was deduced that the 
tertiary amine group was a site of protonation.  Further, it suggested that the 
remaining loss of 17 m/z units for the product ion that retained the primary
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Figure 5.7 First-generation low-energy CID product ion spectrum of 
protonated Compound 5.2 (m/z 389) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
amine group (62 m/z units minus 45 m/z units for the tertiary amine group plus 
the ionising proton) was likely to be a hydroxyl radical; an overall proposed loss 
of C2H8NO
•. 
 
To confirm the hypothesised losses, AMMs were acquired using FT-ICR-MS.  
Figure 5.8 shows the first-generation low-energy SORI-CID product ion 
spectrum of protonated Compound 5.1 in the mass range of interest.  The high 
resolving power of the FT-ICR mass spectrometer allowed mass resolution of 
the two nominally isobaric product ions at m/z 321.  The lowest MME elemental 
formulae, given the precursor ion formula, were consistent with those 
postulated and confirmed that the two losses of 62 m/z units were C2H10N2 and 
C2H8NO
•. 
 
The verification of the elemental composition of the losses allowed postulation 
of dissociation mechanisms leading to the decomposition of the precursor ion.  
The product ion with an elemental formula of C15H13O4S2
+ (Compound 5.3) had 
a ring plus double bond equivalents value of 9.5, confirming that it is an even-
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Figure 5.8 First-generation low-energy SORI-CID product ion spectrum of 
protonated Compound 5.1 (m/z 383) acquired using an Apex III 
FT-ICR mass spectrometer 
 
electron ion.249  Because of the deficiency of this value by 0.5 due to the 
addition of a proton to the molecule,250 it was deduced that the number of rings 
plus double bond equivalents in the product ion was 10.  Figure 5.9 shows a 
proposed mechanism leading to the formation of a product ion which satisfies 
this value; the double bonds of the sulfone group are discounted due to sulfur 
not being in its lowest valence state.249  Protonation is postulated on the 
primary amine to facilitate the loss of the two exchangeable hydrogen atoms as 
part of a molecule of ammonia. 
 
The speculative product ion structure is predominately planar as evinced by the 
molecular model in Figure 5.10.  This is likely to provide the driving force for the 
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energetic rearrangement that involves a high-energy proton shift and leads to 
the loss of dimethylamine.237  The planar structure allows easy delocalisation of 
the charge, making the formation of the product ion thermodynamically 
favourable. 
 
 
Figure 5.9 Proposed mechanism for the formation of Compound 5.3 
through the loss of C2H10N2 as molecules of ammonia and 
dimethylamine from protonated Compound 5.1 
 
 
 
Figure 5.10 Molecular models of Compound 5.3 demonstrating the 
predominately planar structure of the proposed product ion 
 
The product ion with an elemental formula of C15H15NO3S2
+• (Compound 5.4) 
has a ring plus double bond equivalents value of 10 i.e. an odd-electron 
species.249  Figure 5.11 shows a proposed mechanism to form a radical product 
ion structure that is consistent with this value.  The speculative product ion 
structure is again predominately planar, (Figure 5.12), thus allowing facile 
delocalisation of both the charge and the radical site.  This is particularly 
important due to the energetically unfavourable formation of a radical product 
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ion from an even-electron precursor.264  However, the resonance stabilisation 
across the two aromatic rings, and the sulfone and sulfoxide functionalities, is 
likely to facilitate this dissociation. 
 
 
Figure 5.11 Proposed mechanism for the formation of Compound 5.4 
through the loss of C2H8NO
• as a molecule of dimethylamine 
and a hydroxyl radical from protonated Compound 5.1 
 
 
 
Figure 5.12 Molecular models of Compound 5.4 demonstrating the 
predominately planar structure of the proposed product ion 
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Both proposed dissociation mechanisms involve the loss of dimethylamine.  
However, the pathways leading to this loss differ for the two product ions.  The 
formation of Compound 5.3 is postulated to involve the loss of dimethylamine 
facilitated by the shift of a non-exchangeable hydrogen atom.  Conversely, the 
formation of Compound 5.4 proceeds via protonation of the tertiary amine 
followed by a charge-directed inductive cleavage of the carbon-nitrogen bond.  
Thus, an exchangeable hydrogen atom i.e. the ionising proton (deuteron) is 
proposed to facilitate the loss of dimethylamine in this instance.  The loss of 
dimethylamine was also observed in the first-generation low-energy CID 
product ion spectrum of protonated Compound 5.1 (Figure 5.2; product ion at 
m/z 338).  The dissociation of the fully exchanged, deuterated species (Figure 
5.5) showed that the loss increased by 1 m/z unit to produce a peak at m/z 340, 
demonstrating the involvement of a single exchangeable hydrogen atom in the 
dissociation.  The protonated molecule can not be spatially arranged such that 
the two exchangeable hydrogen atoms on the primary amine can be in close 
proximity to the tertiary amine functionality to allow intra-ionic transfer.  Thus, 
they can be excluded as being the source of the exchangeable hydrogen atom 
involved in the loss of dimethylamine.  Hence, the exchangeable hydrogen atom 
must be the ionising proton (deuteron).  From the two mechanisms postulated 
for the losses of 62 m/z units (Figures 5.9 and 5.11), only one involves 
protonation at the tertiary amine and the loss of dimethylamine facilitated by 
an exchangeable hydrogen atom i.e. the loss of C2H8NO
•.  Protonation at the 
primary amine is inferred for the loss of C2H10N2 to facilitate elimination of a 
molecule of ammonia from the precursor ion.  This could not be confirmed 
using solution-phase H/D exchange experiments because the loss of ammonia is 
not observed in the first-generation low-energy CID product ion spectrum of 
protonated Compound 5.1 (Figure 5.2).  However, supportive evidence for the 
proposed mechanisms was obtained through the acquisition of the second-
generation low-energy CID product ion spectrum of fully exchanged, deuterated 
Compound 5.1 using the ion at m/z 340 as the precursor ion for the second 
stage of mass analysis (Figure 5.13).  The dissociation of the fully exchanged, 
deuterated molecule, rather than the protonated molecule, was investigated so
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Figure 5.13 Second-generation low-energy CID product ion spectrum of 
fully exchanged, deuterated Compound 5.1 (m/z 386) using the 
ion at m/z 340 as the precursor ion for the second stage of mass 
analysis acquired using a LCQ Classic QIT mass spectrometer 
with WideBand activation on 
 
that the product ions would be mass-resolved on the QIT mass spectrometer if 
they were both formed.  In the mass range of interest, a product ion was 
observed at m/z 323, which suggested that Compound 5.4 is formed through 
protonation at the tertiary amine, followed by the loss of dimethylamine and 
then elimination of a hydroxyl radical.  The mass difference of 17 m/z units 
between the precursor ion for the second stage of mass analysis and the final 
product ion indicated that the loss of the hydroxyl radical involved a non-
exchangeable hydrogen atom.  If an exchangeable hydrogen atom was involved, 
the loss would become a deuterohydroxyl radical, and thus the mass loss would 
increase to 18 m/z units, under deuterated conditions.  The observations were 
consistent with the proposed mechanism for the dissociation (Figure 5.11).  No 
peak was observed at m/z 321, which indicated that a second dissociation 
pathway existed for the loss of dimethylamine.  This provided supportive 
evidence for a loss of dimethylamine facilitated by the shift of a non-
exchangeable hydrogen atom, which is consistent with the proposed 
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mechanism (Figure 5.9).  The absence of the losses of ammonia and 
dimethylamine facilitated by a non-exchangeable hydrogen atom in the first-
generation low-energy CID product ion spectrum of protonated Compound 5.1 
suggested that the dissociation is concerted, or at least that the intermediates 
undergo rapid decomposition to the final product ion.  Further, the solution-
phase H/D exchange experiments suggested that Compound 5.1 had more than 
one site of protonation in the gas phase because the loss of the tertiary amine 
group was not via protonation at that site in the formation of Compound 5.3.  
Thus, it was plausible that the molecule could protonate at the primary amine, 
further supporting the mechanism proposal. 
 
The discussed work has implications for structural elucidation using low-energy 
CID product ion spectra, particularly for metabolite identification studies.  To 
identify the sites of metabolism on a NCE using MS, the structures of the 
metabolites must be deduced from their low-energy CID product ion spectra.  
From the low-resolution low-energy CID product ion spectrum of protonated 
Compound 5.1, S-oxidation is likely to be proposed based upon the initial 
assignment of the 62 m/z unit loss as methanethial, S-oxide via a four-centred 
rearrangement.  In this case, the proposal of S-oxidation would be correct but 
the assignments of the product ions leading to it would be wrong.  If this were 
an unknown metabolite, oxidation of the parent compound could have 
occurred, for example, through aromatic hydroxylation of the 1-methyl-2-
methylsulfanylbenzene ring and potentially not affected either of the actual 
losses of 62 m/z units.  Nevertheless, the attractive nature of S-oxidation 
facilitating the loss of methanethial, S-oxide via a four-centred rearrangement 
could lead to an incorrect assignment.  Hence, time and money may be spent 
synthesising analogues and/or homologues to protect the methyl sulfide 
functionality of the parent compound only to discover that the hypothesised 
site of oxidation is incorrect.  The discussed example highlights the possibility of 
unexpected rearrangements under low-energy CID conditions, which could 
easily lead to incorrect assignments of product ion structures, and hence sites of 
metabolism in drug discovery studies.  A simple and cost-effective approach to 
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reduce the likelihood of this occurrence is the use of solution-phase H/D 
exchange experiments, which provide a straightforward method of introducing 
isotopic labels into the compound.  Thus, dissociations proposed to involve 
exchangeable hydrogen atoms can be verified.  Further, employment of mass 
spectrometers capable of high-resolution mass measurement, even when 
coupled to fast chromatography as utilised in metabolite identification studies, 
would also reduce the possibility of incorrect product ion structure assignment.  
The study has also been of relevance to the understanding of fragmentation 
under low-energy CID conditions.  The dissociations involve more complex 
rearrangements than that initially proposed.  Further, the formation of an 
energetically unfavourable radical product ion occurred.  However, the final 
shapes of the product ions appear to have a bearing on the dissociation 
pathways followed.  The initially proposed product ion structure formed 
through the loss of methanethial, S-oxide has free rotation about the ether 
linkage.  The product ions actually formed are posited to be predominately 
planar, thus allowing easier delocalisation of the charge.  This may suggest that 
rearrangements leading to the formation of planar product ion structures 
predominate under low-energy CID conditions.  Furthermore, the study 
indicated that solution-phase H/D exchange experiments can be useful in 
determining sites of gas-phase protonation under ESI-low-energy CID-MS/MS 
conditions, as previously reported,265 thus allowing rationalisation of 
dissociation mechanisms. 
 
5.4 Conclusions 
The experimental investigation of the dissociation of a model S-oxidised 
metabolite, Compound 5.1, has been presented.  The product ion at m/z 321 in 
the low-resolution low-energy CID product ion spectrum was initially assigned 
as being formed through the loss of methanethial, S-oxide from the protonated 
molecule.  It was thought that this loss could be used to assign the site of 
oxidation as the sulfur of the methyl sulfide group.  Subsequent deuterium 
labelling experiments and AMMs acquired using a high-resolution low-energy 
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CID product ion spectrum proved that the initial assignment was incorrect.  
Instead, two unexpected rearrangements led to the formation of nominally 
isobaric product ions.  Only through the use of solution-phase H/D exchange 
experiments and high-resolution MS was it possible to mass-resolve these 
species.  Mechanisms consistent with the experimental findings were 
postulated.  Supportive evidence for the proposals was obtained through the 
acquisition of a second-generation low-energy CID product ion spectrum.  The 
speculative planar product ion structures were concluded to provide the driving 
force for the rearrangements, particularly in the formation of an energetically 
unfavourable radical cation.  The study is of relevance to pharmaceutical drug 
metabolite identification because it demonstrated that a rigorous analytical 
approach is required to ensure that incorrect assignment of the sites of 
metabolism of NCEs is precluded.  A greater understanding of fragmentation 
under low-energy CID conditions was also obtained, with the shape of the 
product ion apparently offsetting the complexity of the rearrangement required 
to form it.  Further, the data verified the usefulness of solution-phase H/D 
exchange experiments in determining sites of protonation under ESI-low-energy 
CID-MS/MS conditions. 
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Chapter 6 
 
A rapid methodology for the characterisation of 
dialkyl tertiary amine-N-oxide metabolites using 
structurally dependent dissociation pathways and 
reconstructed ion current chromatograms 
 
6.1 Introduction 
Many pharmaceutical compounds contain amine groups that act as hydrogen 
bond acceptors to affect the solubility and permeability of the molecule in 
biological organisms.266  A particularly common substructure is a dialkyl tertiary 
amine group.  The literature cites many examples of the loss of the nitrogen-
containing group in this substructure under low-energy CID conditions.267-277 
However, only small libraries, or structurally similar compounds, were 
investigated in each case.  Thus, there is no reported comprehensive 
understanding of the dissociation behaviour of this substructure, such as 
whether the loss of the group is always observed under low-energy CID 
conditions when it is present in structurally diverse compounds.  Further, little 
knowledge is available as to whether the oxidised analogue of a dialkyl tertiary 
amine group, representative of an N-oxidised metabolite, also displays the 
corresponding loss mass shifted by 16 m/z units to account for the addition of 
the oxygen.  Lay and co-workers utilised high-energy FAB-MS and FAB-CID-
MS/MS to show that the losses of dimethylamine and N,N-
dimethylhydroxylamine were observed for a series of ethylenediamine, 
ethanolamine and propylamine antihistamine drugs and their tertiary amine-N-
oxides respectively.229  However, equivalent data under low-energy CID 
conditions has never been reported.  To address these voids in knowledge, a 
library of structurally diverse commercially available pharmaceutical 
compounds containing dialkyl tertiary amine groups, as well as a number of 
model, synthetic N-oxides, were analysed by ESI-low-energy CID-MS/MS to gain 
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a greater understanding of the gas-phase ion chemistry.  The acquired 
information allowed the development of a rapid and definitive approach for the 
characterisation of dialkyl tertiary amine-N-oxide metabolites using 
reconstructed ion current chromatograms (RICCs).  The approach uses existing, 
readily available HPLC-MS/MS technology, thus allowing facile implementation.  
This approach could be of benefit in definitively characterising N-oxides early in 
the drug discovery process, which is important as this type of metabolite has 
long been recognised as being a potentially toxic species.278  
 
6.2 Experimental 
 
6.2.1 Chemicals 
A library of seventy commercially available pharmaceutical compounds and 
model, synthetic N-oxides were provided by Pfizer Global Research and 
Development (Sandwich, UK) (The full library can be found in Appendix 1, 
Tables A1-4).  Solutions were prepared for QqTOF-MS experiments as detailed 
in Chapter 3.  The same solutions were used for the QIT-MS experiments.  
Solutions of amitriptyline, amitriptyline-N-oxide, sunitinib and sunitinib-N-oxide 
were prepared for FT-ICR-MS and solution-phase H/D exchange experiments as 
detailed in Chapter 3. 
 
An incubation was performed in a shaking water bath at 37oC.  Tetracaine at a 
concentration of 10 micromolar (µM) was pre-incubated for 15 minutes with rat 
liver microsomes at a concentration of 0.5 µM in 50 millimolar (mM) phosphate 
buffer (pH 7.4).  In addition, 5 mM magnesium chloride (MgCl2), 5 mM isocitric 
acid and 1 unit mL-1 isocitric dehydrogenase were present in the incubation 
mixture.  The incubation was initiated by adding 40 microlitres (µL) of 20 mM 
nicotinamide adenine dinucleotide phosphate (NADP+).  After 60 minutes, the 
incubation was terminated by the addition of 4 mL of cold acetonitrile.  The 
incubate was centrifuged at 3000 revolutions per minute (rpm) for 40 minutes 
at 4oC to precipitate the protein.  The supernatant was removed and 
evaporated to dryness under nitrogen.  The sample was then resuspended in 
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200 µL of LC-MS grade Chromasolv® acetonitrile and HPLC grade water (1:1) in 
preparation for analysis by QqTOF-MS. 
 
6.2.2 Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.  The source conditions were; sheath 
gas, 25 arbitrary units; auxiliary gas, 0 arbitrary units (45 arbitrary units for the 
solution-phase H/D exchange experiments); spray voltage, 4.5 kV; capillary 
voltage, 10 V; capillary temperature, 160oC; tube lens offset, - 5 V.  The 
normalised collision energy was set to either 50% or 60% to cause complete 
dissociation of the precursor ion.  Acquisitions were performed with WideBand 
activation both on and off. 
 
QqTOF-MS experiments were performed as detailed in Chapter 3 to acquire “in-
space” low-energy CID product ion spectra.  Further, full scan spectra of the 
tetracaine incubate were acquired by setting the collision energy to 4 eV.  Low-
energy CID product ion spectra were acquired at 20 eV. 
 
FT-ICR-MS experiments were performed as detailed in Chapter 3 to acquire 
AMM “in-time” low-energy SORI-CID product ion spectra of amitriptyline, 
amitriptyline-N-oxide, sunitinib and sunitinib-N-oxide.  The ion source 
conditions were; capillary voltage, - 4.5 kV; end plate voltage, - 3.8 kV; capillary 
exit voltage, 85 V; skimmer 1, 15 V; skimmer 2, 8.5 V; Offset, 1.25; RF amplitude, 
600 Hz; dry gas temperature, 250oC; dry gas flow rate, 30 arbitrary units; 
nebulising gas pressure, 50 psi.  The excitation amplitude was 7.0 dB.  Low-
energy SORI-CID product ion spectra were acquired for thirty-two scans using 
512K data points.  The MS/MS parameters were; corr sweep pulse length, 
1000 µs; corr sweep attenuation, 28.5 dB; ejection safety belt, 3000 Hz; user 
pulse length, 1000 µs; ion activation pulse length, 250000 µs; ion activation 
attenuation, 38.9 dB; frequency offset from activation mass, - 500 Hz; user 
delay length, 3 s. 
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6.3 Results and discussion 
In an attempt to understand the dissociation of molecules containing dialkyl 
tertiary amine groups, and their corresponding N-oxidised analogues, a library 
of seventy structurally diverse commercially available pharmaceutical 
compounds were analysed by ESI-low-energy CID-MS/MS.   Figures 6.1a-d show 
the composition of the library in terms of the nitrogen-containing groups 
present in the compounds analysed.  The numbers of compounds containing 
each substructure are also shown. 
 
 
Figure 6.1 Composition of the investigated library with respect to the 
nitrogen-containing groups represented.  The number of each 
substructure type analysed are shown below the structures 
 
Two hypotheses were under scrutiny.  The first was that the loss of the 
nitrogen-containing group was generic i.e. always observed in the low-energy 
CID product ion spectrum.  The second was that oxidation of the dialkyl tertiary 
amine group did not change the dissociation behaviour of the compound i.e. if 
the loss of the nitrogen-containing group was observed for the protonated 
parent compound, the corresponding loss was also seen for the protonated N-
oxidised metabolite, and vice versa.  Low-energy CID product ion spectra were 
acquired using both QIT and QqTOF mass spectrometers to assess whether the 
dissociation was observed using both “in-time” and “in-space” MS/MS 
platforms.  Spectra were acquired using QIT-MS with a sufficient collision 
energy value to fragment the entire population of protonated molecules for 
each compound.  Using QqTOF-MS, low-energy CID product ion spectra were 
acquired over a range of collision energies to determine whether second-
generation product ions were formed, thus allowing inferences to be drawn 
regarding the stability of the ions produced through the loss of the nitrogen-
containing group.  The results were collated and are represented in four pie 
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charts (Figures 6.2a-d; relatives abundances for the relevant loss from each 
compound under the various experimental conditions can be found in Appendix 
1, Tables A5-8). 
 
 
Figure 6.2 Frequency of the losses of interest in percentage terms.  
Absolute numbers of compounds are shown in parentheses.  
The pie charts represent the following losses, as denoted by the 
molecular structures shown; a) dimethylamine; b) 
diethylamine; c) N,N-dimethylhydroxylamine; d) N,N-
diethylhydroxylamine  
 
Figure 6.2a shows that 64% of the compounds containing a dimethylamine 
substructure showed the loss of this group at all collision energies utilised.  
Further, the loss of dimethylamine was observed at some of the collision 
energies, but not all, for 24% of the compounds.  A smaller number of the 
compounds, 12%, did not display the loss of dimethylamine despite containing 
the necessary substructure to facilitate it.  Similar percentages were observed 
for the equivalent bins for the compounds that could lose diethylamine and 
N,N-dimethylhydroxylamine (Figures 6.2b-c).  The loss of N,N-
diethylhydroxylamine was observed at all collision energies utilised for both 
compounds containing this group (Figure 6.2d).  Although not analytically 
rigorous due to the small size of the subset, the data gives an indication that the 
loss of N,N-diethylhydroxylamine can be observed for the N-oxides of 
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pharmaceutical compounds containing a diethylamine substituent.  AMMs were 
acquired using FT-ICR-MS to confirm the identities of the losses. Amitriptyline, 
amitriptyline-N-oxide, sunitinib and sunitinib-N-oxide were selected as test 
analytes to represent each subsection of the library.  The greatest MME 
recorded for the four losses was 0.6 ppm, giving confidence that they had been 
correctly assigned. 
 
A number of conclusions can be drawn from the results of the library analysis.  
Combining the four subsets of data shows that the loss of the nitrogen-
containing group is observed in 89% of the low-energy CID product ion spectra 
under all or some of the experimental conditions used.  Thus, the loss of dialkyl 
tertiary amine groups and their N-oxidised analogues will be observed a vast 
majority of the time for compounds containing these substructures, and can 
thus be considered generic.  Further, using the low-energy CID product ion 
spectra for the compounds for which a model, synthetic N-oxide was available, 
it was possible to determine that the dissociation was not altered by the 
oxidation.  All of the pairs of compounds of this nature that were considered 
showed the loss of the dialkyl tertiary amine group as well as the corresponding 
oxidised substructure, with the exception of diphenhydramine and 
diphenhydramine-N-oxide.  This compound did not show loss of either nitrogen-
containing group.  The coverage of pairs of compounds for which the losses of 
interest were observed for either both or neither of the compounds, but not 
only for one, lends support to the conclusion that oxidation does not change the 
dissociation behaviour.  Finally, comparison of the “in-time” and “in-space” 
MS/MS datasets suggested that second-generation dissociation takes place.  
When the loss of interest was observed at only certain collision energies, the 
absence was generally at higher collision energies using the QqTOF mass 
spectrometer (see Appendix 1, Tables A5-8).  Further, there was a general trend 
of decreasing relative abundance as the collision energy was increased, again 
using QqTOF-MS.  These observations suggest that the product ions are formed, 
as evinced by their recording at lower collision energies, but are sufficiently 
unstable that an increase in collision energy causes their decomposition.  This 
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conclusion is supported by the observation that the relative abundances of the 
product ions formed through the losses of interest were generally greater using 
QIT-MS compared to QqTOF-MS.  As fragmentation is effected by resonant 
excitation using QIT-MS,95 the product ions can not undergo second-generation 
dissociation, regardless of their susceptibility to further decomposition.  Thus, 
they survive to detection.  The higher relative abundances using QIT-MS are 
hence consistent with the explanation that the product ions of interest are 
formed via favourable fragmentation pathways under low-energy CID 
conditions, but a significant proportion of the ions undergo second-generation 
dissociation using QqTOF-MS. 
 
To understand the dissociation further, a mechanism was proposed and tested 
using solution-phase H/D exchange experiments.  Figure 6.3 shows a 
generalised mechanism that covers the range of structures present in the 
library. 
 
 
Figure 6.3 Generalised proposed mechanism for the loss of the nitrogen-
containing group 
 
The mechanism proposed protonation at the tertiary amine nitrogen or the 
oxygen atom of the N-oxide group.  This is a reasonable assumption given the 
high solution-phase basicity of these atoms.  Protonation at these sites was 
Chapter 6 
108 
proposed to lead to charge-directed inductive cleavage of the R-N bond, thus 
causing the loss of the nitrogen-containing group as a neutral molecule.  Thus, 
involvement of a single exchangeable hydrogen atom would mean that if the 
mechanism were correct, the loss of interest should increase by 1 m/z unit 
under deuterated conditions.  The proposed mechanism is also consistent with 
the observation of second-generation dissociation.  For a large proportion of the 
library, the nitrogen-containing group was bonded initially to the rest of the 
molecule via a methylene group.  Thus, cleavage of the C-N bond would 
produce a primary carbocation; an unstable species that would be susceptible 
to further dissociation.  Amitriptyline, amitriptyline-N-oxide, sunitinib and 
sunitinib-N-oxide were selected as test analytes from each sub-section of the 
library to probe the hypothesised mechanism.  The first-generation low-energy 
CID product ion spectra acquired using QIT-MS are shown in Figure 6.4. 
 
 
Figure 6.4 First-generation low-energy CID product ion spectra of a) 
deuterated amitriptyline (m/z 279); b) fully exchanged, 
deuterated sunitinib (m/z 403); c) deuterated amitriptyline-N-
oxide (m/z 295); d) fully exchanged, deuterated sunitinib-N-
oxide (m/z 419) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
 
All four compounds demonstrated an increase in the mass of the neutral loss by 
1 m/z unit compared to that observed in protic solvents.  Thus, the low-energy 
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CID product ion spectra indicated that one exchangeable hydrogen atom is 
involved in the loss, and are hence supportive of the proposed mechanism.  The 
understanding of the mechanism allows a rationalisation for the absence of the 
loss of the nitrogen-containing group for some of the compounds analysed to 
be postulated.  The loss requires protonation at either the nitrogen or the 
oxygen atom, depending upon the character of the nitrogen-containing group, 
and does not appear to be facilitated by the shift of a non-exchangeable 
hydrogen atom.  So, if the compound does not protonate at the nitrogen-
containing group, its loss will not be observed in the resultant low-energy CID 
product ion spectrum.  Thus, the compounds that did not show the loss of the 
nitrogen-containing group may preferentially protonate elsewhere on the 
molecule.  Molecular modelling experiments would allow calculation of gas-
phase proton affinities for the different sites of protonation on each compound 
not showing the loss of the nitrogen-containing group.  This would determine 
the likelihood of protonation at the nitrogen or oxygen atom relative to other 
possible sites of ionisation.  Thus, deductions could be made as to whether the 
necessary precursor ions exist in the population of protonated molecules to 
facilitate the loss of the nitrogen-containing group for each compound.  
Previous studies have shown that computational calculations at the DFT level 
can be a useful tool to determine the gas-phase proton affinities of analytes and 
rationalise fragmentation under low-energy CID conditions.230, 265, 279 However, 
such an in-depth study is beyond the scope of the presented work. 
 
At this juncture, an understanding of the fragmentation of pharmaceutical 
compounds containing dialkyl tertiary amine groups and their N-oxidised 
metabolites under low-energy CID conditions has been established.  It appears 
that the losses of N,N-dimethylhydroxylamine and N,N-diethylhydroxylamine 
can be diagnostic for oxidised dialkyl tertiary amine groups.  The losses are 
particularly useful in the context of characterising pharmaceutical drug 
metabolites because they are both of reasonably high mass (61 and 89 m/z 
units).  Thus, the likelihood of a false positive result i.e. characterising a mono-
oxidised metabolite as a dialkyl tertiary amine-N-oxide when the site of 
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oxidation is elsewhere on the molecule, is reduced compared to using a lower 
mass loss. 
 
The diagnostic loss can be integrated into a data interpretation approach that 
allows rapid and definitive characterisation of dialkyl tertiary amine-N-oxides.  
This methodology could be of benefit to metabolite identification scientists, as 
data interpretation is a recognised bottleneck to high-throughput studies.178  
The approach is demonstrated below using the QqTOF mass spectrometer with 
tetracaine as a test analyte (Figure 6.5), which was incubated with rat liver 
microsomes to produce phase I metabolites.  This compound was selected 
because it contains two possible sites for N-oxidation. 
 
 
Figure 6.5 Molecular structure of tetracaine 
 
Using the tools described in Chapter 2, an N-oxidised metabolite could be 
rapidly identified.  However, none of the approaches, apart from the difficult to 
implement ion-molecule reactions, would determine whether the secondary or 
tertiary amine had been oxidised.  Using the methodology described below, 
rapid and definitive characterisation is possible by incorporating the structurally 
dependent dissociation behaviour that is known to be diagnostic of dialkyl 
tertiary amine-N-oxides but not secondary amines.  A positive result would 
indicate that the parent compound has been oxidised at the dialkyl tertiary 
amine.  From a negative result, an analyst could infer that the site of oxidation is 
the secondary amine.  Although the approach is described using an “in-space” 
MS/MS platform, it is equally applicable to a mass spectrometer that performs 
“in-time” MS/MS. 
 
The approach requires a dual scan mass spectrometric experiment, which the 
instrument alternates between throughout the analysis.  The first scan involves 
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the acquisition of a full scan mass spectrum.  This will record all of the species 
produced from the ESI ion source at that time point within the mass range 
employed, including any protonated mono-oxidised metabolites of tetracaine in 
this example.  Combination of all of the full scan mass spectra acquired 
throughout the analysis produces a total ion current chromatogram (TICC) 
(Figure 6.6a).  The second scan is a product ion scan MS/MS experiment.  This 
scan involves dissociating all or some of the precursor ions entering the mass 
spectrometer, either using an MSE experiment280 or data-dependent acquisition 
(DDA).281  An MSE experiment was performed to acquire the presented data.  
The second scan allows structural information about the precursor ions, such as 
the metabolites of tetracaine in the exemplar, to be derived.  Thus, another 
TICC, this time of the low-energy CID product ion spectra, is produced (Figure 
6.6b).  The TICCs are used to characterise any dialkyl tertiary amine-N-oxides 
present by extracting the ion current related to specific m/z values of interest 
i.e. forming RICCs.  From the full scan TICC, the m/z value related to the 
protonated molecule of the parent compound is extracted; m/z 265 in the case 
of tetracaine (Figure 6.6c).  This RICC provides useful information about the 
retention time of the protonated parent compound.  Another RICC is 
constructed from the full scan TICC by extracting the ion current related to the 
m/z value of [M + H + 16 m/z unit]+, which for tetracaine is m/z 281.  This trace 
(Figure 6.6d) shows peaks for all of the protonated mono-oxidised metabolites, 
plus any nominally isobaric species.  The RICC in Figure 6.6d shows a peak 
eluting just after the protonated parent compound (Figure 6.6c) at 5.12 
minutes.  An analyst may assign this chromatographic peak as an N-oxide based 
upon its elution after the protonated parent compound.  However, it is not 
possible to determine whether the secondary or tertiary amine has been 
oxidised using just the RICC in Figure 6.6d.  To achieve this, the analyst would 
have to interrogate the low-energy CID product ion spectra related to the 
chromatographic peak; a potentially time-consuming process.  A faster 
approach to determining the site of oxidation would be to use the product ion 
scan TICC to create an RICC.  From the product ion scan TICC, the m/z value 
related to the diagnostic loss from the relevant dialkyl tertiary amine-N-oxide
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Figure 6.6 Total ion current chromatograms (TICCs) and reconstructed ion  
current chromatograms (RICCs) acquired using a Premier QqTOF 
mass spectrometer; a) Full scan TICC; b) Product ion scan TICC; 
c) RICC of m/z 265 from full scan TICC; d) RICC of m/z 281 from 
full scan TICC; e) RICC of m/z 220 from product ion scan TICC 
 
for the compound under investigation is extracted.  In the case of tetracaine, 
this is m/z 220 due to the loss of N,N-dimethylhydroxylamine from the oxidised 
dialkyl tertiary amine substructure.  The resultant trace shows two 
chromatographic peaks (Figure 6.6e).  The peak at 5.10 minutes aligns with that 
of the protonated mono-oxidised metabolite at 5.12 minutes.  Because the m/z 
value selected is known to relate to diagnostic dissociation behaviour, this peak 
can be definitively assigned as a dialkyl tertiary amine-N-oxide.  The second 
peak in the RICC is due to the same m/z value being observed in the low-energy 
CID product ion spectrum of the protonated parent compound.  This signal is 
important because it confirms that the loss of the nitrogen-containing group is 
observed for the protonated parent compound.  As detailed above, the data 
indicated that the loss or retention of the dialkyl tertiary amine group by the 
protonated parent compound is accompanied by equivalent dissociation 
behaviour for the nitrogen-containing group of the protonated dialkyl tertiary 
amine-N-oxide metabolite.  Therefore, the presence of a chromatographic peak 
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for the protonated parent compound in the product ion scan RICC proves that 
the loss of the nitrogen-containing group will be observed for the dialkyl tertiary 
amine-N-oxide if it is present in the sample.  Thus, if no chromatographic peak 
in the product ion scan RICC aligns with a chromatographic peak of a 
protonated mono-oxidised metabolite from the full scan RICC, an analyst can 
conclude that the metabolite is not formed.  The alternative conclusion, that the 
dialkyl tertiary amine-N-oxide is formed but the diagnostic loss is not observed 
in its low-energy CID product ion spectrum, can be excluded if a 
chromatographic peak is observed in the product ion scan RICC for the 
protonated parent compound.  In addition, the absence of a chromatographic 
peak that aligns with a protonated mono-oxidised metabolite, accompanied by 
the absence of a chromatographic peak for the protonated parent compound, 
would indicate that a dialkyl tertiary amine-N-oxide may have been formed but 
that it could not be characterised using the discussed approach.  This would be 
the case for diphenhydramine because the loss of the nitrogen-containing group 
was observed for neither the parent compound nor the N-oxide metabolite. 
 
6.4 Conclusions 
A rapid and definitive methodology for the characterisation of dialkyl tertiary 
amine-N-oxides has been developed.  The approach builds upon the 
understanding of the fragmentation behaviour under low-energy CID conditions 
of protonated dialkyl tertiary amines gained through the analysis of a 
structurally diverse library of commercially available pharmaceutical 
compounds.  The analyses showed that the loss of the nitrogen-containing 
group occurred in 89% of the low-energy CID product ion spectra, suggesting 
that the dissociation behaviour was generic.  Further, the product ions formed 
were demonstrated to be relatively unstable due to the observation of second-
generation dissociation using QqTOF-MS.  The increased understanding of low-
energy CID and gas-phase ion chemistry could be of use to developers on in 
silico packages for fragmentation prediction by allowing them to create more 
robust algorithms and models upon which the programs work.  Further, the 
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increased understanding of low-energy CID and gas-phase ion chemistry could 
be useful to mass spectrometrists interested in structural elucidation. 
 
The methodology for the characterisation of dialkyl tertiary amine-N-oxides 
overcomes the limitation of other tools for N-oxide identification by utilising 
dissociation behaviour that was shown to be diagnostic for a particular 
structural motif.  This allowed discrimination between potential sites of 
oxidation in different chemical environments in a mono-oxidised metabolite of 
tetracaine.  The approach is a high-throughput method because it removes the 
need for the analyst to interrogate the low-energy CID product ion spectrum of 
the metabolite, which reduces the data interpretation time.  The process could 
be automated, thus further decreasing the time taken.  The methodology is 
better suited to trap-configured mass spectrometers due to the greater ion 
current observed for the product ions of interest using QIT-MS.  However, with 
prudent selection of collision energy, it is amenable to collision cell-configured 
instruments, as evinced by the example of tetracaine on the QqTOF mass 
spectrometer.  Thus, the approach is low-energy CID-MS/MS platform 
independent and hence has scope for wide employment. 
 
The methodology is not applicable for the characterisation of all dialkyl tertiary 
amine-N-oxides because of the absence of the diagnostic loss in its low-energy 
CID product ion spectrum e.g. diphenhydramine-N-oxide.  In this circumstance, 
full interpretation of the low-energy CID product ion spectrum would be 
required to localise the site of oxidation.  However, attempting the RICC 
approach is not detrimental to throughput because full interpretation of the 
low-energy CID product ion spectrum is the method currently used for 
metabolite identification. 
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Chapter 7 
 
Evidence for site-specific intra-ionic 
hydrogen/deuterium exchange in the low-energy 
collision-induced dissociation product ion spectra of 
protonated small molecules generated by 
electrospray ionisation 
 
7.1 Introduction 
The use of isotopic labelling in structural elucidation studies and the 
rationalisation of dissociation mechanisms is a well-established approach in 
MS.282, 283  The use of solution-phase H/D exchange is particularly common due 
to the ease with which the number of exchangeable hydrogen atoms involved in 
a dissociation can be determined.284  
 
It is known that isomerisation of activated ions in the gas phase, leading to 
“scrambling” of the isotopic labels, can occur i.e. transfer of the isotopic label 
from its original location in the ion to another position.285  This observation has 
been documented extensively for ions formed by the highly energetic processes 
that take place in EI.  Under these conditions, randomisation of alkyl and 
aromatic hydrogen and carbons atoms has been detailed.286-295  However, very 
few reports of scrambling under low-energy CID conditions exist for protonated 
small molecules formed by ESI.296-299  Herein, an example of site-specific intra-
ionic H/D exchange in the gas phase for protonated molecules generated by ESI 
is detailed.  This example of ion-chemistry could be used to introduce an 
isotopic label into the carbon skeleton of a molecule without the need to 
produce an analogue synthetically. 
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7.2 Experimental 
 
7.2.1 Chemicals 
Amiodarone, amitriptyline, amitriptyline-N-oxide, benzydamine, cinchocaine, 
cinchocaine-N-oxide, chlorphenamine, chlorpromazine, a tri-oxidised 
chlorpromazine metabolite, a di-oxidised fluorinated chlorpromazine analogue, 
chloroquine, dibenzepin, dicycloverine, doxepin, hydroxychloroquine, 
levomepromazine, metoclopramide, nordoxepin, promethazine, protriptyline, 
sunitinib and sunitinib-N-oxide were provided by Pfizer Global Research and 
Development (Sandwich, UK).  Hexylamine was purchased from Sigma-Aldrich 
Company Ltd. (Gillingham, UK).  Solutions were prepared for QIT-MS and 
solution-phase H/D exchange experiments as detailed in Chapter 3.  A solution 
of amitriptyline was prepared for FT-ICR-MS experiments as detailed in Chapter 
3.  Further solutions of amitriptyline were prepared at 100 ng mL-1 in LC-MS 
grade methanol and analytical grade methanoic acid [99.9:0.1, v/v] for QqQ-MS 
experiments and at 10 mg mL-1 in both >99.5% deuterated methanol and 99.5% 
deuterated methanoic acid [99.9:0.1, v/v], and >99.9% deuterated acetone 
(Apollo Scientific Ltd., Stockport, UK) for NMR spectroscopy experiments. 
 
7.2.2 Instrumental 
QIT-MS experiments were performed as detailed in Chapter 3 to acquire “in-
time” low-energy CID product ion spectra.  The ion source conditions were; 
sheath gas, 25 arbitrary units; auxiliary gas, 0 arbitrary units (45 arbitrary units 
for the solution-phase H/D exchange experiments); spray voltage, 4.5 kV; 
capillary voltage, 10 V; capillary temperature, 160oC; tube lens offset, - 5 V.  
Low-energy CID product ion spectra were acquired using an isolation width of 1 
m/z unit and with WideBand activation on.  The normalised collision energy was 
set to 50%, except for the analyses of amiodarone (60%) and hexylamine (45%). 
 
“In-space” low-energy CID product ion spectra of amitriptyline were acquired 
using a Xevo TQMS QqQ mass spectrometer (Waters Ltd., Elstree, UK).  Positive 
ion ESI-MS/MS was performed by infusing the solutions directly into the nano-
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ESI ion source at a constant flow rate of 0.25 μL min-1.  Nitrogen was used as the 
cone, purge and nanoflow gas.  The ion source conditions were as follows; cone 
gas flow; 0 L hr-1; purge gas flow, 0 L hr-1; nanoflow gas flow, 0.1 bar; capillary 
voltage, 1.5 kV; sampling cone, 30 V; extraction cone, 3 V; source temperature, 
70 oC.  Low-energy CID product ion spectra were acquired at a collision energy 
of 25 eV using argon as the collision gas.  Acquisitions were performed for 
twenty scans.  The scan time was 0.5 s and the interscan time was 0.005 s.  Data 
acquisition was performed using MassLynx version 4.1 (Waters Ltd., Elstree, 
Herts., UK). 
 
FT-ICR-MS experiments were performed as detailed in Chapter 3 to acquire an 
AMM “in-time” low-energy SORI-CID product ion spectrum of amitriptyline.  The 
ion source conditions were; capillary voltage, - 4.5 kV; end plate voltage, - 
3.8 kV; capillary exit voltage, 85 V; skimmer 1, 15 V; skimmer 2, 8.5 V; Offset, 
1.25; RF amplitude, 600 Hz; dry gas temperature, 250oC; dry gas flow rate, 
30 arbitrary units; nebulising gas pressure, 50 psi.  The excitation amplitude was 
7.0 dB.  A low-energy SORI-CID product ion spectrum was acquired for thirty-
two scans using 512K data points.  The MS/MS parameters were; corr sweep 
pulse length, 1000 µs; corr sweep attenuation, 28.5 dB; ejection safety belt, 
3000 Hz; user pulse length, 1000 µs; ion activation pulse length, 250000 µs; ion 
activation attenuation, 38.9 dB; frequency offset from activation mass, - 500 Hz; 
user delay length, 3 s. 
 
Proton (1H) NMR spectra were recorded using a DPX-400 (Bruker, Coventry, UK) 
at 298 K. Chemical shifts for the 1H spectra are reported on the δ scale in ppm 
and were referenced to residual solvent references.  All coupling constants (J 
values) are reported in Hz.  Amitriptyline in deuterated acetone; δH (400 MHz) 
7.33-7.06 (m, 8H, aromatic H), 5.91 (t, 1H, J = 7.3), other peaks obscured by 
water signal at 3.13.  Amitriptyline in deuterated methanol and deuterated 
methanoic acid; δH (400 MHz) 7.30-7.05 (m, 8H, aromatic H), 5.83 (t, 1H, J = 
7.3), 3.25 (t, 2H, J = 7.8), 2.81 (s, 6H), 2.59 (dt, 2H, J = 7.3), other peaks obscured 
by background signal. 
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7.3 Results and discussion 
The experimental data presented in Chapter 6 showed that under low-energy 
CID conditions, dialkyl tertiary amine-containing compounds frequently display 
the loss of dimethylamine in their product ion spectra.  Solution-phase H/D 
exchange experiments were conducted to determine the number of 
exchangeable hydrogen atoms involved in this loss.  During these experiments, 
intra-ionic H/D exchange was noted upon comparison of the low-energy CID 
product ion spectra of protonated amitriptyline and deuterated amitriptyline 
acquired using QIT-MS (Figure 7.1).  Similar observations were made for the 
structurally similar compounds in Compound set 1; doxepin and nordoxepin 
(Figures 7.2-7.4).  Based upon the hypothesis that the deuteron is localised on 
the nitrogen atom in solution (a reasonable assumption given the high solution-
phase basicity of the lone pair of electrons on the nitrogen atom relative to the 
delocalised π-electrons), it would be expected that the loss of dimethylamine 
would involve the deuteron i.e. a loss of deuterodimethylamine (46 m/z units) 
would be observed.  However, dissociation of the deuterated molecule of 
amitriptyline generates product ions formed through the losses of both 
dimethylamine (m/z 234) and deuterodimethylamine (m/z 233).  Further, the 
other annotated product ions in Figure 7.1a appeared to undergo intra-ionic 
H/D exchange.  This is indicated by the presence of pairs of peaks along the 
mass scale under deuterated conditions of similar abundance relative to one 
another as those observed at m/z 233 and 234.  These observations suggested 
that intra-ionic H/D exchange takes place prior to fragmentation when the 
precursor ion is activated under low-energy CID conditions. Low-energy CID 
product ion spectra of protonated and deuterated amitriptyline were also 
acquired using QqQ-MS.  The resultant spectra show the same dissociation 
patterns (Figure 7.5).  This demonstrated that there was no involvement from 
possible traces of water present in the helium buffer gas used in the QIT-MS, 
which would affect the dissociation of ions using these types of instrument.300  
Interferences from water could lead to some of the mass isolated deuterated 
molecules of amitriptyline being converted to protonated molecules prior to
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Figure 7.1 First-generation low-energy CID product ion spectra of a) 
protonated amitriptyline (m/z 278) and b) deuterated 
amitriptyline (m/z 279) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on.  AMMs were 
acquired using an Apex III FT-ICR mass spectrometer 
 
 
 
Figure 7.2 Molecular structures in Compound set 1 
 
dissociation.  This would explain the losses of both dimethylamine and 
deuterodimethylamine.  However, the observation of the same losses using a 
beam-type instrument, where no interference from water is likely to occur, 
lends support to the hypothesis of intra-ionic H/D exchange.  The observation of 
intra-ionic H/D exchange using QqQ-MS also ruled out the involvement of an 
ion-neutral complex in the transfer of the deuterium label.  Extended time 
frames, such as those afforded by the millisecond activation times utilised 
during low-energy CID using QIT-MS, are required to facilitate the formation of 
ion-neutral complexes.  Conversely, the microsecond time frame available for
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Figure 7.3 First-generation low-energy CID product ion spectra of a) 
protonated doxepin (m/z 280) and b) deuterated doxepin 
(m/z 281) acquired using a LCQ Classic QIT mass spectrometer 
with WideBand activation on 
 
 
 
 
 
Figure 7.4 First-generation low-energy CID product ion spectra of a) 
protonated nordoxepin (m/z 266) and b) fully exchanged, 
deuterated nordoxepin (m/z 268) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
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ion activation during low-energy CID on QqQ mass spectrometers does not 
allow their formation.301  Therefore, as the intra-ionic H/D exchange is seen 
irrespective of the time available for ion activation, it can be concluded that an 
ion-neutral complex does not facilitate the isomerisation that is observed. 
 
 
Figure 7.5 Product ion spectra of a) protonated amitriptyline (m/z 278) 
and b) deuterated amitriptyline (m/z 279) acquired using a Xevo 
TQMS QqQ mass spectrometer 
 
Two alternative hypotheses were considered and excluded.  The first 
postulation was that the peak at m/z 234 was formed through the loss of 
dimethylamine from the 13C-isotopologue of the protonated molecule of 
amitriptyline.  This hypothesis was discounted because a high auxiliary gas 
pressure (45 arbitrary units) was utilised to prevent back-exchange in the gas 
phase.296  This led to a low intensity of protonated amitriptyline relative to 
deuterated amitriptyline (9%:100%) being observed in the full scan mass 
spectrum (data not shown).  Thus, the contribution of the 13C-isotopologue of 
protonated amitriptyline to the isolated precursor ion signal at m/z 279 was 
deemed negligible.  Further, it was concluded that any 13C-isotopologue of 
protonated amitriptyline present would provide insufficient ion current to be 
exclusively responsible for the product ion intensity at m/z 234, particularly 
given that some of the ion current would be distributed through the other 
dissociation pathways that exist for amitriptyline.  The second hypothesis was 
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that two losses of dimethylamine took place; one facilitated by the ionising 
proton and one involving the shift of a non-exchangeable hydrogen atom.  This 
postulation was consistent with the experimental observations under 
deuterated conditions.  The loss involving the non-exchangeable hydrogen atom 
would remain as 45 m/z units whilst the ionising deuteron would cause the 
second loss to become 46 m/z units.  This hypothesis would require a 
heterogeneous population of protonated molecules to be produced by the ESI 
ion source.  Some of the members of the population would be protonated at 
the nitrogen atom to facilitate the loss involving an exchangeable hydrogen 
atom.  Other members of the population would be ionised at a site other than 
the nitrogen atom to allow the loss involving a non-exchangeable hydrogen 
atom.  Ion mobility spectrometry (IMS) experiments have shown that small 
molecules ionised by ESI can protonate at more than one site.42  Thus, this 
hypothesis could not be completely excluded on the basis of the experimental 
data obtained through the analysis of amitriptyline.  However, it was deemed 
less likely than the intra-ionic H/D exchange hypothesis due to the absence of a 
second heteroatom in the structure of amitriptyline to provide a plausible site 
of protonation under ESI conditions.  Hence, the most logical rationalisation was 
intra-ionic H/D exchange in the gas phase prior to dissociation.  
 
The hypothesis of intra-ionic H/D exchange was investigated further by 
conducting NMR spectroscopy measurements in deuterated solvents.  The 
experiments were undertaken to determine whether intra-ionic H/D exchange 
took place in solution.  Two samples were prepared; one in solvents with acidic 
deuterons i.e. deuterated methanol and deuterated methanoic acid, and one 
without i.e. deuterated acetone.  Given that the pKa of amitriptyline is 9.4,
302 
the ionised form of the compound, by virtue of deuteration, would exist in the 
sample in deuterated methanol and deuterated methanoic acid.  Thus, intra-
ionic H/D exchange was feasible.  The sample in deuterated acetone acted as a 
control because amitriptyline would not be ionised through deuteration due to 
the absence of acidic deuterons in the solvent.  Thus, the amitriptyline would 
exist as the free base and no intra-ionic H/D exchange would be possible.  
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Comparison of the signals in the two 1H NMR spectra suggested that all of the 
hydrogen atoms were localised on the carbon skeleton of amitriptyline in 
solution, regardless of whether the solvents contained acidic deuterons or not.  
This observation supports the hypothesis of intra-ionic H/D exchange taking 
place in the gas phase. 
 
Further investigations were undertaken using FT-ICR-MS.  AMMs were acquired 
and indicated that all of the product ions thought to undergo transfer of the 
deuterium label involve the loss of the nitrogen atom during their formation 
(Figure 7.1a).  Concurrent loss of the deuterium atom would be expected if 
intra-ionic H/D exchange did not take place, assuming that the deuteron was 
localised on the nitrogen atom.  However, the AMMs added confidence to the 
hypothesis that the deuterium atom was inserted into the carbon skeleton of 
the molecule via intra-ionic H/D exchange prior to dissociation. 
 
A sample of amitriptyline-N-oxide was analysed to determine the effect that a 
different site of ionisation would have on the intra-ionic H/D exchange.  For this 
compound, ionisation would be expected to take place at the oxygen of the N-
oxide substructure c.f. the nitrogen atom of amitriptyline.  The spectra in Figure 
7.6 show that intra-ionic H/D exchange of the deuterium atom does take place, 
although to a lesser extent than for amitriptyline. 
 
The observation of intra-ionic H/D exchange for the compounds analysed led to 
the question of whether the proposed exchange is site-specific, or whether 
complete randomisation of all of the hydrogen and deuterium atoms takes 
place.  It was hypothesised that the exchange involves the γ-hydrogen relative 
to the nitrogen atom.  To determine whether the intra-ionic H/D exchange is 
facilitated by the γ-hydrogen relative to the nitrogen atom, and is thus site-
specific, first-generation low-energy CID product ion spectra of dibenzepin and 
promethazine were acquired (Compound set 2, Figure 7.7).  These compounds 
lack a γ-hydrogen relative to the nitrogen atom and do not exhibit intra-ionic 
H/D exchange (Figures 7.8-7.9).  This suggested that the intra-ionic H/D
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Figure 7.6 First-generation low-energy CID product ion spectra of a) 
protonated amitriptyline-N-oxide (m/z 294) and b) deuterated 
amitriptyline-N-oxide (m/z 295) acquired using a LCQ Classic QIT 
mass spectrometer with WideBand activation on 
 
exchange is dependent upon the presence of a γ-hydrogen relative to the 
nitrogen atom, and thus is site-specific.  By extension, this excluded the 
exchanged hydrogen atom in amitriptyline and amitriptyline-N-oxide from being 
originally located on the α, β or aromatic carbon atoms.  If any of the hydrogen 
atoms at these sites were exchanged, analogous behaviour would be expected 
of dibenzepin and promethazine.  The combination of observations thus far 
leads to the conclusions that the intra-ionic H/D exchange is site-specific, 
requiring a γ-hydrogen relative to the nitrogen atom, and takes place in the gas 
phase.  The NMR spectroscopy measurements support the final conclusion by 
showing that the alkene hydrogen atom to aromatic hydrogen atom signal ratio 
 
 
Figure 7.7 Molecular structures in Compound set 2 
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Figure 7.8 First-generation low-energy CID product ion spectra of a) 
protonated dibenzepin (m/z 296) and b) deuterated dibenzepin 
(m/z 297) acquired using a LCQ Classic QIT mass spectrometer 
with WideBand activation on 
 
 
 
 
 
Figure 7.9 First-generation low-energy CID product ion spectra of a) 
protonated promethazine (m/z 285) and b) deuterated 
promethazine (m/z 286) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
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stays constant, regardless of the solvents used.  This indicates that the γ-
hydrogen relative to the nitrogen atom remains bonded to the carbon atom in 
solution.  Thus, no intra-ionic H/D exchange takes place in solution, otherwise a 
decrease in the alkene hydrogen atom to aromatic hydrogen atom signal ratio 
would be observed. 
 
Two sets of compounds were analysed to further confirm the site-specificity of 
the intra-ionic H/D exchange.  Compound set 3 contained amiodarone and 
dicycloverine (Figure 7.10).  Instead of a γ-hydrogen relative to the nitrogen 
atom, both compounds have an oxygen atom at this position.  Thus, no intra-
ionic H/D exchange would be expected if the transfer were site-specific due to 
the absence of the relevant hydrogen atom.  The comparison between the 
compound sets is like for like because the hybridisation states of an oxygen 
atom and a methylene group are identical i.e. sp3.  Thus, no significant change in 
the shape of the chain, nor its ability to rotate, should result from the 
modification in substructure.  As a result, no difference in the likelihood of other 
hydrogen atoms exchanging with the deuterium label should result; an 
occurrence that could affect the interpretation of the data.  The first-generation 
low-energy CID product ion spectra of amiodarone and dicycloverine in protic 
and deuterated solvents show no evidence of intra-ionic H/D exchange (Figures 
7.11-7.12). 
 
 
Figure 7.10 Molecular structures in Compound set 3 
 
The second group of compounds, Compound set 4, contained cinchocaine, 
cinchocaine-N-oxide, metoclopramide, sunitinib and sunitinib-N-oxide (Figure 
7.13).  The molecules in Compound set 4 contain a γ-hydrogen relative to the
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Figure 7.11 First-generation low-energy CID product ion spectra of a) 
protonated amiodarone (m/z 646) and b) deuterated 
amiodarone (m/z 647) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.12 First-generation low-energy CID product ion spectra of a) 
protonated dicycloverine (m/z 310) and b) deuterated 
dicycloverine (m/z 311) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
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Figure 7.13 Molecular structures in Compound set 4 
 
nitrogen atom, but in this case it is an exchangeable hydrogen atom.  Thus, 
under deuterated conditions in solution, it exchanges for a deuterium atom.  If 
the intra-ionic H/D exchange in the gas phase were indeed site-specific as 
postulated, the ionising deuteron localised at the tertiary amine group would 
exchange for another deuteron.  Thus, subsequent loss of the tertiary amine 
group in the low-energy CID product ion spectrum would show no evidence of 
transfer of the deuterium label even if intra-ionic H/D exchange had taken 
place.  Figure 7.14 shows the first-generation low-energy CID product ion 
spectra of sunitinib in protic and deuterated solvents as an exemplar for the 
compound set.  The first-generation low-energy CID product ion spectrum 
acquired under deuterated conditions only displays the loss of 
deuterodiethylamine, consistent with exchange of the deuteron at the tertiary 
amine group taking place with another deuterium atom.  The first-generation 
low-energy CID product ion spectra of the other four compounds in the 
compound set also only show the losses of deuterodiethylamine and 
deuterodiethylhydroxylamine, depending upon whether the tertiary amine 
group is oxidised or not (Figures 7.15-7.18).  The analysis of Compound sets 3 
and 4 provide supportive evidence for site-specific intra-ionic H/D exchange by 
showing that in the absence of a γ-hydrogen relative to the nitrogen atom, no 
evidence for the transfer of the deuterium label could be obtained.
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Figure 7.14 First-generation low-energy CID product ion spectra of a) 
protonated sunitinib (m/z 399) and b) fully exchanged, 
deuterated sunitinib (m/z 403) acquired using a LCQ Classic QIT 
mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.15 First-generation low-energy CID product ion spectra of a) 
protonated cinchocaine (m/z 344) and b) fully exchanged, 
deuterated cinchocaine (m/z 346) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
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Figure 7.16 First-generation low-energy CID product ion spectra of a) 
protonated cinchocaine-N-oxide (m/z 360) and b) fully 
exchanged, deuterated cinchocaine-N-oxide (m/z 362) acquired 
using a LCQ Classic QIT mass spectrometer with WideBand 
activation on 
 
 
 
 
 
Figure 7.17 First-generation low-energy CID product ion spectra of a) 
protonated metoclopramide (m/z 300) and b) fully exchanged, 
deuterated metoclopramide (m/z 304) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
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Figure 7.18 First-generation low-energy CID product ion spectra of a) 
protonated sunitinib-N-oxide (m/z 415) and b) fully exchanged, 
deuterated sunitinib-N-oxide (m/z 419) acquired using a LCQ 
Classic QIT mass spectrometer with WideBand activation on 
 
Thus far, the intra-ionic H/D exchange has been observed for compounds with 
the exchanged hydrogen atom bonded to an alkene carbon.  To determine 
whether the exchange is dependent upon the hybridisation state of the carbon 
atom, a fifth set of compounds was analysed; chlorpromazine, a tri-oxidised 
chlorpromazine metabolite, a di-oxidised chlorpromazine analogue, 
chloroquine, hydroxychloroquine, levomepromazine and protriptyline (Figure 
7.19).  All of these compounds contain a γ-hydrogen, relative to the nitrogen 
atom, which is bonded to a sp3 hybridised carbon atom.  The first-generation 
low-energy CID product ion spectra of chlorpromazine (Figure 7.20) show 
evidence of intra-ionic H/D exchange for the three most abundant product ions.  
The other compounds in the set also display intra-ionic H/D exchange (Figures 
7.21-7.26).  This suggests that the intra-ionic H/D exchange can take place with 
a γ-hydrogen relative to a nitrogen atom, irrespective of whether the hydrogen 
is bonded to an sp2 or sp3 hybridised carbon atom. 
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Figure 7.19 Molecular structures in Compound set 5 
 
 
 
 
 
Figure 7.20 First-generation low-energy CID product ion spectra of a) 
protonated chlorpromazine (m/z 319) and b) deuterated 
chlorpromazine (m/z 320) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
Chapter 7 
133 
 
Figure 7.21 First-generation low-energy CID product ion spectra of a) a 
protonated tri-oxidised chlorpromazine metabolite (m/z 367) 
and b) fully exchanged, deuterated tri-oxidised chlorpromazine 
metabolite (m/z 369) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.22 First-generation low-energy CID product ion spectra of a) a 
protonated di-oxidised chlorpromazine analogue (m/z 385) and 
b) deuterated di-oxidised chlorpromazine analogue (m/z 386) 
acquired using a LCQ Classic QIT mass spectrometer with 
WideBand activation on 
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Figure 7.23 First-generation low-energy CID product ion spectra of a) 
protonated chloroquine (m/z 320) and b) fully exchanged, 
deuterated chloroquine (m/z 322) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.24 First-generation low-energy CID product ion spectra of a) 
protonated hydroxychloroquine (m/z 336) and b) fully 
exchanged, deuterated hydroxychloroquine (m/z 339) acquired 
using a LCQ Classic QIT mass spectrometer with WideBand 
activation on 
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Figure 7.25 First-generation low-energy CID product ion spectra of a) 
protonated levomepromazine (m/z 329) and b) deuterated 
levomepromazine (m/z 330) acquired using a LCQ Classic QIT 
mass spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.26 First-generation low-energy CID product ion spectra of a) 
protonated protriptyline (m/z 264) and b) fully exchanged, 
deuterated protriptyline (m/z 266) acquired using a LCQ Classic 
QIT mass spectrometer with WideBand activation on 
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A further set of compounds was analysed to investigate the intra-ionic H/D 
exchange.  This set contained benzydamine and chlorphenamine (Compound 
set 6, Figure 7.27), both of which contain a γ-hydrogen relative to a nitrogen 
atom.  However, the carbon bearing the γ-hydrogen is also bonded to an 
electron-withdrawing group; an oxygen atom and a chlorinated phenyl ring for 
benzydamine and chlorphenamine respectively.  Neither of these compounds 
display intra-ionic H/D exchange in their first generation low-energy CID product 
ion spectra (Figures 7.28-7.29).  The absence of intra-ionic H/D exchange 
suggests that the presence of an electron-withdrawing group adjacent to the 
carbon atom bearing the γ-hydrogen can prevent exchange from taking place.  
However, the properties of the electron-withdrawing group appear to 
determine whether the intra-ionic H/D exchange is precluded.  This is because 
the presence of the nitrogen atom bonded to the γ-carbon in chlorpromazine, 
the tri-oxidised chlorpromazine metabolite, the di-oxidised fluorinated 
chlorpromazine analogue and levomepromazine (Figure 7.19) does not prevent 
intra-ionic H/D exchange in these compounds (Figures 7.20-7.22 and Figure 
7.25).  This observation may be consistent with the fact that nitrogen has a 
lower electronegativity than oxygen or a chlorinated phenyl ring.  However, the 
compounds available in this study did not provide an extensive enough dataset 
on which to draw any robust conclusions. 
 
 
Figure 7.27 Molecular structures in Compound set 6 
 
Finally, to address whether the chemical environment of the alkyl chain affects 
the observation of intra-ionic H/D exchange, first-generation low-energy CID 
product ion spectra of a “linear” tertiary amine with a γ-hydrogen, hexylamine, 
were acquired (Figure 7.30).  Comparison of the product ion spectra shows that
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Figure 7.28 First-generation low-energy CID product ion spectra of a) 
protonated benzydamine (m/z 310) and b) deuterated 
benzydamine (m/z 311) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
 
 
 
 
 
Figure 7.29 First-generation low-energy CID product ion spectra of a) 
protonated chlorphenamine (m/z 275) and b) deuterated 
chlorphenamine (m/z 276) acquired using a LCQ Classic QIT 
mass spectrometer with WideBand activation on 
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no intra-ionic H/D exchange takes place (Figure 7.31).  The additional peaks 
observed under deuterated conditions that are not observed under protonated 
conditions are due to noise i.e. the peaks were not seen repeatably.  The 
absence of intra-ionic H/D exchange suggests that the chemical environment 
provided by the molecule influences whether the deuterium label is transferred.  
Specifically, the molecules for which intra-ionic H/D exchange was observed 
were all pharmaceutical compounds containing substructures such as aromatic 
rings.  These more complex molecules may provide chemical environments that 
facilitate intra-ionic H/D exchange.  However, the exact substructures that assist 
the intra-ionic H/D exchange could not be determined from the compounds 
that were available.  Additional experiments are being conducted to further 
investigate the facilitating substructures. 
 
 
Figure 7.30 Molecular structure of hexylamine 
 
 
 
 
Figure 7.31 First-generation low-energy CID product ion spectra of a) 
protonated hexylamine (m/z 130) and b) deuterated 
hexylamine (m/z 131) acquired using a LCQ Classic QIT mass 
spectrometer with WideBand activation on 
 
The experimental investigation has demonstrated the conditions under which 
the site-specific intra-ionic H/D exchange is observed.  The observations have 
relevance to structural elucidation studies by providing a simple, non-synthetic 
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means of introducing a deuterium label into the carbon skeleton of a molecule.  
If an analyst has a compound containing a tertiary amine or tertiary amine-N-
oxide with a γ-hydrogen, analysis in deuterated solvents will cause exchange of 
this hydrogen atom for the ionising deuteron under low-energy CID conditions.  
Thus, the product ions known to lose the nitrogen-containing group, but which 
display intra-ionic H/D exchange, must retain the γ-carbon relative to the 
nitrogen atom.  The γ-carbon can be either sp2 or sp3 hybridised but adjacent 
electron-withdrawing groups can preclude the occurrence of intra-ionic H/D 
exchange.  Further, if an analyst is working with an unknown compound in 
deuterated solvents, the observation of intra-ionic H/D exchange under low-
energy CID conditions, which is rare, may indicate that a tertiary amine or 
tertiary amine-N-oxide with a γ-hydrogen not adjacent to specific electron-
withdrawing groups is present in the molecule. 
 
7.4 Conclusions 
Site-specific intra-ionic H/D exchange under low-energy CID conditions in a 
series of protonated small molecules has been observed.  Experiments have 
shown that the exchange takes place between the deuteron that ionises either 
a tertiary amine or tertiary amine-N-oxide group and a γ-hydrogen relative to 
the nitrogen atom.  The presence of an electron-withdrawing group bonded to 
the carbon atom bearing the γ-hydrogen can prevent the site-specific intra-ionic 
H/D exchange in some circumstances.  Further, the chemical environment in 
which the γ-hydrogen relative to the nitrogen atom structural motif is present 
appears to influence the ion’s propensity to undergo site-specific intra-ionic H/D 
exchange.  The observations could aid structural elucidation studies by 
providing a simple, non-synthetic means of introducing an isotopic label into the 
carbon skeleton of a molecule in a site-specific manner when a particular 
structural motif is present in the compound.  This is of practical benefit because 
it would enable faster completion of structural elucidation studies, as well as 
reducing costs because a deuterium-labelled analogue would not have to be 
produced synthetically. 
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Chapter 8 
 
Concluding remarks 
 
8.1 Summary and conclusions 
The aim of the presented study was to elucidate structurally dependent 
dissociation pathways that could be used to rapidly and definitively identify and 
characterise pharmaceutical drug metabolites using low-energy CID-MS/MS.  
The work was initiated as a result of promising data from the study by Wright 
and co-workers.230  Their work demonstrated that distinctive fragmentation 
behaviour under low-energy CID conditions could be used to characterise S-
oxidised metabolites.  Very few other groups had demonstrated this approach 
to definitively identify oxidised metabolites i.e. through the understanding of 
the dissociation behaviour of the substructure containing the site of oxidation.  
Therefore, the lack of existing literature, in combination with the recognition of 
the potential of the approach to shift the accepted bottleneck in modern 
pharmaceutical drug metabolite identification studies i.e. data interpretation 
and the associated time-commitment of skilled analysts,303 meant that further 
investigation was desirable.  
 
The study has been successful in identifying two potentially useful dissociation 
pathways that could allow definitive characterisation of certain S- and N-
oxidised metabolites (see Chapters 4 and 6).  These pathways were elucidated 
by understanding, through both experimental and computational approaches, 
the dissociation of the substructure containing the site of oxidation in a similar 
manner to Wright and co-workers.  It was recognised early in the study that the 
marginal change to a drug’s structure that occurs when oxidation takes place 
would rarely alter the dissociation behaviour significantly enough to cause 
distinctly different product ions or losses for the metabolite compared to the 
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parent compound.  Thus, diagnostic product ions and losses arising solely from 
the S+-O-, N+-O- and C-OH moieties is unlikely because the structural change is 
almost certainly insufficient to create a substructure that will drive the 
dissociation differently.  Therefore, it is the author’s opinion that completely 
generic dissociation behaviour i.e. the same product ion or loss being formed 
due to the presence of S+-O-, N+-O- or C-OH bond in the metabolite regardless of 
the overall molecular structure, is not possible under low-energy CID conditions.  
However, by understanding how the dissociation is driven by the chemical 
environment in which the oxidised group is positioned, it is possible to elucidate 
structurally dependent dissociation pathways that can be used to definitively 
characterise pharmaceutical drug metabolites using low-energy CID-MS/MS, as 
evinced by the presented study.  As dissociation is known to be driven by the 
structure of the molecule, it should be possible to determine further 
substructures that drive particular fragmentation pathways.  Thus, further work 
in the area of understanding fragmentation under low-energy CID conditions is 
required due to the current lack of knowledge.  The potential benefit to the 
area of structural elucidation, including metabolite identification, and the 
likelihood of success is demonstrated by the presented study.  Furthermore, the 
investigation of the dissociation of pharmaceutical drug metabolites using other 
ion activation techniques should be conducted.  In particular, electron capture 
dissociation (ECD) is garnering interest as a method to dissociate small 
molecules.304  Recent work has shown that, contrary to widespread belief, singly 
charged molecules can be dissociated using ECD.305  The study demonstrated 
that the product ions formed are complementary to those observed under low-
energy CID conditions.  Most interestingly, the work reports cleavages across 
benzene rings, which are resistant to fragmentation under low-energy CID 
conditions.  ECD may therefore enable definitive assignment of the site of 
hydroxylation on a benzene ring, which is a challenging proposition using the 
current technology and approaches.  A related ion activation technique, 
electron transfer dissociation (ETD),306 has yet to be applied to the area of small 
molecule structural elucidation.  It is therefore the author’s opinion that 
investigation of the application of both types of radical-induced dissociation 
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techniques should be performed, as they could provide useful additions to the 
small molecule structural elucidation approaches.  Further studies of MS/MS 
dissociation, regardless of the employed ion activation technique, will also be of 
use to developers of in silico packages for fragmentation prediction.  These 
software packages generally use rules derived from EI mass spectra for small 
molecule fragmentation prediction,234 which are not necessarily directly 
applicable to CID, ECD or ETD product ion spectra, or are based on case-specific 
information derived from compiled MS/MS databases.307  Therefore, increased 
knowledge and understanding of MS/MS dissociation would be useful to make 
these packages more accurate and robust, and hence more useful. 
 
In addition to the original aim of the study, extensive interrogation and 
interpretation of product ion spectra has enabled an increased understanding of 
ion-chemistry under low-energy CID conditions.  Each chapter has made a 
contribution to the body of knowledge in this area.  Chapter 4 showed that 
sequential radical losses can take place from an even-electron precursor ion 
under low-energy CID conditions.  This would not be expected on energetic 
grounds based upon the even-electron rule.251  Further, the experimental 
observations suggested a preference for the formation of planar product ion 
structures under low-energy CID conditions.  This proposal was supported by 
the observations detailed in Chapter 5, which again suggested that planar 
product ion structures are preferentially formed over those that have a greater 
number of bonds which have free rotation.  Chapter 5 also showed that 
unexpected rearrangements take place under low-energy CID conditions.  This 
highlighted the need for an analytically rigorous experimental methodology 
when performing structural elucidation studies to prevent incorrect ion 
structure assignments.  Chapter 6 demonstrated that dialkyl tertiary amines and 
their N-oxides generally dissociate in a predictable way, with the neutral loss of 
this group observed in the low-energy CID product ion spectrum.  The loss 
appeared to be governed by ionisation taking place at this substructure and is 
likely to only occur when this prerequisite is fulfilled.  The data also suggested 
that the product ions formed through the loss of the dialkyl tertiary amine 
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group or its N-oxidised analogue are relatively unstable and thus susceptible to 
further dissociation.  Finally, Chapter 7 illustrated that site-specific intra-ionic 
H/D exchange can take place such that the ionising deuteron can be swapped 
with a non-exchangeable γ-hydrogen and thus be inserted into the carbon 
skeleton of the compound.  This is a rare observation, and the site-specificity of 
the exchange also allows it to be a useful tool for structural elucidation studies. 
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Appendix 1 
 
Table A1 Molecular structures of compounds containing a dimethylamine 
substructure 
 
Compound Molecular structure 
Alimemazine 
 
Almotriptan 
 
Amitriptyline 
 
Amlodipine structural 
analogue 1 
 
Amlodipine structural 
analogue 2 
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Amlodipine structural 
analogue 3 
 
Amlodipine structural 
analogue 4 
 
Benzydamine 
 
Chlorphenamine 
 
Chlorpromazine 
 
Chlorpromazine 
structural analogue 1 
 
Chlorpromazine 
structural analogue 2 
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Chlorprothixene 
 
Citalopram 
 
Clomipramine 
 
Cyclopentolate 
 
Demeclocycline 
 
Dibenzepin 
 
Diltiazem 
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Diphenhydramine 
 
Doxepin 
 
Doxycycline 
 
Imipramine 
 
Iprindole 
 
Levomepromazine 
 
Metformin 
 
Moxisylyte 
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Olopatadine 
 
Orphenadrine 
 
Promazine 
 
Promethazine 
 
Ranitidine 
 
Rivastigmine 
 
Sibutramine 
 
Sumatriptan 
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Sunitinib structural 
analogue 
 
Tamoxifen 
 
Tetracaine 
 
Tramadol 
 
Trimipramin 
 
Venlafaxine 
 
Zimelidine 
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Table A2  Molecular structures of compounds containing a diethylamine 
substructure 
 
Compound Molecular structure 
Amiodarone 
 
Amlodipine structural 
analogue 5 
 
Chloroquine 
 
Cinchocaine 
 
Clomifene 
 
Dicycloverine 
 
Disulfiram 
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Lidocaine 
 
Macrogol 
 
Metoclopramide 
 
Naftidrofuryl 
 
Oxybuprocaine 
 
Oxybutynin 
 
Procainamide 
 
Procaine 
 
Sunitinib 
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Table A3 Molecular structures of compounds containing an N,N-
dimethylhydroxylamine substructure 
 
Compound Molecular structure 
Amitriptyline-N-oxide 
 
Chlorpromazine-N-oxide 
1 
 
Chlorpromazine-N-oxide 
2 
 
Chlorpromazine 
structural analogue-N-
oxide 1 
 
Chlorpromazine 
structural analogue-N-
oxide 2 
 
Diphenhydramine-N-
oxide 
 
Ephedrine structural 
analogue-N-oxide 
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Tamoxifen structural 
analogue-N-oxide 1 
 
Tamoxifen structural 
analogue-N-oxide 2 
 
Tetracaine-N-oxide 
 
 
 
 
Table A4 Molecular structures of compounds containing an N,N-
diethylhydroxylamine substructure 
 
Compound Molecular structure 
Cinchocaine-N-oxide 
 
Sunitinib-N-oxide 
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Table A5 Relative abundances (RA) for the product ion formed through 
the loss of dimethylamine from a series of pharmaceutical 
compounds using QqTOF-MS and QIT-MS at various collision 
energies 
 
Compound RA using 
QqTOF-
MS at 15 
eV / % 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Alimemazine 6 4 1 41 37 
Almotriptan 52 100 31 17 16 
Amitriptyline 76 64 20 100 100 
Amlodipine 
structural 
analogue 1 
11 4 1 94 89 
Amlodipine 
structural 
analogue 2 
23 18 - 100 100 
Amlodipine 
structural 
analogue 3 
2 1 - 63 71 
Amlodipine 
structural 
analogue 4 
5 4 2 100 100 
Benzydamine 11 5 1 100 100 
Chlorphenamine 100 100 100 100 100 
Chlorpromazine 4 3 2 100 100 
Chlorpromazine 
structural 
analogue 1 
- - - 7 7 
Chlorpromazine 
structural 
analogue 2 
1 8 3 21 21 
Chlorprothixene 100 100 66 100 42 
Citalopram 8 2 - 12 16 
Clomipramine 6 4 3 100 100 
Cyclopentolate - - - - - 
Demeclocycline - - - - - 
Dibenzepin 100 100 100 100 100 
Diltiazem 19 3 - 18 33 
Diphenhydramine - - - - - 
Doxepin 39 18 9 100 100 
Doxycycline - - 2 3 - 
Imipramine 4 3 2 21 15 
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Iprindole 2 4 5 1 1 
Levomepromazine 8 4 4 100 99 
Metformin 33 23 14 15 14 
Moxisylyte 9 5 1 100 100 
Olopatadine 8 13 6 16 19 
Orphenadrine - - - - - 
Promazine 7 4 3 55 47 
Promethazine 15 12 5 100 100 
Ranitidine 7 2 - 71 100 
Rivastigmine 100 49 11 100 100 
Sibutramine - - - - - 
Sumatriptan 100 71 12 100 81 
Sunitinib 
structural 
analogue 
100 63 33 89 100 
Tamoxifen 2 1 - 100 100 
Tetracaine 11 10 5 16 17 
Tramadol - 2 - 16 - 
Trimipramin 4 4 2 21 18 
Venlafaxine - - - - - 
Zimelidine 14 6 3 79 80 
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Table A6 Relative abundances (RA) for the product ion formed through 
the loss of diethylamine from a series of pharmaceutical 
compounds using QqTOF-MS and QIT-MS at various collision 
energies 
 
Compound RA using 
QqTOF-MS 
at 15 eV / 
% 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Amiodarone - - 2 100 100 
Amlodipine 
structural 
analogue 5 
3 1 - 59 61 
Chloroquine 100 100 100 100 100 
Cinchocaine 100 100 81 100 100 
Clomifene - 1 - 7 7 
Dicycloverine 41 59 24 100 100 
Disulfiram - - - 18 13 
Lidocaine - - - - - 
Macrogol 100 100 64 100 100 
Metoclopramide 100 100 100 100 100 
Naftidrofuryl 8 3 - 38 55 
Oxybuprocaine 28 28 26 46 53 
Oxybutynin - - - - - 
Procainamide 100 100 51 100 100 
Procaine 50 46 21 100 100 
Sunitinib 100 100 80 100 100 
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Table A7 Relative abundances (RA) for the product ion formed through 
the loss of N,N-dimethylhydroxylamine from a series of 
pharmaceutical compounds using QqTOF-MS and QIT-MS at 
various collision energies 
 
Compound RA using 
QqTOF-
MS at 15 
eV / % 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Amitriptyline-N-
oxide 
100 65 22 100 100 
Chlorpromazine-
N-oxide 1 
2 5 3 6 5 
Chlorpromazine-
N-oxide 2 
13 52 13 100 100 
Chlorpromazine 
structural 
analogue-N-oxide 
1 
79 100 26 100 100 
Chlorpromazine 
structural 
analogue-N-oxide 
2 
32 100 73 100 100 
Diphenhydramine-
N-oxide 
- - - - - 
Ephedrine 
structural 
analogue-N-oxide 
97 30 9 21 19 
Tamoxifen 
structural 
analogue-N-oxide 
1 
- 2 1 31 43 
Tamoxifen 
structural 
analogue-N-oxide 
2 
1 2 1 29 35 
Tetracaine-N-
oxide 
100 100 44 100 100 
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Table A8 Relative abundances (RA) for the product ion formed through 
the loss of N,N-diethylhydroxylamine from a series of 
pharmaceutical compounds using QqTOF-MS and QIT-MS at 
various collision energies 
 
Compound RA using 
QqTOF-
MS at 15 
eV / % 
RA using 
QqTOF-
MS at 20 
eV / % 
RA using 
QqTOF-
MS at 25 
eV / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
on / % 
RA using 
QIT-MS at 
50%, 
WideBand 
activation 
off / % 
Cinchocaine-N-
oxide 
100 100 96 100 100 
Sunitinib-N-oxide 100 100 100 100 100 
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